

APRIL 2023

CURRICULUM VITAE

STEPHEN MICHAEL STAHL, M.D., Ph.D., D.Sc. (Hon.)

Professional Addresses:

36 Grand Corniche Drive
Las Vegas, NV 89011
Phone: (760) 444-9903
Fax : (760) 931-8517

Department of Psychiatry
School of Medicine
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0603

Department of Psychiatry
and Neurosciences
University of California, Riverside
900 University Avenue
Riverside, CA 92521

EDUCATION AND DEGREES

- | | | |
|------|-------------|---|
| 1973 | B.S. | Pre-Medical, Six Year Honors Program in Medical Education,
Northwestern University, Evanston, Illinois |
| 1974 | M.D. | Northwestern University Medical School, Chicago, Illinois |
| 1976 | Ph.D. | Neuropharmacology
Department of Pharmacological and Physiological Sciences
University of Chicago, Chicago, Illinois |
| 2018 | D.Sc.(Hon.) | Üsküdar University Istanbul, Turkey |

CLINICAL TRAINING

- | | |
|-------------|--|
| 1976 - 1977 | RESIDENT IN INTERNAL MEDICINE
University of Chicago, Billings Hospital
Chicago, Illinois |
| 1977 - 1979 | RESIDENT IN NEUROLOGY
University of California, San Francisco Medical Center
San Francisco, California |
| 1979 - 1981 | RESIDENT IN PSYCHIATRY
Stanford University Medical Center
Stanford, California |

RESEARCH AND TRAINING POSITIONS

- | | |
|---------------|--|
| 1971 - Summer | GRADUATE STUDENT (Sterling Morton Traveling Fellowship)
Biochemistry Research, Universität Konstanz, Germany |
| 1971 - 1976 | M.D.- Ph.D. PROGRAM Medical Scientist Fellow, National Institute
of General Medical Sciences, Northwestern University (M.D.)
and University of Chicago, (Ph.D. dissertation) |

RESEARCH AND TRAINING POSITIONS (Cont'd)

- 1979 - 1981 BARBRA STREISAND SCHOLAR FOR DYSTONIA RESEARCH
 Fellow in Neuropsychopharmacology Stanford University
- 1981 - 1985 ASSISTANT DIRECTOR
 Stanford Mental Health Clinical Research Center, Stanford
 University Medical Center, Stanford, California
- 1983 - 1985 GUEST RESEARCH PHYSICIAN
 Donner Laboratory - Positron Emission Tomography Unit,
 Lawrence Berkeley Laboratories, University of California,
 Berkeley, California
- 1991 –2001 MEDICAL DIRECTOR
 Institute for Psychopharmacology Research (IPR),
 San Diego and Carlsbad, California

EDUCATION POSITIONS

- 1997 – present CHAIRMAN
 Neuroscience Education Institute
 Carlsbad, California
- 2001 – present CHAIRMAN
 The Arbor Scientia Group
 Carlsbad, CA

ACADEMIC POSITIONS

- 1981 - 1985 ASSISTANT PROFESSOR OF PSYCHIATRY AND BEHAVIORAL
 SCIENCES
 Stanford University, Stanford, California
- 1985 - 1988 ADJUNCT ASSOCIATE PROFESSOR OF PSYCHIATRY AND
 BEHAVIORAL SCIENCES AND OF PHARMACOLOGY,
 University of California, Los Angeles, California
- 1985 - 1988 HONORARY SENIOR LECTURER
 Institute of Psychiatry, London
- 1987 - 1988 HONORARY SENIOR LECTURER
 Institute of Neurology and the National Hospital for Nervous
 Diseases, Queen Square, London
- 1988 - 1994 PROFESSOR OF PSYCHIATRY
 University of California, San Diego

ACADEMIC POSITIONS (Cont'd)

- 1994 – present ADJUNCT PROFESSOR OF PSYCHIATRY
University of California, San Diego
- 2009 - present HONORARY VISITING SENIOR FELLOW
Department of Psychiatry, University of Cambridge
- 2020 – present CLINICAL PROFESSOR OF PSYCHIATRY AND NEUROSCIENCE,
University of California, Riverside, School of Medicine

HOSPITAL POSITIONS

- 1981 - 1985 DIRECTOR
Movement Disorders & Psychopharmacology Research Clinic,
Veterans Affairs Medical Center, Palo Alto, California
- 1981 - 1985 MEDICAL DIRECTOR
Schizophrenia Biological Research Center
Veterans Affairs Medical Center, Palo Alto, California
- 1981 - 1985 WARD CHIEF AND STAFF PHYSICIAN
Psychiatry Service
Veterans Affairs Medical Center, Palo Alto, California
- 1982 - 1985 DIRECTOR
Laboratory of Neuropsychopharmacology
Veterans Affairs Medical Center, Palo Alto, California
- 1985 - 1988 HONORARY CONSULTANT
The Royal Bethlem-Maudsley Hospital, London
- 1988 - 1989 CHIEF, PSYCHIATRY SERVICE
Veterans Affairs Medical Center, San Diego, California
- 1989 - 1994 CHIEF, PSYCHOPHARMACOLOGY
Veterans Affairs Medical Center, San Diego, California
- 1992 - 1994 CHIEF, MENTAL HEALTH OUTPATIENT CLINICS
Veterans Affairs Medical Center, San Diego, California
- 1988 - 1997 DIRECTOR, LABORATORY OF CLINICAL NEUROSCIENCE
Veterans Affairs Medical Center, San Diego, California
- 2011 – 2012 FORENSIC PSYCHOPHARMACOLOGY CONSULTANT
Patton State Hospital, Patton, California

HOSPITAL POSITIONS (Cont'd)

2012 – present DIRECTOR OF PSYCHOPHARMACOLOGY
Statewide Clinical Operations for Department of State
Hospitals, Sacramento, California

PROFESSIONAL EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

1982 - 1985 DIRECTOR OF CLINICAL SCIENCES, ASSOCIATE MEDICAL
DIRECTOR AND PRINCIPAL SCIENTIST
Alza Corporation
Palo Alto, California

1985 - 1988 EXECUTIVE DIRECTOR OF CLINICAL NEUROSCIENCE
DIRECTOR OF THE LABORATORY OF CLINICAL
NEUROPHARMACOLOGY
Neuroscience Research Center
Merck Sharp and Dohme Research Laboratories
Harlow, Essex (United Kingdom)

CONSULTING EXPERIENCE AND ADVISORY BOARDS WITH THE PHARMACEUTICAL INDUSTRY

Abbott Laboratories

AbbVie

Acadia

Adamas

Alkermes

Allergan

Amylin

Angelini

Arena

Arbor

Asahi Chemical

Assure RX

Astra Zeneca

Avanir

Avera

Axovant

Axsome

Bausch

Bayer AG

Biogen

Biopharma

BioMarin

Biolaunch Canada

Biovail

Boehringer Ingelheim

Braebron

Mead Johnson

Mede Corp.

Meiji

Merck

Merrell Dow

Mylan

Neos

Neurawell

Noema

Neurocrine Biosciences

Neuromolecular

Neuronetics

NovaDel

Novartis

Noveida

Orexigen

Organon

Otsuka

PamLabs

Parke Davis

PaxMedica

Perrigo

Pfizer/Roerig

Pfizer

Pharmacia and Upjohn

Pharmasquire

CONSULTING EXPERIENCE AND ADVISORY BOARDS WITH THE
PHARMACEUTICAL INDUSTRY (Cont'd)

Bristol Myers Squibb
Burroughs Wellcome
Cenerex
Cerevel
Celgene
Ciba Geigy
Clearview
Clexio
Concert
Covance
CSC Pharmaceuticals
Cyberonics
Cypress Biosciences
Delix
DepoMed
Dainippon
Digestome
Dey
Forest
Eisai
Eli Lilly
EDM Sirona
Enveric
EnVivo
Epix
Eurolink
Fabre Kramer
Fanapt
Ferring
Forest
Forum
Gate Neuroscience
G.D. Searle
Gedeon Richter
Genetech
Genomind
Glaxo Smith Kline
Glaxo Wellcome
Hoechst-Roussel
Impel
Intra-Cellular Therapies
Innovative Science Solutions
Ironshore
Janssen
Jazz
Karuna

Marinus
Lundbeck
Pierre Fabre Cephalo
Prexa Pharmaceuticals
Procter and Gamble
Propagate Pharma
Proxymm
Quintiles Pacific Inc.
Reviva
Rexahn
Recordati
Relmada
Roche
Royalty Pharma
Sage
Sanofi
Schering Plough
Servier
Shionogi
Shire
SK Corporation
Smith Kline Beecham
Soffinova
Solvay
Sprout
Sumitomo
Sunovion
Supernus
Takeda
Taliaz
Taisho
Teragenix
Teva
Tikvah
Teva
Tikvah
TMS Neurohealth
Tonix
Torrent
Tris
Trius
UCB Pharma
Vanda
Valeant
Vertex
Viforpharma

CONSULTING EXPERIENCE AND ADVISORY BOARDS WITH THE
PHARMACEUTICAL INDUSTRY (Cont'd)

LaboPharm
Levo Therapeutics
Lipidio
Longboard
Lorex

VistaGen
Vivus
Watson
Wyeth
Yamanouchi

CONSULTING EXPERIENCE WITH MANAGED CARE

BLUE CROSS OF CALIFORNIA

Blue Cross California Care Occupational Health Network -
Psychiatric illnesses

HEALTH PAYMENT REVIEW, BOSTON, MASSACHUSETTS

Psychiatry Payment Review Board -
Matching ICD-9 Diagnostic Codes with CPT Service Codes

KAISER PERMANENTE, HONOLULU, HAWAII

Depression Treatment Guidelines

VALUE OPTIONS, PHOENIX, ARIZONA

Fiscal Pharmacology of the Atypical Antipsychotics

CONSULTING EXPERIENCE WITH GENOMICS/DIAGNOSTICS

BRAZILIAN INSTITUTE OF PSYCHOPHARMACOLOGY AND PHARMACOGENETICS

GENOMIND

MINDX SCIENCE, INC.

TALIAZ HEALTH, LTD.

TEACHING EXPERIENCE

1981 - 1985

STANFORD UNIVERSITY

Department of Human Biology

-Lecturer for "Psychobiology: The Biological Basis of Psychiatric Disorders"

-Lecturer for "Neurochemistry of Severe Behavioral Disturbances of Childhood"

Department of Anthropology and Psychology

-Graduate Seminar in Clinical Process

Department of Psychiatry and Behavioral Sciences

-Psychopharmacology (psychiatry residents)

Pediatric Psychopharmacology (child psychiatry fellows)

-Basic Psychiatry Clerkship (medical students)

TEACHING EXPERIENCE (Cont'd)

-Advanced Psychiatry Clerkship (medical students)

- 1982 – 1985 PALO ALTO VETERANS AFFAIRS MEDICAL CENTER
Division of Psychology, Clinical Psychology Intern Training Program
-"Psychopharmacology for Clinical Psychologists"
- 1985 - 1988 UNIVERSITY OF CALIFORNIA, LOS ANGELES
Medical School
-Lecturer for basic pharmacology course
- 1985 - 1988 INSTITUTE OF PSYCHIATRY
Maudsley Hospital, London
-Lecturer for Psychopharmacology Course
-Research Advisor for Research Registrars in
Neurology and Psychiatry
- 1987 - 1988 INSTITUTE OF NEUROLOGY
National Hospital for Nervous Disease
Queen Square, London
-Lecturer in Neuropharmacology
- 1988 - present UNIVERSITY OF CALIFORNIA, SAN DIEGO
Department of Psychiatry, School of Medicine
-Lecturer in Psychopharmacology for medical students, graduate
neuroscience and pharmacology students, psychiatry and medicine
residents and psychiatry research fellows
-Faculty Mentor Program for Undergraduate Independent Studies
-Howard Hughes Mentor Program for Minority Students
-Ph.D. dissertation committee, Department of Pharmacology
Graduate Students
-Chairman of the Steering Committee, Postdoctoral
Fellowship in Psychobiology and Psychopharmacology
-Advanced Psychopharmacology Course (CME)
-Geriatric Psychopharmacology Course (CME)
- 1988 – 2008 UNIVERSITY OF CALIFORNIA, SAN DIEGO
Department of Psychiatry, School of Medicine
-"Psychopharmacology Images," a home study CME course
approved by UCSD for 35 hours of Category I credit
- 2009 – present UNIVERSITY OF CAMBRIDGE, CAMBRIDGE, UK
Department of Psychiatry and Psychiatry and Behavioral Clinical
Neuroscience Institute
-lectures in psychiatry and psychopharmacology
- 2020 – present UNIVERSITY OF CALIFORNIA RIVERSIDE
Department of Psychiatry and Neuroscience, School of Medicine
- lectures in psychiatry, psychopharmacology and neuroscience

COMMITTEES AND REVIEW BOARDS

1981 - 1985	HUMAN SUBJECTS RESEARCH COMMITTEE (IRB) Palo Alto Veterans Administration Medical Center
1983 - 1985	MEDICAL STUDENT EDUCATION COMMITTEE Department of Psychiatry and Behavioral Sciences Stanford University
1988 - 1992	RESEARCH AND DEVELOPMENT COMMITTEE San Diego Veterans Affairs Medical Center
1988 - 1992	CLINICAL PRACTICE COMMITTEE UCSD School of Medicine
1996 – 2016	CONTINUING MEDICAL EDUCATION COMMITTEE UCSD School of Medicine
1997 – 2012	EXPERT MEDICAL REVIEWER Medical Board of California
1997 - 2014	MEDI-CAL (Medicaid) DRUG USE REVIEW (DUR) BOARD State of California Medicaid Program
1997 – 2014	-Member
2005- 2007	-Vice Chair
2007 – 2013	-Chair
2008 – 2018	UCSD Geisel Library, University Librarian's Advisory Board

LICENSES AND CERTIFICATION

1975	Diplomate of the Federal Licensure Examination
1977	Diplomate of the National Board of Medical Examiners
1983	Diplomate, American Board of Psychiatry and Neurology
1985 - 1988	Visiting Overseas Doctor Registration, General Medical council, UK
1975 – present	Medical Licensure, State of Indiana, #01026376,
1975 – present	Medical Licensure, State of Ohio, #35-03-8911,
1977 – present	Medical Licensure, State of California, #G34507,
1993 - 1997	Qualified Medical Evaluator, State of California, #908730,

HONORS

1971, 1973, 1977	Illinois Psychiatric Society Award
1972	Roche Award in Neuropsychiatry
1973	Neuropsychiatric Research Foundation Award
1974	Saul R. Korey Award in Basic Research
1974	A.E. Bennett Award in Basic Research
1974	Alpha Omega Alpha Basic Research Award
1974	G.D. Searle Award

HONORS (Cont'd)

- 1975 G. Milton Shy Award
- 1983 Merrell-Dow Visiting Professor of Psychiatry and Pharmacology, Chicago, Illinois
- 1984 French Ministry Visiting Professor of Psychiatry and Neurology, Lyon, France
- 1997 Honorable Mention, Association of American Publishers' Award for Best Medical Textbook published in the U.S. for Essential Psychopharmacology
- 2000 Communicator Award, Educational Videotape Series
Communicator Award, Written and Illustrated Antipsychotic workbook
- 2001 Honorary Adjunct Professor of Psychiatry
New York College of Osteopathic Medicine
New York Institute of Technology
Old Westbury, New York
- 2002 Lundbeck International Neuroscience Foundation Prize
- 2004 San Diego Psychiatric Society/American Psychiatric Association Education Award
- 2008 UCSD Residency Teaching Award
- 2009 The British Medical Association Medical Book Competition Award, Stahl's Essential Psychopharmacology 3rd Edition
- 2009 Honorary Visiting Senior Fellow, Department of Psychiatry, University of Cambridge, Cambridge, UK
- 2010 The British Medical Association Book of the Year Award for The Prescribers Guide 3rd Edition
- 2011 The British Medical Association Medical Book Competition Award, Stahls Illustrated Antipsychotics
- 2012 The Feldman Lecture, Edmonton, Canada
- 2013 Distinguished Psychiatrist Lecturer and Award, American Psychiatric Association
- 2016 The Stephen M. Stahl Young Psychiatrist Award, named in honor of Stephen Stahl and awarded to the Northwestern University medical student who has the best performance in psychiatry, given annually by the Department of Psychiatry at Northwestern University Medical School, Chicago, Illinois
- 2016 David A. Mrazek Lecture and Award for Pharmacogenomics in Psychiatry, American Psychiatric Association
- 2016 The British Medical Association Medical Book Competition Award for Best Digital Book, Stahl Masterclass, Cambridge University
- 2017 Honorary President, Italian Brain Research Foundation
- 2018 Honorary Doctorate, Üsküdar University, Istanbul Turkey
- 2018 Honorary Citizen, City of Lucca, Italy for contributions to psychiatry
- 2018 Honorary Member, Italian Medical Society, for contributions to mental health
- 2020 Aristotle Gold Medal, Lifetime Achievement Award, Society of Neurosciences and Rehabilitation, International Congress on Neurobiology, Psychopharmacology and Treatment Guidance, Greece

HONORS (Cont'd)

- 2022 British Medical Association Book of the Year Award for Handbook on Suicide Prevention, Cambridge University Press
- 2023 The Paykel Lecture, Cambridge University, Honorary Lecture for a Distinguished International Figure in Psychiatry honoring the first chair of psychiatry at the University of Cambridge, UK
- 2023 Sapienza University of Rome, Lifetime Achievement Award for contributions to psychiatry, Rome, Italy

EDITORIAL BOARDS

- 1988 - 1989 Psychological Medicine
- 1988 – present International Review of Psychiatry
- 1991 - 1992 Stress Management Advisor
- 1996 - present Journal of Psychiatry in Clinical Practice
- 1996 – 1997 Editor, "Psychopharm Psnapshts," Psychiatric Annals
- 1997 - 2011 Editor, "Brainstorms," Journal of Clinical Psychiatry
- 1997 – 2008 Clinical Field Editor, International Journal of Neuropsychopharmacology
- 1999 – 2009 CNS News
- 1999 - 2007 Journal of Depression and Anxiety/African Journal of Psychiatry
- 2000 – present Neuropsychopharmacology
- 2003 – present CNS Spectrums
- 2012 – present -Editor-in-Chief, CNS Spectrums
- 2004 – present Journal of Psychotic Disorders
- 2005 – present Clinical Neuropsychiatry
- 2005 – present Psychiatry/Innovations in Clinical Neuroscience
- 2005 – present Expert Opinion on Pharmacotherapy
- 2005 – present Acta Psychiatrica Scandinavica
- 2005 – present -Editorial Board
- 2007 – 2016 -Associate Editor
- 2010 – 2018 Neurotherapeutics
- 2010 – present Therapeutic Advances in Psychopharmacology
- 2010 – present Neuropsychiatry
- 2010 – present Frontiers in Psychopharmacology

SCIENTIFIC ADVISORY BOARDS

- 1990 – 2000 National Anxiety Foundation
- 1993 – 2000 San Diego Phobia Foundation
- 1996 – 2012 Obsessive-Compulsive Foundation (National)
- 1996 – 2012 California Obsessive-Compulsive Foundation
- 2001 – 2004 EthicAd
- 2001 – 2004 Acurian
- 2001 – 2004 BioExpertise
- 2001 – 2015 Healthcare Technology Systems (HTS)
- 2001 – 2012 Decision Resources

SCIENTIFIC ADVISORY BOARDS (Cont'd)

2002	Academy of Judges, International Health and Medical Media Awards (Freddie Awards)
2010 – present	Genomind
2010 – present	Mind X Sciences
2021 – present	Delix Therapeutics, Inc
2021 – present	Neurawell

PROFESSIONAL SOCIETIES

American Academy of Neurology
American Academy of Psychiatry and the Law
American College of Neuropsychopharmacology
Ad Hoc Awards Committee, 1984
Task Force on Drug Safety, 1985 - 1988
Liaison committee with government agencies and the pharmaceutical industry 1986 - 1989
Fellow, 1989 - present
Education Committee – 1998 - 2002
American Psychiatric Association
Member 1981-2000
Fellow, 2000 – 2003
Distinguished Fellow – 2003 – 2014
Distinguished Life Fellow 2014 - present
American Society for Neurochemistry
American Society of Clinical Psychopharmacology
British Association of Psychopharmacology, 1985 – 1988
Council, 1987 - 1988
British Pharmacology Society, 1985 - 1989
Collegium Internationale Neuro-psychopharmacologium
Chairman, Education Committee, 1997 –2004
Fellow, 1986 – present
Counsellor, 2000 – 2004
Scientific Program Committee, 2000-2002
Scientific Program Committee, 2002-2004
Scientific Program Committee, 2004-2006
Vice President, 2004-2008
International Society of Neurochemistry, 1976 - 1993
Royal Society of Medicine
Society for Neurosciences
Society of Biological Psychiatry
Membership Committee, 1982 - 1988
West Coast College of Biological Psychiatry
Membership Committee, 1990 - 1999

REVIEW OF SCIENTIFIC MANUSCRIPTS

Acta Psychiatrica Scandinavica	Journal of Clinical Investigation
American Journal of Psychiatry	Journal of Clinical Psychiatry
Annals of Neurology	Journal of Neural Transmission
Archives of General Psychiatry	Journal of Neurochemistry
Biochemical Pharmacology	Journal of Psychiatry in Clinical Practice
Biological Psychiatry	Journal of Studies on Alcohol Life Sciences
Brain	Int'l J Clin Psychopharmacology Science
Brain Research	Neuropsychopharmacology
Clinical Therapeutics	Psychiatry Research
Clinical Neuropsychiatry	Psychiatric Services
CNS Spectrums	Psychological Medicine
Depression	Psychopharmacology
Epilepsia	Psychosomatic Medicine Sleep
Expert Opinion on Pharmacotherapy	Trends in Pharmacological Sciences
Internat'l Journal of Neuropsychopharmacology	
Journal of Affective Disorders	
Journal of the American Medical Assoc.	

REVIEW OF THE SCIENTIFIC MERIT OF GRANT APPLICATIONS

Preclinical Psychopharmacology (National Institute of Mental Health)
Clinical Psychopharmacology (National Institute of Mental Health) Neurology B (National Institute of Neurological and Communicative Diseases and Stroke)

REVIEW OF THE SCIENTIFIC MERIT OF GRANT APPLICATIONS (Cont;d)

Scottish Rite Foundation for Schizophrenia
Dystonia Medical Research Foundation
Mental Health Clinical Research Centers Branch (National Institute of Mental Health)
Research Advisory Group, Veterans Administration Central Office
March of Dimes
Ontario Mental Health Foundation
Tourette Syndrome Association
Mental Health Foundation (UK)
Medical Research Council (UK)
Medical Research Council (Canada)
Veterans Affairs Merit Review Board (Neurobiology) ad hoc reviewer
Brain Disorders and Clinical Neurosciences Study Section (NIMH), ad hoc reviewer
Catalan Agency for Health Technology (Spain)

MANAGEMENT COURSES

- 1986 Management skills course, MAST, Management and Skills Training, Cambridge University, Cambridge, United Kingdom.
- 1986 Counseling for performance improvement course, MAST, Management and Skills Training, Cambridge University, Cambridge, United Kingdom.
- 1987 Financial Planning and Forecasting, Templeton College of Business of Oxford University, The Oxford Centre for Management Studies, Oxford, United Kingdom.
- 1987 Oxford Executive Programme for Senior Management: Managing for Competitive Advantage and Profitability, Templeton College of Business of Oxford University, The Oxford Centre for Management Studies, Oxford, United Kingdom.
- 1987 Performance Appraisals, MAST, Management and Skills Training, Cambridge University, Cambridge, United Kingdom.

RESEARCH IN COLLABORATION WITH THE PHARMACEUTICAL INDUSTRY

RESEARCH AT STANFORD UNIVERSITY (1979 - 1985)

1. Gamma-vinyl-GABA (Merrell-Dow) in tardive dyskinesia, Tourette syndrome and other movement disorders.
2. RO22-1319 (piquindone) (Roche) in schizophrenia.
3. RO22-1319 (piquindone) (Roche) in Tourette syndrome.
4. Fenfluramine (Robins) in schizophrenia.
5. Albuterol (Glaxo) in depression.
6. Alprazolam (Upjohn) in depression.
7. Lisuride (Schering AG) in dystonia.
8. Bromocriptine (Sandoz) in dystonia.
9. Clonidine (Boehringer-Ingelheim) in movement disorders.
10. Lecithin and choline chloride in movement disorders (tardive dyskinesia, Huntington's disease, Tourette syndrome).
11. Physostigmine (O'Neal) in movement disorders (tardive dyskinesia, Huntington's disease, Tourette syndrome).
12. Fenfluramine (Robins) in the malignant carcinoid syndrome.
13. Levodopa (Lakeside, Nutritional Biochem) in Parkinson's disease and dementia .
14. Diazepam (Roche) in the Stiff-Man syndrome.

RESEARCH AT ALZA CORPORATION (1982 - 1985)

1. Transdermal fentanyl in postoperative pain and in chronic cancer pain.
2. Transdermal testosterone in male hypogonadism.
3. OROS verapamil, OROS propranolol and OROS hydrochlorothiazide in hypertension.
4. Transdermal estradiol in female menopause.
5. Topical safety, transdermal naloxone.

RESEARCH AT MERCK (1985 - 1988)

1. First administration of new chemical entities to man: alpha-2 antagonist, glutamate antagonist, oral sustained release dopamine agonist, transdermal dopamine agonist.
2. Entering new chemical entities into Phase IIA clinical development: glutamate antagonist, oral sustained release dopamine agonist, transdermal dopamine agonist, skeletal muscle relaxant, cholecystokinin-A antagonist, alpha-2 antagonist.
3. Entering new chemical entities into Phase IIB/III clinical development: oral sustained release dopamine agonist.
4. New drug application (NDA) filing: oral sustained release antiparkinsonian (Sinemet CR).
5. Clinical research: fluorinated analogues of glutamate antagonists for positron emission tomography; neuropharmacology of cognition and memory in human volunteers.
6. Preclinical research: neuroprotective glutamate antagonist lead compounds; cholinomimetic Alzheimer lead compound, beta adrenergic and serotonin receptor regulation by antidepressants/anxiolytics.
7. Licensing-in agreements for CNS compounds.

RESEARCH AT INSTITUTE FOR PSYCHOPHARMACOLOGY RESEARCH, SAN DIEGO/CARLSBAD (1988 - 2004)

1. Gepirone (Bristol-Myers) in major depressive disorder
2. Xanax sustained release (Upjohn) in panic disorder
3. Sertraline (Pfizer) vs. amitriptyline, quality of life study in depression
4. Sertraline (Pfizer) crossover from fluoxetine in depression
5. Sertraline (Pfizer) vs. clomipramine in obsessive compulsive disorder
6. Ipsapirone (Miles) in depression
7. Nefazodone (Bristol-Myers Squibb) in depression
8. Adinazolam (Upjohn) vs. nortriptyline, effects on serotonin receptors in major depressive disorder
9. CGS-18102A (Ciba-Geigy) in generalized anxiety disorder
10. Bupropion sustained-release (Burroughs Wellcome) in major depressive disorder
11. Xanax (Upjohn) in long-term treatment of panic disorder
12. Buspirone (Bristol-Myers Squibb) in mixed anxiety depression
15. Sertraline (Pfizer) vs. fluoxetine, quality of life study in depression
14. Sertraline (Pfizer) vs. desipramine in comorbid obsessive compulsive disorder plus major depressive disorder
15. Fluvoxamine (Upjohn-Solvay) in panic disorder
16. Paroxetine (SmithKline Beecham) in depression
17. DN-2327 (Takeda Abbott Pharmaceuticals) in generalized anxiety disorder
18. Nefazodone (Bristol-Myers Squibb) crossover from fluoxetine, in depression
19. Nefazodone (Bristol-Myers Squibb) crossover from sertraline, in depression
20. Tansospirone (Pfizer) in depression
21. Klonopin (Roche) in obsessive compulsive disorder
22. Klonopin (Roche) in panic disorder
23. Mentane (Hoechst) in Alzheimer's disease

24. Nefazodone (Bristol-Myers Squibb) in inpatients with depression
25. Olanzapine (Lilly) in inpatients with schizophrenia
26. Pharmacokinetic study of ziprasidone in inpatients with schizophrenia
27. Bupropion sustained-release (Burroughs Wellcome) in depression
28. BMS-181,101 (Bristol-Myers Squibb) open label treatment in depression
29. CP-93,393 (Pfizer) in generalized anxiety disorder
30. Sertindole (Abbott) in schizophrenia
31. Sabeluzole (Janssen) in Alzheimer's disease
32. Sertraline (Pfizer) in relapse of symptoms in obsessive compulsive disorder
33. BMS-181,101 (Bristol-Myers Squibb) double-blind treatment in depression
34. Venlafaxine (Wyeth-Ayerst) in depression
35. Bupropion sustained-release (Burroughs Wellcome) vs. sertraline in depression
36. Sertraline (Pfizer) in treatment refractory obsessive compulsive disorder
37. ORG 4428 (Organon) in depression
38. Flesinoxan (Solvay) vs. buspirone in generalized anxiety disorder
39. CP-93,393 (Pfizer) in depression
40. Hippurate LY 228729 (Lilly) in treatment refractory depression
41. Ipsapirone (Miles/Bayer) sustained release in major depressive disorder
42. Fluoxetine (Lilly) in relapse of symptoms of obsessive compulsive disorder
43. Ziprasidone (Pfizer) vs. risperidone in outpatients with schizophrenia
44. Serzone (Bristol-Myers Squibb) in general psychiatric practices
45. CP93,393 (Pfizer) in major depressive disorder
46. CP93,393 (Pfizer) in generalized anxiety disorder
47. Fluoxetine Plus Pindolol (Lilly) in depression
48. Citalopram (Forest) in depression
49. Fluoxetine (Lilly) in relapse of symptoms of bulimia
50. Remeron (mirtazapine) (Organon) in major depressive episode
51. Iloperidone (Titan) in schizophrenia.
52. Compass (Bristol-Myers Squibb) in all disorders
53. Flibanserin (Boehinger Ingelheim) in major depressive disorder
54. SR58611A (Sanofi) in major depression
55. Olanzapine (Lilly) in resistant major depressive disorder without psychotic features.
56. Risperidone (Janssen) in Treatment Resistant Major Depressive Disorder.
57. Estrogen as an adjunct to Zoloft (Pfizer) for Panic Disorder in Peri/Post Menopausal Women.
58. SR142801 (Sanofi) in major depression.
59. Neurokinin - CP122-721 (Pfizer) in major depression.
60. Reboxetine (Pharmacia Upjohn) in Major Depressive Disorder.
61. St. John's Wort (Pfizer) in major depression.
62. Nefazodone (Bristol Myers Squibb) A multicenter, double-blinded placebo controlled, randomized fixed dose study of Nefazodone ER in the treatment of depressed patients.
63. Celexa (Forest Laboratories) Depression study
64. Paxil GAD (SmithKlineBeecham) A Randomized double blind placebo controlled flexible dose trial to evaluate the efficacy and tolerability of paroxetine in patients with generalized anxiety disorder.
65. Olanzapine (Lilly) Randomized double blinded parallel study of patients who have responded to acute (6 to 12) weeks open label olanzapine treatment and are in symptomatic remission of an index manic, mixed, or depressed episode (with or

- without psychotic features).
66. Citalopram (Forest Laboratories) Panic
 67. Citalopram (Forest Laboratories) Depression
 68. Effexor XR (Wyeth Ayerst) Social Phobia
 69. CP 448, 187 – Pfizer Depression
 70. Reboxetine – Pharmacia and Upjohn
 71. Duloxetine in Major Depression - Lilly

PROFESSIONAL NEWSLETTER ARTICLES

- (NL-1) Stahl SM. Clinical applications of the neuropharmacology of receptor ligands appear to be promising. The Psychiatric Times VIII (3):40-41, 1991.
- (NL-2) Stahl SM. Treating Adolescents and Children with Antidepressants: Damned If you do, damned if you don't. Part 1 – What we know and what we don't Know. PsychEd Up, Volume 1, Issue 1, p.6-7, 2005.
- (NL-3) Stahl SM. Treating Adolescents and Children with Antidepressants: Damned if you do, damned if you don't. Part 2 – What we should do. PsychEd Up, Volume 1, Issue 2, p. 6-7, 2005.
- (NL-4) Stahl SM. It Takes Two to Entangle: Separating Medical Education from Pharmaceutical promotion. PsychEd Up, Volume 1, Issue 3, p. 6-7, 2005.
- (NL-5) Stahl SM. Detecting and Dealing with Bias in Psychopharmacology, PsychEd Up, Volume 1, Issue 4, p. 6-7, 2005.
- (NL-6) Stahl SM. Finding Better Answers for Sleep Disorders. Shift Happens. PsychEd Up, Volume 1, Issue 5, p.6-7, 2005.
- (NL-7) Coopan R and Stahl SM. Metabolic Issues: A Psychiatrist's Perspective. Clinical Psychiatry News Supplement, Psychoarmacology: Beyond Conventional Wisdom, p 14-16, 2005.
- (NL-8) Stahl SM. A Rash Proposal for Psychopharmacologists Treating Bipolar Disorder. PsychEd Up, Volume 1, Issue 6, p. 6-7, 2005.
- (NL-9) Stahl SM and Shayegan DK. Assessing the Assessments in Psychopharmacology. PsychEdUp, Volume 1, Issue 7, p 6-7, 2005.
- (NL-10) Stahl SM. Specifying the Unspecified in Bipolar Disorder, PsychEdUp, Volume 1, Issue 8, p. 6-7. 2005.
- (NL-11) Stahl SM. Let Them Eat Generics. PsychEdUp, Volume 1, Issue 9, p. 6-7, 2005.
- (NL-12) Stahl SM. Fixing Pharma and the Feds. PsychEdUp, Volume 1, Issue 10, p.5-6, 2005.

PROFESSIONAL NEWSLETTER ARTICLES (Cont'd).

- (NL-13) Stahl SM. Strategies for Innovating New Treatments in Psychiatry. PsychEdUp, Volume 1, Issue 11, p. 6-7, 2005.
- (NL-14) Stahl SM. Prescribing Off-Label in Psychopharmacology. PsychEdUp, Volume 1, Issue 12, p. 5-6, 2005.
- (NL-15) Stahl SM and Grady M. Symptoms and Circuits: Deconstructing Psychiatric Disorders to Achieve Remission. PsychEdUp, Volume 2, Issue 1, p. 6-7, 2006.
- (NL-16) Stahl SM. Will CATIE Change Your Practice? PsychEdUp, Volume 2, Issue 2, p.6-7, 2006.
- (NL-17) Stahl SM. Processes Influencing Wakefulness. PsychEdUp, Volume 2, Issue 3, p. 6-7, 2006.
- (NL-18) Stahl SM. Signal Transduction. PsychEdUp, Volume 2, Issue 4, p. 6-7, 2006.
- (NL-19) Stahl SM. Effects of Sleepiness. PsychEdUp, Volume 2, Issue 5, p. 6-7, 2006.
- (NL-20) Stahl SM. Targeting Executive Dysfunction. PsychEdUp, Volume 2, Issue 6, p. 5-6, 2006.
- (NL-21) Stahl SM. Neuromodulators of Arousal. PsychEdUp, Volume 2, Issue 7, p. 5-6, 2006.
- (NL-22) Stahl SM. Diagnosing Obstructive Sleep Apnea, PsychEdUp, Volume 2, Issue 8, p. 5-7, 2006.
- (NL-23) Stahl SM and Grady MM. ADHD: From Syndrome to Symptoms. Part 1: Inattention. PsychEdUp, Volume 2, Issue 9, 6-7, 2006.
- (NL-24) Stahl SM and Grady MM. ADHD: From Syndrome to Symptoms. Part 2: Hyperactivity. PsychEdUp, Volume 2, Issue 10, 6-7, 2006.
- (NL-25) Stahl SM and Buckley PF. Diagnostic and Treatment Approaches to the Negative Symptoms of Schizophrenia, Part 1: Diagnosis. PsychEd Up, Volume 2, Issue 11, 6-7, 2006.
- (NL-26) Stahl SM and Buckley PF. Diagnostic and Treatment Approaches to the Negative Symptoms of Schizophrenia, Part 2: Neurobiology. PsychEd Up, Volume 2, Issue 12, 6-7, 2006.
- (NL-27) Stahl SM and Buckley PF. Diagnostic and Treatment Approaches to the Negative Symptoms of Schizophrenia, Part 3: Treatment. PsychEd Up, Volume 3, Issue 1, 6-7, 2007.

PROFESSIONAL NEWSLETTER ARTICLES (Cont'd).

- (NL-28) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part One: Case One, Who is the Patient? WakeUp!, Volume 1, Issue 1, 6, 2007.
- (NL-29) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part Two: Case One, Results and Action. WakeUp!, Volume 1, Issue 2, 6, 2007.
- (NL-30) Stahl SM. Overview of Trends in Psychopharmacology. PsychEd Up, Volume 3, Issue 5, 6-7, 2007.
- (NL-31) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part Three: Case One, Summary. WakeUp!, Volume 1, Issue 3, 6, 2007.
- (NL-32) Stahl SM. Beyond the Dopamine Hypothesis of Schizophrenia. NMDA receptor hypofunction. PsychEd Up, Volume 3, Issue 6, 6-7, 2007.
- (NL-33) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part One: Case Two, Who Is the Patient? WakeUp! Volume 1, Issue 4, 6, 2007.
- (NL-34) Stahl SM. Novel Therapeutics for Schizophrenia: Targeting glycine modulation of NMDA receptors. PsychEd, Volume 3, Issue 11, 2007.
- (NL-35) Stahl SM. Genetics of Schizophrenia Converge Upon the NMDA Glutamate Receptor. Psych Ed Up, Volume 3, Issue 12, 2007.
- (NL-36) Stahl SM. Novel Therapeutics for Depression: L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent. PsychEd Up, Volume 4, Issue 4, 2008.
- (NL-37) Stahl SM. Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics? PsychED Up, Volume 4, Issue 6, 2008.
- (NL-38) Wise D and Stahl SM. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Psychiatric Disorders (Part 1 of 2). PsychEd Up, Volume 4, Issue 8, 2008.
- (NL-39) Wise D and Stahl SM. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Psychiatric Disorders (Part 2 of 2). PsychEd Up, Volume 4, Issue 9, 2008.
- (NL-40) Stahl SM, Wise D and Felker A. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy, Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology (Part 1 of 2). PsychEd Up, Volume 5, Issue 1, 2009.

PROFESSIONAL NEWSLETTER ARTICLES (Cont'd).

- (NL-41) Stahl SM, Wise D and Felker A. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy, Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology (Part 2 of 2) PsychEd Up, Volume 5, Issue 2, 2009.

MONOGRAPHS

- (M-1) Stahl SM. Down regulation of neurotransmitter receptors: a new hypothesis on the mechanism of antidepressant drugs. Depression Dialogue, Merrell-Dow Pharmaceuticals Publications, 1985.
- (M-2) Stahl SM. New drug delivery systems - a new approach to Parkinson's Disease. In: Marsden CD and Trimble M (Eds), Future Trends in the Treatment of Parkinson's Disease and Epilepsy, Franklin Scientific Projects Publications, London, 1985, pp. 16-18.
- (M-3) Stahl SM. Serotonin regulators and obsessive compulsive disorder. Clinical Advances in the Treatment of Psychiatric Disorders 6(1):12-16, 1992.

MONOGRAPHS (Cont'd).

- (M-4) Stahl SM. Why does depression hurt? Insights into Depression, September 2006.

BOOK REVIEWS

- (BR-1) Stahl S. Senile Dementia - and Where Are We Now? for Senile Dementia of the Alzheimer Type. Traber J and Gispen WH (Eds), Springer-Verlag, Berlin, 1985. Review in Trends in Pharmacological Sciences 7:514-515, 1986.
- (BR-2) Stahl SM. Book Review: The Role of Serotonin in Psychiatric Disorders. Brown SL and van Praag HM (Eds), Brunner/Mazel, New York. Review in Psychological Medicine 22:1063-1068, 1992.

INSTRUCTIONAL VIDEOTAPES

- (V-1) Stahl SM. Essential Psychopharmacology of Serotonergic Antidepressants. Executive Producer and Writer, Stahl/Browne/Rader Productions, 1997.
- (V-2) Stahl SM. Mechanism of Action of Remeron (mirtazapine). Producer, Stahl Productions, 1997.
- (V-3) Stahl SM. Psychopharmacology of Noradrenaline in Depression. Stahl Productions, 1998.
- (V-4) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 1: Neurotransmitter interactions and the Pharmacology of Antipsychotics. Stephen M. Stahl, producer, 1998.

INSTRUCTIONAL VIDEOTAPES (Cont'd).

- (V-5) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 2: Serotonin-Dopamine Receptor Antagonism Improves Therapeutic Actions and Side Effects of Atypical Antipsychotics. Stephen M. Stahl, producer, 1998.
- (V-6) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 3: Novel Applications of Atypical Antipsychotics for Treating Psychosis, Cognition, Hostility and Mood in Schizophrenia and Other Psychiatric Illnesses. Stephen M. Stahl, producer, 1998.
- (V-7) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 3, revised: Novel Applications of Atypical Antipsychotics for Treating Psychosis, Cognition and Mood in Schizophrenia and Other Psychiatric Illnesses. Stephen M. Stahl, producer, 2001.
- (V-8) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 4: Three Classes of Mood Stabilizers for Contemporary Treatment of Bipolar Disorder: Lithium, Anticonvulsants, and Atypical Antipsychotics. Stephen M. Stahl, producer, 2001
- (V-9) Stahl SM. Psychopharmacology of Fatigue and Motivation in Depression. Stephen M. Stahl, producer, 2001.
- (V-10) Stahl SM. Psychopharmacology of the Emotional and Physical Symptoms in Depression. Stephen M. Stahl, producer, 2002.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS

- CME-1 Stahl SM. Psychopharmacology Images: A programmed Home Study Program approved for 35 hours of Category I CME credit, University of California, San Diego, 1998.
- CME-2 Stahl SM. Mechanism of Action of Antidepressants: A four-part audiotape series with programmed text accredited for 11 hours of Category I CME credit, University of California, San Diego, 1998.
- CME-3 Stahl SM. Psychopharmacology of Atypical Antipsychotics. A three part video tape series accredited for 6 hours of Category I CME credit, University of California, San Diego, 1998.
- CME-4 Stahl SM. Serotonin Dopamine Antagonism and the Atypical Antipsychotics. A home study program approved for 2 hours of Category 1 CME credit, University of California, San Diego, 1998.
- CME-5 Stahl SM. Achieving Wellness: Advances in the Treatment of Depression and anxiety. An audio home study program approved for 2 hours of Category 1 CME credit, University of California San Diego, 1998.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS(Cont'd).

- CME-6 Dailey G and Stahl SM. Pathway To Control. Home study Package approved for 8 hours of Category 1 CME credit, University of California San Diego, 1999.
- CME-7 Dailey G and Stahl SM. Pathway To Control. Home Study Package approved for 20 hours of Category 1 CME credit, University of California San Diego, 1999.
- CME-8 Stahl SM. The New Cholinesterase Inhibitors: Their Similarities Are Different. Home Study Package approved for 8 hours of Category 1 CME Credit, University of California San Diego, 1999.
- CME-9 Stahl SM. The Not So Selective Serotonin Reuptake Inhibitors. Home Study Package approved for 6 hours of Category 1 CME Credit, University of California San Diego, 1999.
- CME-10 Stahl SM. Essential Psychopharmacology, 2nd Edition. Home Study Package approved for 54 hours of CME Category 1 CME credit, University of California San Diego, 2000.
- CME-11 Stahl SM. Atypical Antipsychotics: From Pharmacology to Clinical Practice. Home study package approved for 4 hours of Category 1 CME Credit, University of California San Diego, 2001.
- CME-12 Stahl SM. Psychopharmacology of Atypical Antipsychotics. A two part video tape series accredited for a total of 4 hours of Category 1 CME Credit, University of California San Diego. 2001.
- CME-13 Stahl SM. Fiscal Pharmacology of the Atypical Antipsychotics: Getting The Biggest Bang Out of the Bucks. Home study program approved for 6 Hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-14 Stahl SM. Fiscal Pharmacology of the Atypical Antipsychotics. A CD-ROM Home study program approved for 3 hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-15 Stahl SM. Psychopharmacology Academy Audio CD. Home study program approved for 2 hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-16 Stahl SM. Psychopharmacology Academy Syllabus. Home study program Approved for 16 hours of Category 1 CME Credit through the University Of California San Diego, 2002.
- CME-17 Stahl SM. The Not So Selective Serotonin Reuptake Inhibitors, 2nd Edition. Home Study Package approved for 7 hours of Category 1 CME Credit, University of California San Diego, 2002.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS(Cont'd).

- CME-18 Stahl SM. Psychopharmacology Academy CD-ROM. Home study program Approved for 4 hours of Category 1 CME Credit through the University Of California San Diego, 2002.
- CME-19 Stahl SM. Quality of Life Algorithms for Primary Care: Women's Health, Sexuality, Depression and Anxiety. A home study program approved for 4 hours of Category 1 CME credit through the University of Of California San Diego, 2002.
- CME-20 Stahl SM. Psychopharmacology of the Emotional and Physical Symptoms in Depression. Home study program approved for 1 hour of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-21 Stahl SM. Clinical Issues in the Treatment of Panic and Anxiety Disorder. Home study program approved for 4 hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-22 Stahl SM. New Horizons in the Treatment of Schizophrenia: Beyond Dopamine Antagonism. Home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2002.
- CME-23 Stahl SM. Extending the Breadth of Efficacy of Antidepressants. Home Study program approved for 6 hours of Category 1 CME credit through The University of California San Diego 2002.
- CME-24 Lieberman III, Joseph A, Berry Sally, Miller Del, Saltz Bruce and Stahl SM. Safety Considerations in the Use of Atypical Antipsychotics. Audio/CD-ROM. The Primary Care Companion to The Journal of Clinical Psychiatry, Volume 2, Number 2, August 2003.
- CME-25 Stahl SM. Psychopharmacology Academy CD-ROM Series. Home study Program approved for 16 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-26 Stahl SM. Targeting Neurocircuitry Underlying Cognitive and Affective Symptoms in Schizophrenia Audio CD. Home study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2003.
- CME-27 Stahl SM. Targeting Neurocircuitry Underlying Cognitive and Affective Affective Symptoms in Schizophrenia DVD. Home Study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2003.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS (Cont'd).

- CME-28 Stahl SM. Emerging Data and Cost Implications: Maximizing Synergies Between Mood Stabilizers and Atypical Antipsychotics. A CD-ROM Home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-29 Stahl SM. Emerging Data and Cost Implications: Maximizing Synergies Between Mood Stabilizers and Atypical Antipsychotics Syllabus. A home study program approved for 4 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-30 Stahl SM. Brain Circuits Determine Destiny in Depression CD-ROM. A home study program approved for 5 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-31 Stahl SM. Brain Circuits Determine Destiny in Depression Syllabus. A home study program approved for 4 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-32 Stahl SM. Psychopharmacology of Energy and Fatigue Audio CD. A home study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2003.
- CME-33 Stahl SM. The New A.R.T. of Psychiatry DVD Series. A home study program approved for 3 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-34 Stahl SM. The New A.R.T. of Psychiatry Syllabus. Home study program approved for 3 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-35 Stahl SM. Genes, Circuits and Pharmacology: Clinical Connections in Schizophrenia DVD. A home study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2004.
- CME-36 Stahl SM. Psychopharmacology Academy Workbook Part 1: Bipolar and Psychosis. A home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-37 Stahl SM. Psychopharmacology Academy Workbook Part 2: Depression and Anxiety. A home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-38 Stahl SM. Psychopharmacology Academy Interactive CD-ROM Series. A home study program approved for 12 hours of Category 1 CME credit through the University of California San Diego, 2004.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS(Cont'd).

- CME-39 Stahl SM and Sheikh J. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Anxiety: Treatment Issues, 2004.
- CME-41 Stahl SM and Gitlin M. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Bipolar Disorder: Defining Treatment Options, 2004.
- CME-42 Stahl SM and DeBattista C. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Depression: Treating to Remission, 2004.
- CME-43 Stahl SM and Weinberger D. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Psychosis: Treating Beyond Positive Symptoms, 2004.
- CME-44 Stahl SM. Psychopharmacology Academy Self-Directed CD ROM. A home study program approved for 1 hour of Category 1 CME credit. Depression: Brain Circuits Determine Destiny in Depression: A Novel Approach to Improving Energy and Executive Function in Major Depressive Disorder, 2004.
- CME-45 Stahl SM. Psychopharmacology Academy Self-Directed CD-ROM. A home study program approved for 1 hour of Category 1 CME credit. Bipolar Disorder: Maximizing Synergies Between Anticonvulsants and Atypical Antipsychotics, 2004.
- CME-46 Stahl SM. Psychopharmacology Academy Self-Directed CD-ROM. A home study program approved for 1 hour of Category 1 CME credit. Psychosis: The Atypical Psychopharmacology Theorem: Relating Function to Receptor, Receptor to Drug, and Drug to Function, 2004.
- CME-47 Stahl SM. Psychopharmacology Academy Self-Directed CD-ROM. A home study program approved for 1 hour of Category 1 CME credit. Anxiety: Neurobiology and Pharmacology of Anxiety, 2004.
- CME-48 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study program approved for 3 hours of Category 1 CME Credit. Depression: Diagnosis and Treatment, 2005.
- CME-49 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study Program approved for 3 hours of Category 1 CME Credit. Psychosis and Bipolar Disorder, 2005.
- CME-50 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study Program approved for 3 hours of Category 1 CME Credit. Mood Stabilizers and Atypical Antipsychotics, 2005.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS(Cont'd).

- CME-51 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study Program approved for 3 hours of Category 1 CME Credit. Sleep: Symptoms Circuits, 2005.
- CME-52 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Anxiety: Symptoms and Circuits, 2005.
- CME-53 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Sleepiness, 2005.
- CME-54 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Antidepressant Remission Rates, Safety and Tolerability, 2005.
- CME-55 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Mood Stabilizers and Atypical Antipsychotics, 2005.
- CME-56 Stahl SM. Psychopharmacology Academy Workbook. A home study program approved for 3 hours of Category 1 CME Credit. Treatment Issues for Depression and Bipolar Disorder, 2006.
- CME-57 Stahl SM and Nemeroff C. Distinguishing the Diagnosis and Treatments for Bipolar Mania, Mixed Mania, and Difficult to Treat Depression Within the Bipolar Spectrum. A home study DVD program approved for 1.5 hours of Category 1 CME Credit, 2006.
- CME-58 Stahl SM and Swift R. Sages of Psychopharmacology Audio CD. Bipolar Spectrum and Treatment Issues. A home study program approved for 1 hour of Category 1 CME Credit, 2006.
- CME-59 Stahl SM and Jensen PS. Sages of Psychopharmacology Audio CD. ADHD Development and Treatment. A home study program approved for 1 hour of Category 1 CME Credit, 2006.
- CME-60 Stahl SM and Nemeroff CB. Sages of Psychopharmacology Audio CD. Bipolar Disorder: Differential Diagnosis Problems and Novel Treatment Choices in Adults and Children. A home study program approved for 1 hour of Category 1 CME Credit, 2006.
- CME-61 Stahl SM and Cooppan R. Sages of Psychopharmacology Audio CD. Merging Psychiatry and Endocrinology: Screening and Managing Severely Mentally Ill Patients for Metabolic Disorders, 2006.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS (Cont'd).

- CME-62 Stahl SM and Ancoli-Israel S. Sages of Psychopharmacology Audio CD. Sleep Disorders: Their Definition and Treatment, 2006.
- CME-63 Stahl SM. Psychopharmacology of ADHD, 2006.
- CME-64 Stahl SM Executive Function and Dysfunction in ADHD, 2006.
- CME-65 Stahl SM and Ancoli-Israel S. Sages of Psychopharmacology Audio CD. Excessive Sleepiness: Signs, Symptoms and Treatments, 2007.
- CME-66 Stahl SM. Insights into the Diagnosis and Treatment of Bipolar Disorder, 2007.
- CME-67 Stahl SM. Diagnosis and Treatment of Sleep Wake Disorders, 2007.
- CME-68 Stahl SM. Neurobiology of Sleep/Wakefulness and Its Impact on Psychiatric Illness, 2007.
- CME-69 Stahl SM. Neurobiology and Treatment of Alcohol Abuse, 2007.
- CME-70 Stahl SM. Linking Symptoms to Circuits in ADHD, 2007.
- CME-71 Stahl SM and Schwartz T. Psychopharmacology of Executive Dysfunction in Mental Illness, 2007.
- CME-72 Stahl SM. Controversies and Tips for Managing Difficult Cases of Bipolar Disorder, 2008.
- CME-73 Stahl SM and Cutler AJ. Identifying and Treating All Aspects of Fibromyalgia: A New Look Into A Painful Syndrome: Deconstructing the Syndrome of Fibromyalgia, 2008.
- CME-74 Stahl SM and Cutler AJ. Differentiating, Dosing, and Combining Mood Stabilizing Drugs: Dosing Atypical Antipsychotics as Mood Stabilizers, 2008.
- CME-75 Stahl SM and Cutler AJ. Differentiating, Dosing, and Combining Mood Stabilizing Drugs: Classes of Mood Stabilizers, 2008.
- CME-76 Stahl SM and Weinberger D. Insights on Personalized Medicine: Is Pharmacogenetics the Wave of the Future, 2008.
- CME-78 Cutler A, Ball S and Stahl SM. Dosing Atypical Antipsychotics, 2008.
- CME-79 Stahl SM. Signal Transduction and Targets of Psychopharmacological Drug Action: Transporters and G Protein-Linked Receptors, 2009.
- CME-80 Stahl SM. Chemical Neurotransmission, 2009.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS (Cont'd).

- CME-81 Stahl SM. Stahl's Essential Psychopharmacology, 3rd Edition, 2009.
- CME-82 Stahl SM and Cutler AJ. Differentiating, Dosing and Combining Mood Stabilizing Drugs: Rationally Combining Mood Stabilizers for Optimum Outcomes, 2009.
- CME-83 Stahl SM and Cutler AJ. Identifying and Treating All Aspects of Fibromyalgia: Management of All Fibromyalgia Symptoms, 2009.
- CME-84 Stahl SM and Cutler AJ. Identifying and Treating All Aspects of Fibromyalgia: Pain, Depression and Sleep, 2009.
- CME-85 Stahl SM. Black Box Warnings: Implications for Clinical Practice, Antidepressants, and Suicide. Part 1: Neurobiology of Suicidality and Mechanisms of Antidepressant Medications, 2009.
- CME-86 Stahl SM. Black Box Warnings: Implications for Clinical Practice, Antidepressants, and Suicide. Part 2: Activation, Agitation, and Mania: Symptoms or Antidepressant Side Effects?, 2009.
- CME-87 Stahl SM. Black Box Warnings: Implications for Clinical Practice, Antidepressants, and Suicide. Part 3: Depression Treatment and Suicide Rates Following the Black Box Warnings, 2009.
- CME-88 Stahl SM. Confessions of a Psychopharmacologist: Prescribing Outside the Bureaucratic Lines 2010.
- CME-89 Stahl SM and Cutler AJ. Sages of Psychopharmacology, From Clinical Trials to Clinical Practice: Recent Developments in Antipsychotic Therapy, 2010.
- CME-90 Stahl SM and Cutler AJ. Sages of Psychopharmacology Webinar, Contemporary Treatment of Schizophrenia, 2010.
- CME-91 Stahl SM. Depression Session: New Treatment Progression, 2010.
- CME-92 Stahl SM. Antipsychotics as Multifunctional Drugs Across the Mental Health Spectrum: From Psychosis to Bipolar Disorder, Unipolar Depression and Beyond, 2010.

SELF-INSTRUCTIONAL MULTIMEDIA CD-ROM

- CD-ROM-1 Stahl SM. Psychopharmacology of Noradrenaline, An Animated Powerpoint Presentation for Speakers and Lecturers In Psychopharmacology, 1999.
- CD-ROM-2 Stahl SM. Psychopharmacology of Noradrenaline and Reboxetine. selective noradrenaline reuptake inhibitor. An animated, powerpoint Presentation for speakers and lecturers, 2001.
- CD-ROM-3 Stahl SM. Bridging the Gap to Wellness. An animated, case-based Powerpoint presentation for speakers on the psychopharmacology of depression and generalized anxiety disorder, 2001.
- CD-ROM-4 Stahl SM. Depression and Anxiety Powerpoint Library. An animated, case-based resource center of 241 slides on depression, anxiety and their psychopharmacologic treatments, 2001.
- CD-ROM-5 Stahl SM. Psychopharmacology of Energy and Fatigue. An animated, powerpoint presentation for speakers and lecturers, 2002.
- CD-ROM-6 Stahl SM. Symptoms and Circuits: A Brain Game. Interactive program For students, residents, and prescribers, 2003.
- CD-ROM-7 Stahl SM Deconstructing Syndromes into Symptoms: Emphasizing Mood, Fatigue, Concentration and Sleepiness, 2004.
- CD-ROM-8 Stahl SM. Neurobiology of Depression Slides. A powerpoint presentation for students, residents and prescribers, 2008
- CD-ROM-9 Stahl SM. Mechanism of Action of L-methylfolate as a Trimonoamine Modulator: Potential Therapeutic Role in Depression, 2008
- CD-ROM-19 Stahl SM. Methylated Spirits: Role of Methylation in the Cognitive and Negative Symptoms of Schizophrenia and L-Methylfolate as a Novel Treatment Strategy, 2011.

PRESENTATIONS AND ABSTRACTS (2013-PRESENT)

(Total of 1337 presentations plus 231 published abstracts from 1970 through 2012)

PRESENTATIONS AND ABSTRACTS (1)

- 2013 Stahl SM. Emerging Personalized Medicine in Mental Health: Targeting Treatments for Depression. Personalized Medicine World Conference, Mountain View, CA, January 28, 2013.
- 2013 Stahl SM. From Symptoms to Circuits in Psychopharmacology: Imaging Brain Circuits and Applying Pharmacogenomics in Modern Clinical Practice. West Coast Geriatric Psychiatry Conference, San Diego, CA, Feb. 20-21, 2013.
- 2013 Stahl SM. Depression: Deeper Evaluation of Symptoms and Neurobiology. New York, New York, March 5, 2013
- 2013 Stahl SM. From Symptoms to Circuits in Psychopharmacology: Imaging Brain Circuits and Applying Pharmacogenomics in Modern Clinical Practice. Mt. Sinai School of Medicine, Department of Psychiatry, New York, New York, March 5, 2013.
- 2013 Stahl SM. Depression: Deeper Evaluation of Symptoms and Neurobiology. Chicago, Illinois, March 6, 2013.
- 2013 Stahl SM. Depression: Deeper Evaluation of Symptoms and Neurobiology. Dallas, Texas, March 20, 2013
- 2013 Stahl SM. The Mechanism of Action of Atypical Antipsychotics in Bipolar Mania: Are There Any Meaningful Differences? London, United Kingdom, April 15, 2013.
- 2013 Stahl SM. The Mechanism of Action of Atypical Antipsychotics in Bipolar Mania: Are There Any Meaningful Differences? Birmingham, United Kingdom, April 16, 2013.
- 2013 Stahl SM . Glutamate: The Emerging Frontier of Psychopharmacology for Schizophrenia and Mood Disorders. Birmingham, United Kingdom, April 16, 2013.
- 2013 Stahl SM. Master Class: Latest Advances in Psychopharmacology, Cambridge, United Kingdom, April 18-20, 2013.
- 2013 Stahl SM. Optimizing Care for Patients with Schizophrenia, Zagreb, Croatia, May 7, 2013.
- 2013 Stahl SM. Advancing the Care and Optimizing the Treatment, Dubai, UAE, May 10, 2013.

PRESENTATIONS AND ABSTRACTS (2)

- 2013 Stahl SM. Challenges and Opportunities in Schizophrenia Treatment. American Psychiatric Association Annual Meeting, San Francisco, CA May 19, 2013
- 2013 Stahl SM. Emerging Personalized Medicine in Mental Health: Targeting Treatments for Depression. American Psychiatric Association Annual Meeting, San Francisco, CA May 19, 2013.
- 2013 Stahl SM. Frontiers in Neuroscience, San Francisco, CA May 20, 2013.
- 2013 Stahl SM. What is a 21st Century Neurobiologically Empowered Psychiatrist? Lessons from Crime Scene Investigators. American Psychiatric Association Annual Meeting, San Francisco, CA May 21, 2013.
- 2013 Stahl SM. Mood Disorders: A Lifespan Perspective, honoring the contributions of Lewis L. Judd, M.D. May 23, 2013, San Diego, CA.
- 2013 Stahl SM. Neurobiological mechanisms mediating the treatment effect in bipolar Disorder. 3rd International Congress on Neurobiology and Psychopharmacology. Athens, Greece. Webcast May 31, 2013.
- 2013 Stahl SM. Stahl's Essential Psychopharmacology 4th Edition Master Course, Part 1, Carlsbad, CA June 7-9, 2013.
- 2013 Stahl SM. Master Class in Depression, Rio de Janeiro, Brazil, June 14, 2013.
- 2013 Stahl SM. Psychoses, Bipolar Disorders and Cardiometabolic Risk: Office Systems for Assessment and Treatment. Chicago, Illinois, June 25, 2013.
- 2013 (A-233) Maxwell NM, Nevin RL, Stahl SM, Block J, Shugarts S, Wu A, Dominy S, Alonso M, Blanco S, Kappelman-Culver S, Lee-Messer C and Maldonado J. A 16 Year Old Girl with Acute and Prolonged Psychosis following Chloroquine Toxicity and Polypharmacology: Utility of Personalized Pharmacogenetic Testing. Up Close and personalized Conference, Paris, France, July 25-28, 2013.
- 2013 (A-234) Burton B, Feigenbaum A, Grant M, Hendren R, Singh R, Stahl SM, Zhang C and Prasad S. Neuropsychiatric Outcomes in PKU Patients with ADHD Symptoms Treated with Sapropterin: Results from the Randomized Controlled PKU ASCEND Trial. 12th International Congress of Inborn Errors of Metabolism (ICIEM), September 3-6, 2013, Barcelona, Spain.
- 2013 Stahl SM. Depression: Deeper Evaluation of Symptoms and Neurobiology. Los Angeles, CA , September 17, 2013.
- 2013 Stahl SM. The Psychopharmacology of Violence. Orange County Psychiatric Association, Irvine, California, September 18, 2013.

PRESENTATIONS AND ABSTRACTS (3)

- 2013 Stahl SM. Stahl's Essential Psychopharmacology 4th Edition Master Course, Part 2, Carlsbad, CA Sept. 20-22, 2013.
- 2013 Stahl SM. NEI Psychopharmacology Clinical Update: Antipsychotics and ADHD. Carlsbad, CA September 27, 2013.
- 2013 Stahl SM. Treatment of Anxiety-Depression Continuum: Biological and Pharmacological Basis. ECNP Congress, Barcelona, Spain, October 7, 2013.
- 2013 Stahl SM. The new nomenclature in action: D2 antagonists and D2 partial agonist. ECNP Congress, Barcelona, Spain, October 7, 2013.
- 2013 Stahl SM. Depression – From Symptoms to Circuits – Disease State and Neurobiology. Depression Network Speaker Training, Chicago, Illinois, November 8-9, 2013
- 2013 Stahl SM. Bipolar Depression: Presentation, diagnosis and Treatment in the Outpatient Psychiatry Practice Setting. Chicago, Illinois, November 6, 2013.
- 2013 Stahl SM. It's Personal: Genotyping to Improve Patient Outcomes. NEI Psychopharmacology Congress, Colorado Springs, Colorado, November 14-17, 2013.
- 2013 Stahl SM. Looking to the Horizon: Novel Agents in Development for the Treatment Of Depression. NEI Psychopharmacology Congress, Colorado Springs, Colorado, November 14-17, 2013.
- 2013 Stahl SM. Impulsive and Compulsive Disorders. NEI Psychopharmacology Congress, Colorado Springs, Colorado, November 14-17, 2013.
- 2013 Stahl SM. Improving Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment. NEI Psychopharmacology Congress, Colorado Springs, Colorado, November 14-17, 2013.
- 2013 Stahl SM. Depression-From Symptoms to Circuits-Disease State and Neurobiology. Depression Network Speaker Training, Dallas, Texas, November 22-23, 2013.
- 2013 Stahl SM. Unveiling a new treatment option for MDD in Adults. Dallas, Texas, December 5, 2013.
- 2014 Stahl SM, Cutler A and Culpepper L. Illuminating Advances in the Treatment of Major Depressive Disorder. Satellite Broadcast, January 30, 2014.
- 2014 Stahl SM. Brintellix: Key Clinical Points. Las Vegas, Nevada, February 25, 2014.

PRESENTATIONS AND ABSTRACTS (4)

- 2014 Stahl SM. Master Class: Latest Advances in Psychopharmacology, Clare College, Cambridge, UK. April 3-5, 2014.
- 2014 Stahl SM. Neurosciences 277: Depression: Antidepressants, UCSD Resident Lecture , April 10, 2014.
- 2014 Stahl SM. Advances in Managing the Side Effects of Psychotropic Medications. American Psychiatric Association Annual Meeting, New York, New York, May 6, 2014.
- 2014 Stahl SM. Depression-From Symptoms to Circuits – Disease State and Neuro-Biology. Chicago, Illinois, June 13, 2014.
- 2014 Stahl SM. Depression – From Symptoms to Circuits – Disease State and Neuro-Biology. Dallas, Texas June 27, 2014.
- 2014 Stahl SM. An Update of Psychopharmacology, October 15, 2014. London, UK.
- 2014 Stahl SM. The New Mission of Forensic Mental Health Systems: Assessment and Treatment of Violence. October 17, 2014, Institute of Psychiatry, London, UK.
- 2014 Stahl SM. Aripiprazole Once Monthly and the paradigm shift in schizophrenia treatment. October 20, 2014, Berlin, Germany.
- 2014 Stahl SM. Pharmacology-based nomenclature: a joint ECNP, CINP, ACNP and AsCNP Task Force. From antipsychotic to D2 antagonists and D2 partial agonists. October 21, 2014, 27th ECNP Congress, Berlin, Germany.
- 2014 Stahl SM. Agomelatine: A Novel Antidepressant Exploiting Synergy between Monoaminergic and Melatonergic Properties, October 28, 2014. Satellite Presentation, Carlsbad, California.
- 2014 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia. November 3, 2014, London, UK.
- 2014 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia. November 5, 2014, Birmingham, UK.
- 2014 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia. November 6, 2014, Leicestershire, UK
- 2014 Stahl SM. Overview of Latuda (lurasidone) and Patient Case Studies. CMHP Satellite Broadcast, November 7, 2014, Leicestershire, UK.
- 2014 Stahl SM. Nature vs. Nurture: Epigenetics and Personalized Medicine. NEI Psychopharmacological Congress, November 13-16, 2014, Colorado Springs, CO.

PRESENTATIONS AND ABSTRACTS (5)

- 2014 Stahl SM. Binge Eating as an Impulsive-Compulsive Disorder: Neurobiological Links to Addiction. NEI Psychopharmacological Congress, November 13-16, 2014, Colorado Springs, CO.
- 2014 Stahl SM. Serotonin Receptors and Serotonergic Drugs. NEI Psychopharmacological Congress, November 13-16, 2014, Colorado Springs, CO.
- 2014 Warburton K and Stahl SM. Addressing agitation and Aggression in Patients with Mental Illness. NEI Psychopharmacological Congress, November 13-16, 2014, Colorado Springs, CO.
- 2014 (A-235) Koenig G, Townsend M, Stoiljkovic M, Leventhal L, Tang C, Hurst R, Piser T, Chen T, Hilt D, Majos M, Stahl S and Flood D. Bridging the gap between alpha-7 receptor priming and cognitive enhancement in the clinic and in pre-clinical animal models. ACNP 53rd Annual Meeting, December, 10, 2014, Phoenix, AZ.
- 2015 Stahl SM. Half Day Workshop on Forensic Violence, January 16, 2015, Worcester, MA.
- 2015 Stahl SM. Tricks of the Trade: Treatment of Resistant Mood, Anxiety or Psychotic Disorders. Psychopharmacology, 2015: A Master Class, April 24-25, 2015, Harvard Psychopharmacology Course, Boston, MA.
- 2015 Stahl SM. Differentiating BRINTELLIX: Clinical Perspectives, May 1, 2015, Chicago, IL.
- 2015 Stahl SM. Nature vs. Nurture: Epigenetics and Personalized Medicine, May 7, 2015, Abu Dhabi.
- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, May 26, 2015, Birmingham, UK
- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, May 26, 2015, Leeds, UK
- 2015 Stahl SM. Forensic Violence: Psychopharmacology, Carstairs High Security Hospital, May 28, 2015, Carstairs, Scotland.
- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, July 26, 2015, Bristol, UK
- 2015 Stahl SM, British Association of Psychopharmacology Satellite Symposium: Optimising care in Schizophrenia: The Challenge of Treating Early Non-Responders, July 27, 2015, Bristol, UK.
- 2015 Stahl SM. Psychopharmacology of Violence, Broadmoor High Security Hospital, July 28, 2015, Crowthorne, Berkshire, UK.

PRESENTATIONS AND ABSTRACTS (6)

- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, July 29, 2015, London, UK
- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, July 31, 2015, London, UK
- 2015 Stahl SM. New Developments in Schizophrenia Treatment: Emerging Role of D2 Partial Agonists. ECNP Congress, August 29 – September 1, 2015, Amsterdam, Holland.
- 2015 Stahl SM. Reducing Confusion Naming Antipsychotics: Pharmacology, Non-Clinical Target for Nomenclature. ECNP Congress, September 1, 2015, Amsterdam, Holland.
- 2015 Stahl SM. Department of State Hospitals: CAL – VAT (Violence Treatment) Guidelines, September 16, 2015, Western Psychiatric State Hospital Association, Provo, UT.
- 2015 Stahl SM. Schizophrenia Pharmacotherapy – Current Landscape, September 18, 2015, Dallas, TX.
- 2015 Stahl SM. Osher Lecture, Shell Shock, UCSD, October 15, 2015, San Diego, CA.
- 2015 Stahl SM. Overview of Psychopharmacology: Managing Antidepressants and Antidepressant Side Effects, UCSD, October 26, 2015, San Diego, CA.
- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia. November 4, 2015, Manchester, UK.
- 2015 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia. November 6, 2015, Belfast, Ireland.
- 2015 Stahl SM. Basic Neuroscience: From Circuits to Symptoms, NEI Psychopharmacological Congress, November 12-15, 2015, Orlando, FL.
- 2015 Stahl SM. One Neurotransmitter to Rule Them All: The Serotonin Network, NEI Psychopharmacological Congress, November 12-15, 2015, Orlando, FL.
- 2015 Stahl SM. Binge Eating and Other Eating Disorders, NEI Psychopharmacological Congress, November 12-15, 2015, Orlando, FL.
- 2015 Stahl SM. Shell Shock Lecture, NEI Psychopharmacological Congress, November 12-15, 2015, Orlando, FL.
- 2015 Stahl SM. Presentation on Gepirone Mechanism of Action, Gepirone FDA Advisory Committee Meeting, December 1, 2015, Washington, DC.

PRESENTATIONS AND ABSTRACTS (7)

- 2016 Stahl SM. Overview of Psychopharmacology and Managing Antipsychotic and Antidepressant Side Effect, UCSD Department of Psychiatry Grand Rounds, January 5, 2016, San Diego, CA.
- 2016 Stahl SM. Shell Shock Lecture, UCSD Department of Psychiatry Grand Rounds, January 14, 2016, San Diego, CA.
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, February 11, 2016, New York, NY.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology – Schizophrenia, February 20, 2016, Melbourne, Australia.
- 2016 Stahl SM. Stahl's Essentials on the Psychopharmacology of Valdoxan: A prescribers Guide, February 21, 2016, Melbourne, Australia.
- 2016 Stahl SM. Identification & Considerations in Pseudobulbar Affect (PBA), February 24, 2016, Los Angeles, CA.
- 2016 Stahl SM. Identification & Considerations in Pseudobulbar Affect (PBA), March 2, 2016, New York, NY.
- 2016 Stahl SM. Hope on the Horizon: An update to the Early Detection and Treatment of Alzheimer's Disease, March 5, 2016, Jersey City, NJ.
- 2016 Stahl SM. Dangerous Liaison: Understanding the Connection Between Violence and Mental Illness, March 6, 2016, Jersey City, NJ.
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, March 8, 2016, Los Angeles, CA.
- 2016 Stahl SM. Expert Panel – Mock Board for Pramipexole in Parkinson Disease Psychosis, March 16, 2016, San Diego, CA.
- 2016 Stahl SM. Innovative Treatment of Resistant Psychiatric Disorders, Psychopharmacology, 2016: A Master Class, April 1-2, 2016, Harvard Psychopharmacology Course Boston, MA.
- 2016 Stahl SM. NUEDEXTA Interactive Evening Symposium, April 12, 2016, Phoenix, AZ.
- 2016 Stahl SM. Neuropsychopharmacology Lecture on Antidepressants, UCSD, April 28, 2016, San Diego, CA.
- 2016 Stahl SM. NUEDEXTA Interactive Evening Symposium, May 3, 2016, Dallas, TX.

PRESENTATIONS AND ABSTRACTS (8)

- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, May 4, 2016, Dallas, TX.
- 2016 Stahl SM. Beyond Laughter & Tears: A Journey of Hope, APA, May 13, 2016, Atlanta, GA.
- 2016 Stahl SM. The Story Behind Going Global: Whither Medical Affairs, APA, May 13, 2016, Atlanta, GA.
- 2016 Stahl SM. David A. Mrazek Memorial Lecture and Award: Psychiatric Pharmacogenomics, APA, May 16, 2016, Atlanta, GA.
- 2016 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, May 16, 2016, Atlanta, GA.
- 2016 Stahl SM. Using Fiction to Tell the Story of Aktion T4, APA, May 16, 2016, Atlanta, GA.
- 2016 Stahl SM. Using Neuroscience Based Nomenclature to Classify Antipsychotics by Pharmacological Mechanisms, APA, May 17, 2016, Atlanta, GA.
- 2016 Stahl SM. Is it Depression or Something More, May 17, 2016, Atlanta, GA.
- 2016 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, May 17, 2016, Atlanta, GA.
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, May 18, 2016, New York, NY.
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, June 10, 2016, Chicago, IL.
- 2016 Stahl SM. The Neurotransmitter to Rule All: The Serotonin Network, June 25, 2016, Dallas, TX.
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, June 27, 2016, San Francisco, CA.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, July 14, 2016, Los Angeles, CA.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, July 18, 2016, Depew, NY.

PRESENTATIONS AND ABSTRACTS (9)

- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, July 19, 2016, Amherst, NY.
- 2016 Stahl SM. NUEDEXTA Interactive Evening Symposium, July 19, 2016, Pittsburgh, PA.
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, July 20, 2016, Philadelphia, PA.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, July 21, 2016, Allentown, PA.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, July 21, 2016, Philadelphia, PA.
- 2016 Stahl SM. Impulsion & Compulsions: Modern Neurochemistry and Pharmacological Approaches, August, 5, 2016, Sao Paulo, Brazil.
- 2016 Stahl SM. Biomarkers of Psychiatric Illnesses, August 6, 2016, Sao Paulo, Brazil.
- 2016 Stahl SM. Psychopharmacology of Traumatic Brain Injury, Camp Pendleton, Navy Psychiatry Department, August 26, 2016, Camp Pendleton, CA
- 2016 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, September 6, 2016, Baltimore, MD.
- 2016 Stahl SM. Future of Psychopharmacology: Is New Treatment Innovation Still Alive, Johns Hopkins Grand Rounds, September 6, 2016, Baltimore, MD.
- 2016 Stahl SM. Psychopharmacology of Violence, Northern Virginia Mental Health Institute, September 7, 2016, Falls Church, VA.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, September 7, 2016, Bethesda, MD.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, September 8, 2016, Orland Park, IL.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, September 8, 2016, Oaklawn, IL.

PRESENTATIONS AND ABSTRACTS (10)

- 2016 Stahl SM. Expert Neurology and Psychiatry Perspectives, September 8, 2016, Chicago, IL.
- 2016 Stahl SM. From Clinical to Functional Remission in Depression: How big is the Gap, ECNP, September, 18, 2016, Vienna, Austria.
- 2016 Stahl SM. What is New In Psychosis and How is that Reflected in Neuroscience Based Nomenclature, September 20, 2016, Vienna, Austria.
- 2016 Stahl SM. Expert Neurology and Psychiatry Perspectives: Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, September 27, 2016, San Francisco, CA.
- 2016 Stahl SM. Expert Neurology and Psychiatry Perspectives, October 6, 2016, New York, NY.
- 2016 Stahl SM. Treat the Mind, Respect the Body, October 21, 2016, Sydney, Australia.
- 2016 Stahl SM. Achieving Efficacy While Maintaining Neurological Side Effects in Patients with Psychiatric Illness, October 23, 2016, Sydney, Australia.
- 2016 Stahl SM. Shared Decision Making and Treating Strategy in Major Depressive Disorder, October 23, 2016, Sydney, Australia.
- 2016 Stahl SM. Treat the Mind, Respect the Body, October 25, 2016, Brisbane, Australia.
- 2016 Stahl SM. Future of Psychopharmacology: Is New Treatment Innovation Still Alive, PsychU Virtual Forum, November 1, 2016, Carlsbad, CA.
- 2016 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, November 2, 2016, Denver, CO.
- 2016 Stahl SM. Violent Means: When Mental Illness and Aggressive Behavior Collide, November 3, 2016, Colorado Springs, CO.
- 2016 Stahl SM. Opioid Therapy is Associated with Abuse and Misuse: Tips to Manage in Your Practice, November 3, 2016, Colorado Springs, CO.
- 2016 Stahl SM. Mood Disorders: A "Spectrum" Analysis, November 4, 2016, Colorado Springs, CO.
- 2016 Stahl SM. Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, November 7, 2016, Coral Gables, FL.

PRESENTATIONS AND ABSTRACTS (11)

- 2016 Stahl SM. Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, November 8, 2016, Miami, FL.
- 2016 Stahl SM. Innovative Treatments for Resistant Psychiatric Disorders, Tricks of the Trade, University of Miami, Grand Rounds, November 9, 2016, Miami, FL.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, November 11, 2016, Stockholm, Sweden.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, November 14, 2016, Lausanne, Switzerland.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, November 16, 2016, Lucerne, Switzerland.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, November 18, 2016, Dundee, Scotland.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, November 21, 2016, London, UK.
- 2016 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, November 23, 2016, Glasgow, Scotland.
- 2017 Stahl SM. Arbor Pharmaceuticals Unbranded ADHD Videos, January 3, 2017, Carlsbad, CA
- 2017 Stahl SM. Valdoxan's Efficacy on Functional Remission: The Point of View of the Pharmacologist, International Webinar, January 18, 2017, Carlsbad, CA
- 2017 Stahl SM. Using Atypical Antipsychotic Receptor Pharmacology Principles to Guide Switching to Pimavanserin, January 20, 2017, San Diego, CA
- 2017 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, January 25, 2017, Los Angeles, CA
- 2017 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, February 1, 2017, Las Vegas, NV
- 2017 Stahl SM. One Neurotransmitter to Rule Them All: The Serotonin Network, February 18, 2017, Lisbon, Portugal
- 2017 Stahl SM. Combining Serotonergic Antidepressant Mechanisms to Attain Best Outcomes, February 18, 2017, Lisbon, Portugal

PRESENTATIONS AND ABSTRACTS (12)

- 2017 Stahl SM. Pharmacotherapy for PTSD and Its Comorbidities, International Society for the Study of Women's Sexual Health, February 23, 2017, Atlanta, GA
- 2017 Stahl SM. Psychopharmacology of Tardive Dyskinesia, Teva Advisory Board, February 25, 2017, Atlanta GA
- 2017 Stahl SM. Opioid Pharmacology: Mu and Kappa, March 3, 2017, Boston, MA
- 2017 Stahl SM. More Than Just Mood – The Neurobiology of Major Depressive Disorder, Pain, and Antidepressant Action, March 11, 2017, Yokohama, Japan
- 2017 Stahl SM. More Than Just Mood – The Neurobiology of Major Depressive Disorder, Pain, and Antidepressant Action, March 12, 2017, Tokyo, Japan
- 2017 Stahl SM. Depression, Japan Web Lecture and Video, March 13, 2017, Tokyo, Japan
- 2017 Stahl SM. Symptoms, Circuits, Neurotransmitters and the Antipsychotic Armamentarium, Janssen International Webinar, Portugal, March 15, 2017, San Diego, CA
- 2017 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, March 16, 2017, Chicago, IL
- 2017 Stahl SM. An Effective Treatment Option for Adults with Schizophrenia and Acute Manic or Mixed Episodes Associated with Bipolar I Disorder, March 16, 2017, Rosemont, IL
- 2017 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, March 24, 2017, Santa Barbara, CA
- 2017 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, March 24, 2017, Santa Barbara, CA
- 2017 Stahl SM. Serotonin Receptor Pharmacology, ACADIA Speaker Training, April 1, 2017, Dallas, TX
- 2017 Stahl SM. All day course on psychopharmacology for psychiatric residents, Shepherd Pratt, April 6, 2017, Baltimore, MD
- 2017 Stahl SM. The Future of Psychopharmacology: Is Pharmacogenomics Relevant? Psychopharmacology, 2017: A Master Class, April 7-8, 2017, Harvard Psychopharmacology Course Boston, MA.
- 2017 Stahl SM. Serotonin Receptor Pharmacology, ACADIA Speaker Training, April 8, 2017, Denver, CO

PRESENTATIONS AND ABSTRACTS (13)

- 2017 Stahl SM. Parkinson's Disease Psychosis, New York, NY
- 2017 Stahl SM. Neuronal Networks in ADHD, Shire Scout Expert Meeting, April 15, 2017, Boston, MA
- 2017 Stahl SM. One Neurotransmitter to Rule Them All: The Serotonin Network, UCSD Grand Rounds, April 27, 2017, San Diego, CA
- 2017 Stahl SM. Addressing Aggression in Patients with Mental Illness, UCSD Case Conference, April 27, 2017, San Diego, CA
- 2017 Stahl SM. Depression Network, Takeda Speaker Training, April 29, 2017, Dallas, TX
- 2017 Stahl SM. Eating Disorders, NEI Synapse, May 5, 2017, Washington, DC
- 2017 Stahl SM. So You Think It's Depression? Making a Differential Diagnosis, NEI Synapse, May 6, 2017, Washington, DC
- 2017 Stahl SM. Treatment Strategies for Mixed Depression, NEI Synapse, May 6, 2017, Washington, DC
- 2017 Stahl SM. Dementia, NEI Synapse, May 7, 2017, Washington, DC
- 2017 Stahl SM. Using Neuroscience Based Nomenclature to Classify Drugs for Psychosis by Pharmacological Mechanisms, Presidential Session, APA, May 20, 2017, San Diego, CA
- 2017 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, APA, May 21, 2017, San Diego, CA
- 2017 Stahl SM. Treatment Advances in Parkinson's Disease Psychosis: Transforming the Standard of Care for Hallucinations and Delusions, APA, May 23, 2017, San Diego, CA
- 2017 Stahl SM. Treatment Lab: To Treat or Not to Treat, APA, May 23, 2017, San Diego, CA
- 2017 Stahl SM. Pharmacology Concepts Underlying the Use of Medications for Psychosis, Indian Psychiatric Association, May 27, 2017, New Delhi, India
- 2017 Stahl SM. How to Use Medications for Psychosis in Clinical Practice Including Combinations and Augmentation Strategies, Indian Psychiatric Association, May 28, 2017, New Delhi, India
- 2017 Stahl SM. ACADIA Video shoot, Parkinson's Psychosis, June 2, 2017, Carlsbad, CA

PRESENTATIONS AND ABSTRACTS (14)

- 2017 Stahl SM. Shell Shock Lecture, Brain Behavior and Emotion Congress, June 14, 2017, Porto Alegre, Brazil
- 2017 Stahl SM. Strategies of the Treatment of Refractory Depression, Brain Behavior and Emotion Congress, June 15, 2017, Porto Alegre, Brazil
- 2017 Stahl SM. Pressing Interfaces Between Neurology and Psychiatry, Brain Behavior and Emotion Congress, June 16, 2017, Porto Alegre, Brazil
- 2017 Stahl SM. Are All Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) the Same? Brain Behavior and Emotion Congress, June 16, 2017, Porto Alegre, Brazil
- 2017 Treatment of Violence: Rational Targeting of Symptoms in Circuits Utilizing High Dosing and Polypharmacy for Treatment Resistance, Department of State Hospitals, June 18, 2017, Sacramento, CA
- 2017 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, June 26, 2017, Bern, Switzerland
- 2017 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, June 28, 2017, Zwolle, Netherlands
- 2017 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, June 30, 2017, Amsterdam, Netherlands
- 2017 Stahl SM. Deuteration for CNS Compounds, Concert Advisory Board, July 11, 2017, Boston, MA
- 2017 Stahl SM. Tardive Dyskinesia, Teva Ad Board, July 14-15, 2017, Houston, TX
- 2017 Stahl SM. Great debates on optimizing treatment for major depressive disorder, Expert Science Exchange, September 3, 2017, ECNP, Paris, France
- 2017 Stahl SM. The Depressed Patient's Perspective in Achieving Remission, Servier Satellite Symposium, September 3, 2017, ECNP, Paris, France
- 2017 Stahl SM. Managing Serotonergic Antidepressant Mechanisms to Attain Best Outcomes, September 15, 2017, Bern, Switzerland
- 2017 Stahl SM. One Neurotransmitter to Rule Them All: The Serotonin Network, September 15, 2017, Bern, Switzerland
- 2017 Stahl SM. Serotonin Network, Grand Rounds, University of Zurich, September 16, 2017, Zurich, Switzerland
- 2017 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, September 26, 2017, Helsinki, Finland

PRESENTATIONS AND ABSTRACTS (15)

- 2017 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, September 28, 2017, Oslo, Norway
- 2017 Stahl SM. Expert Seminar in Psychopharmacology: Schizophrenia, October 2, 2017, Copenhagen, Denmark
- 2017 Stahl SM. Future of Psychopharmacology: Is New Treatment Innovations Dead or Alive? October 3, 2017, Copenhagen, Denmark
- 2017 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, October 10, 2017, Boston, MA
- 2017 Stahl SM. Effective Message Delivery: Using Communication Science to Tell the Medical Education Story, Alkermes, October 11, 2017, Boston, MA
- 2017 Stahl SM. Parkinson's Disease Psychosis, October 12, 2017, Boston, MA
- 2017 Stahl SM. Tardive Dyskinesia and Pharmacology of VMAT 2 Inhibitors, Teva Speaker Training, October 13, 2017, Salt Lake City, Utah
- 2017 Stahl SM. ABILIFY MAINTENA As a Maintenance Monotherapy Treatment Option for Adults with Bipolar Disorder, October 25, 2017, Los Angeles, CA
- 2017 Stahl SM. ABILIFY MAINTENA As a Maintenance Monotherapy Treatment Option for Adults with Bipolar Disorder, October 26, 2017, Phoenix, AZ
- 2017 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, November 1, 2017, Atlanta, GA
- 2017 Stahl SM. Recognition of Inadequate Treatment Response in Major Depressive Disorder (MDD) and a Potential Option for Adjunctive Therapy, November 2, 2017, New York, NY
- 2017 Stahl SM. Role of 5H2A Receptors in the Pharmacology of Alzheimer's Disease Psychosis, Clinical Trials in Alzheimer's Disease Meeting, November 3, 2017, Boston, MA
- 2017 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, November 7, 2017, Dallas, TX
- 2017 Stahl SM. What to Do When Nothing Else Works, NEI Congress, November 9, 2017, Colorado Springs, CO
- 2017 Stahl SM. The Age of Personalized Medicine: The Role of Pharmacogenetics, NEI Congress, November 9, 2017, Colorado Springs, CO

PRESENTATIONS AND ABSTRACTS (16)

- 2017 Stahl SM. Differential Diagnosis of Depressive States, NEI Congress, November 10, 2017, November 10, 2017, Colorado Springs, CO
- 2017 Stahl SM. Successful Aging as the Brain Changes: This is Your Brain on Life, NEI Congress, November 10, 2017, Colorado Springs, CO
- 2017 Stahl SM. Recognition of Inadequate Treatment Response in Major Depressive Disorder (MDD) and a Potential Option for Adjunctive Therapy, November 15, 2017, Los Angeles, CA
- 2017 Stahl SM. Shell Shock, University of Pisa, Italy, November 21-November 27, 2017
- 2017 Stahl SM. The Future of Psychopharmacology: Is Treatment Innovation Dead or Alive? Italian Mental Health Research Foundation, Lucca, Italy, November 27, 2017
- 2017 Stahl SM. Recognition of Inadequate Treatment Response in Major Depressive Disorder (MDD) and a Potential Option for Adjunctive Therapy, November 28, 2017, Philadelphia, PA
- 2017 Stahl SM. ABILIFY MAINTENA As a Maintenance Monotherapy Treatment Option for Adults with Bipolar Disorder, November 29, 2017, New York, NY
- 2017 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, December 5, 2017, Palm Desert, CA
- 2017 Stahl SM. Efficacy of Cariprazine in Patients with Bipolar Depression and Mixed Features: Post Hoc Analysis of a Randomized, Double-blind, Placebo-Controlled Phase II Trial, American College of Neuropsychopharmacology Meeting, December 6, 2017, Palm Desert, CA
- 2018 Stahl SM. Basic Neuroscience of Neurotransmitter Neural Networks: Using the Serotonin Network as an Example of How One Neurotransmitter Can Rule Them All, January 27, 2018, Southern California Psychiatric Association branch of the American Psychiatric Association, Los Angeles, CA
- 2018 Stahl SM. Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis, February 8, 2018, San Diego, CA
- 2018 Stahl SM. Treatment Resistant Psychosis, Napa State Hospital, January 30, 2018, Napa, CA
- 2018 Stahl SM. Role of Serotonin in Psychosis, Virtual Advisory Board, February 2, 2018, San Diego, CA
- 2018 Stahl SM. Parkinson's Disease Psychosis, February 8, 2018, La Jolla, CA

PRESENTATIONS AND ABSTRACTS (17)

- 2018 Stahl SM. Advances in Managing the Side Effects of Antipsychotics, February 19, 2018, Brisbane, Australia
- 2018 Stahl SM. Advances in Managing the Side Effects of Antipsychotics, February 20, 2018, Sydney, Australia
- 2018 Stahl SM. Advances in Managing the Side Effects of Antipsychotics, World Psychiatric Association Meeting, February 22, 2018, Melbourne, Australia
- 2018 Stahl SM. Famine or Feast? The New Generation of Antipsychotic Treatments, World Psychiatric Association Meeting, February 26, 2018, Melbourne, Australia.
- 2018 Stahl SM. Does a “Whiff” Mean Treatment with an Atypical Antipsychotic and Not an Antidepressant? World Psychiatric Association Meeting, February 26, 2018, Melbourne, Australia
- 2018 Stahl SM. Switching Antipsychotics, World Psychiatric Association Meeting, World Psychiatric Association Meeting, February 26, 2018, Melbourne, Australia
- 2018 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, March 8, 2018, Los Angeles, CA
- 2018 Stahl SM. Neuropharmacology of Anxiety Disorders, European Webcast to Brazil, March 8, 2018
- 2018 Stahl SM. Neuropharmacology of Psychosis, March 9, 2018, Denver, CO
- 2018 Stahl SM. Beyond Serotonin: The Serotonin Network Shows How Each Transmitter Rules Them All, Turkish Psychiatry Summit, March 17, 2018, Antalya, Turkey
- 2018 Stahl SM. What Do You Do When Nothing Else Works? Turkish Psychiatry Summit, March 17, 2018, Antalya, Turkey
- 2018 Stahl SM. How to Switch Antipsychotics, Turkish Psychiatry Summit, March 17, 2018, Antalya, Turkey
- 2018 Stahl SM. Comparing the Pharmacology and Clinical Perspective of Antipsychotics: Which One Should You Choose? March 18, 2018, Ismir, Turkey
- 2018 Stahl SM. Comparing the Pharmacology and Clinical Perspective of Antipsychotics: Which One Should You Choose? March 19, 2018, Ankara, Turkey
- 2018 Stahl SM. Comparing the Pharmacology and Clinical Perspective of Antipsychotics: Which One Should You Choose? March 20, 2018, Istanbul, Turkey
- 2018 Stahl SM. Depression, Its Impact, and the Importance of Recognition and Treatment, March 28, 2018, Los Angeles, CA

PRESENTATIONS AND ABSTRACTS (18)

- 2018 Stahl SM. UCSD Grand Rounds, Adult ADHD, April 12, 2018, La Jolla, CA
- 2018 Stahl SM. Neuropharmacology of Dementia, April 13, 2018, Denver, CO
- 2018 2018 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, April 18, 2018, Tampa, FL
- 2018 Stahl SM. Neurobiology for the Practicing Clinician, Psychopharmacology, 2018: A Master Class, Harvard Psychopharmacology Course, April 20, 2018, Boston, MA
- 2018 Stahl SM. Newer “Trick of the Trade”; What to do When Nothing Works for Treatment Resistant Psychiatric Disorders, Psychopharmacology, 2018: A Master Class, Harvard Psychopharmacology Course, April 20, 2018, Boston, MA
- 2018 Stahl SM. Losing a Patient to Suicide: A Panel Discussion, NEI Synapse, April 22, 2018, Las Vegas, NV
- 2018 Stahl SM. OMG-enomics! When Psychopharmacology Gets Personal, NEI Synapse, April 22, 2018, Las Vegas, NV
- 2018 Stahl SM. Efficacy of Cariprazine in Patients With Bipolar Depression and Mixed Features: Post Hoc Analysis of a Randomized, Double-blind, Placebo-Controlled Phase II Trial, CPNP, April 22-25, 2018, Indianapolis, IN.
- 2018 Stahl SM. Mechanism of Action of Dextromethorphan – Bupropion Combination, April 24, 2018, New York, NY
- 2018 Stahl SM. Rationale for Dextromethorphan – Bupropion Combination in Alzheimer’s Agitation and Treatment Resistant Depression, April 28, 2018, Phoenix, AZ
- 2018 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, May 3, 2018, Nashville, TN
- 2018 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, American Psychiatric Association Annual Meeting, May 5, 2018, New York, NY
- 2018 Stahl SM. DAT’s So Cool! Balancing Neuronal NET-works in ADHD, American Psychiatric Association Annual Meeting, May 6, 2018, New York, NY
- 2018 Stahl SM. A Personalized Approach to the Treatment of Depression and Anxiety Based on Symptom Profiles, May 8, 2018, New York, NY
- 2018 Stahl SM. Translating Experience from other Neuropsychiatric Disorders, May 12, 2018, Montreal, Canada
- 2018 Stahl SM. Mood Disorders: A Spectrum Analysis, UCSD Lecture, May 22, 2018, San Diego, CA

PRESENTATIONS AND ABSTRACTS (19)

- 2018 Stahl SM. An Update on the Cognitive Deficits of Depression, WebEx, May 23, 2018, San Diego, CA
- 2018 Stahl SM. An Update on the Cognitive Deficits of Depression, WebEx, May 31, 2018, San Diego, CA
- 2018 Stahl SM. Neuropharmacology of Tardive Dyskinesia, June 1, 2018, Dallas, TX
- 2018 Stahl SM. Neurobiology and Treatment of Resistance, DSH Mental Health Forum, June 7, 2018, Sacramento, CA
- 2018 Stahl SM. More Than Just Mood – The Neurobiology of Major Depressive Disorder, Pain and Antidepressant Action, June 22, 2018, Porto Alegre, Brazil
- 2018 Stahl SM. What Do You Do for Treatment Resistance in Psychiatry: When Nothing Works and Nothing is Tolerated, June 22, 2018, Porto Alegre, Brazil
- 2018 Stahl SM. Pharmacology of Antipsychotics and Introducing Lurasidone, June 22, 2018, Porto Alegre, Brazil
- 2018 Stahl SM. The Curious Case of Dopamine and Its Receptors, June 23, 2018, Porto Alegre, Brazil
- 2018 Stahl SM. Optimizing Care for Patients with Schizophrenia, June 30, 2018, Bucharest, Romania
- 2018 Stahl SM. How to Improve the Chances of a Complete Recovery in Depression: Good Pharmacology and Bad Math, July 1, 2018, Madrid, Spain
- 2018 Stahl SM. Parkinson's Disease Psychosis, July 30, 2018, Solana Beach, CA
- 2018 Stahl SM. Treatment Resistant Depression, DSH Patton, August 21-23, 2018, Patton, CA
- 2018 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, September 5, 2018, Seattle, WA
- 2018 Stahl SM. An Adjunctive Treatment Option for Adult Patients With Major Depressive Disorder (MDD) With an Inadequate Response to Antidepressants, September 6, 2018, Chicago, IL
- 2018 Stahl SM. The Path to Recovery in Major Depressive Disorder; Role of Efficacy Tolerability and How to Switch and Combine Antidepressant Mechanisms, September 17, 2018, Capetown, South Africa
- 2018 Stahl SM. Combining Mechanisms of Action to Target Cognitive Impairment in Major Depressive Disorder, September 22, 2018, Pretoria, South Africa

PRESENTATIONS AND ABSTRACTS (20)

- 2018 Stahl SM. Beyond Serotonin: The Serotonin network Shows How Each Neurotransmitter Rules Them All, September 22, 2018, Pretoria, South Africa
- 2018 Stahl SM. Mood Disorders: A Spectrum Analysis, September 22, 2018, Pretoria, South Africa
- 2018 Stahl SM. New Drugs and New Concepts in the Second Edition of Neuroscience Based Nomenclature, European College of Neuropsychopharmacology, October 7, 2018, Barcelona, Spain
- 2018 Stahl SM. Pathways to Recovery: Matching Symptoms with Brain Circuits for Personalized Treatment of Major Depressive Disorder, European College of Neuropsychopharmacology, October 7, 2018, Barcelona, Spain
- 2018 Stahl SM. Dopamine Antagonists or Partial Antagonists: Which to Favor and the Role of Dopamine Receptor Subtypes, European College of Neuropsychopharmacology, Barcelona, Spain, October 7, 2018
- 2018 Stahl SM. Comparing the Pharmacology and Pharmacokinetics of Antipsychotics: Choosing and Antipsychotic Dosing in Long Acting Injectables, Laza Lazarevic National Congress of Hospital Psychiatry, October 11, 2018, Belgrade, Serbia
- 2018 Stahl SM. An Adjunctive Treatment Option for Adult Patients With Major Depressive Disorder (MDD) With an Inadequate Response to Antidepressants, October 22, 2018, Houston, TX
- 2018 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, October 23, 2018, New Orleans, LA
- 2018 Stahl SM. Emerging Mechanisms and Treatments of Depression, American Psychiatric Nurses Association Annual Meeting, October 24, 2018, Columbus, OH
- 2018 Stahl SM. The Future of Psychopharmacology, Atascadero State Hospital, October 30, 2018, Atascadero, CA
- 2018 Stahl SM. Spotlight on Serotonin: Serotonin Dysfunction in Parkinson's Disease and Psychosis, November 5, 2018, Seattle, WA
- 2018 Stahl SM. Anxiety Disorders in Children, NEI Child and Adolescent Academy, Congress, November 7, 2018, Orlando, FL
- 2018 Stahl SM. Psychosis in Children, NEI Child and Adolescent Academy, NEI Congress, November 7, 2018, Orlando, FL
- 2018 Stahl SM. Alcohol Use Disorder: Treatment in the Context of Mental Illness, NEI Congress, November 8, 2018, Orlando, FL

PRESENTATIONS AND ABSTRACTS (21)

- 2018 Stahl SM. Modifiable Risk Factors and Early Detection: The Sight, Smell, Sound, Taste, and Touch of Dementia, NEI Congress, November 8, 2018, Orlando, FL
- 2018 Stahl SM. Avoiding Nursing Home Placement: Treatment of Secondary Behavioral Symptoms of Dementia, NEI Congress, November 8, 2018, Orlando, FL
- 2018 Stahl SM. Keeping up With the Clinical Advances: Depression, NEI Congress, November 8, 2018, Orlando, FL
- 2018 Stahl SM. From Unipolar to Bipolar to Mixed: Update on Mood Disorders and Their Treatments, November 19, 2018, Lucca, Italy
- 2018 Stahl SM. The Future of Psychiatry: How Precision Medicine Will Personalize the Selection of a Treatment for Each Individual, November 21, 2018, address at the Italian Parliament, Rome, Italy
- 2018 Stahl SM. One Neurotransmitter to Rule Them All: The Serotonin Network, November 22, 2018, Vatican University, Rome, Italy
- 2018 Stahl SM. From Unipolar to Bipolar to Mixed: Update on Mood Disorders and Their Treatments, November 23, 2018, Sicily, Italy
- 2018 Stahl SM. Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features: Results of a 12-Week Open Label Extension Study, Society of Mental Health Research Annual Conference, November 28-30, 2018, Queensland, Australia
- 2018 Stahl SM. Cariprazine Efficacy in Bipolar I Depression with and Without Concurrent Manic Symptoms: Post Hoc Analysis of 3 Randomized, Placebo-Controlled Studies, ACNP, December 2, 2018, Hollywood, FL
- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors: Learning about D3 and D1 receptors as well as D2 receptors and their clinical relevance, Napa State Hospital, January 16, 2019, Napa, CA
- 2019 Stahl SM. Primavanserin Mechanism of Action and Mechanism of Disease, ACADIA Advisory Board, January 21, 2019, San Diego, CA
- 2019 Stahl SM. What to Do When Nothing Works, UCSD Grand Rounds, January 24, 2019, San Diego, CA
- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors: Learning about D3 and D1 receptors as well as D2 receptors and their clinical relevance, Coalinga State Hospital, January 29, 2019, Coalinga, CA

PRESENTATIONS AND ABSTRACTS (22)

- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors: Learning about D3 and D1 receptors as well as D2 receptors and their clinical relevance, Atascadero State Hospital, January 30, 2019, Atascadero, CA
- 2019 Stahl SM. Achieving Recovery in Opioid Use Disorder: A Guide to Prescribing Medication Assisted Treatment, Grand Rounds, California Department of State Hospital, February 6, 2019, Sacramento, CA
- 2019 Stahl SM. PTSD: Pathophysiology and Psychopharmacologic Targets, Otsuka / Lundbeck Advisory Board, February 8, 2019, New York, NY
- 2019 Stahl SM. Pathophysiology of Tardive Dyskinesia, Teva Speaker Training, February 12, Las Vegas, NV
- 2019 Stahl SM. Dopamine, serotonin and glutamate hypotheses for psychosis in Alzheimer's, Parkinson's and Schizophrenia, Patton State Hospital, February 19, 2019, Patton, CA
- 2019 Stahl SM. Dopamine, serotonin and glutamate hypotheses for psychosis in Alzheimer's, Parkinson's and Schizophrenia, Metro State Hospital, February 21, 2019, Los Angeles, CA
- 2019 Stahl SM. Antipsychotics and Their Usage – Schizophrenia, Major Depressive Disorder, and Bipolar Disorder, Neuroscience Education Institute Synapse, February 12, 2019, Las Vegas, NV
- 2019 Stahl SM. EPS and TD from the Psychiatrist's Perspective, Neuroscience Education Institute Synapse, February 12, 2019, Las Vegas, NV
- 2019 Stahl SM. Tardive Dyskinesia in Different Settings of Care, Neuroscience Education Institute Synapse, February 12, 2019, Las Vegas, NV
- 2019 Stahl SM. Dopamine, serotonin and glutamate hypotheses for psychosis in Alzheimer's, Parkinson's and Schizophrenia, Patton State Hospital, February 19, 2019, San Bernardino, CA
- 2019 Stahl SM. Dopamine, serotonin and glutamate hypotheses for psychosis in Alzheimer's, Parkinson's and Schizophrenia, Metropolitan State Hospital, February 20, 2019, Norwalk, CA
- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, February 28, 2019, Chandler, AZ
- 2019 Stahl SM. Keeping Up with the Clinical Advances I: Treatment of Depression, March 16, 2019, Antalya, Turkey

PRESENTATIONS AND ABSTRACTS (23)

- 2019 Stahl SM. Keeping Up with the Clinical Advances II: Treatment of Schizophrenia, March 16, 2019, Antalya, Turkey
- 2019 Stahl SM. Case Challenges for Chronic Mental Disorders, March 16, 2019, Antalya, Turkey
- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, March 26, 2019, Louisville, KY
- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, March 27, 2019, Lansing, MI
- 2019 Stahl SM. Psychopharmacological Treatment of the Difficult to Treat Patients with OCD and Borderline Personality Disorder, Psychopharmacology, 2019: A Master Class, Harvard Psychopharmacology Course, March 29, 2019, Boston, MA
- 2019 Stahl SM. Newest “Tricks of the Trade”: What To Do When Nothing Works For the Treatment of Resistant Psychiatric Disorders, Psychopharmacology, 2019: A Master Class, Harvard Psychopharmacology Course, March 29, 2019, Boston, MA
- 2019 Stahl SM. Where Serotonin Ends: Novel Mechanisms of Antidepressants, NEI Synapse, April 26, 2019, Asheville, NC
- 2019 Stahl SM. Does DSM5 Adequately Capture Depression with Mixed Features, NEI Synapse, April 26, 2019, Asheville, NC
- 2019 Stahl SM. Tardive Dyskinesia, Teva Webcast, May 13 – 15, 2019
- 2019 Stahl SM. When Why and How to Integrate Pharmacogenetics Testing into Clinical Practice, American Psychiatric Association Annual Meeting, Genomind, May 17, 2019, San Francisco, CA
- 2019 Stahl SM. Exploring the Role of Norepinephrine in Modulating Dopamine and Serotonin active in Symptoms of Major Depressive Disorder, Schizophrenia and Bipolar Disorder, American Psychiatric Association Annual Meeting, May 19, 2019, San Francisco, CA
- 2019 Stahl SM. What Does Precision Medicine Promise for Psychiatric Treatment? American Psychiatric Association Annual Meeting, May 20, 2019, San Francisco, CA
- 2019 Stahl SM. Psychopharmacology and Ethnicity, American Psychiatric Association Annual Meeting, May 20, 2019, San Francisco, CA
- 2019 Stahl SM. Cariprazine Efficacy in Patients With Bipolar Depression and Concurrent Manic Symptoms, American Psychiatric Association Annual Meeting, May 21, 2019, San Francisco, CA

PRESENTATIONS AND ABSTRACTS (24)

- 2019 Stahl SM. Parkinson's Disease Psychosis, May 21, 2019, San Francisco, CA
- 2019 Stahl SM: Dopamine, Serotonin and Glutamate - Hypotheses for psychosis in Alzheimer's, Parkinson's and Schizophrenia, Congress on Brain Behavior and Emotions, June 7, 2019, Brasilia, Brazil
- 2019 Stahl SM: Long-acting Injectable Antipsychotics: Shall the Last Be First, Congress on Brain Behavior and Emotions, June 7, 2019, Brasilia, Brazil
- 2019 Stahl SM: New Evidence of desvenlafaxine, Congress on Brain Behavior and Emotions, June 8, 2019, Brasilia, Brazil
- 2019 Stahl SM. Psychopharmacology of Diversion from the Criminal Justice System, DSH Forum, June 11, 2019, San Francisco, CA
- 2019 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, Allergan Faculty Training, June 15, 2019, Miami, FL
- 2019 Stahl SM. Cariprazine in Bipolar Depression, Allergan VRAYLAR Launch Sales Meeting, June 18, 2019, Miami, FL
- 2019 Stahl SM. Cariprazine in Bipolar Depression, Allergan Speaker Training, June 22, 2019, Miami, FL
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, June 24, 2019, Bethesda, MD
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, June 25, 2019, Nashville, TN
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, July 8, 2019, New Orleans, LA
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, July 9, 2019, Las Vegas, NV
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, July 11, 2019, San Francisco, CA
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, July 15, 2019, Boston, MA
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, July 16, 2019, St. Louis, MO

PRESENTATIONS AND ABSTRACTS (25)

- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, July 18, 2019, Columbus, OH
- 2019 Stahl SM. Engage in a Case Through Problem-Based Learning Full-time Student Struggles Day-to-Day, July 23, 2019, Houston, TX
- 2019 Stahl SM. Engage in a Case Through Problem-Based Learning Full-time Student Struggles Day-to-Day, July 24, 2019, Tampa, FL
- 2019 Stahl SM. Engage in a Case Through Problem-Based Learning Full-time Student Struggles Day-to-Day, July 25, 2019, Boston, MA
- 2019 Stahl SM. NbN Neuroscience Based Nomenclature and Medications for Psychosis, ECNP, September 8, 2019, Copenhagen, Denmark
- 2019 Stahl SM. Meet the Expert, Managing MDD Better, ECNP, September 9, 2019, Copenhagen, Denmark
- 2019 Stahl SM. Targeting Mental Health Disorders to Reduce the Burden of Non-Communicable Diseases, ECNP, September 9, 2019, Copenhagen, Denmark
- 2019 Stahl SM: Transition in Schizophrenia: Symptoms, Treatment and Diagnostis Challenges from Adolescence to Adulthood, ECNP, September 9, 2019, Copenhagen, Denmark
- 2019 Stahl SM. Norepinephrine in Major Depression and Schizophrenia, October 1, Minneapolis, MN
- 2019 Stahl SM. Norepinephrine in Major Depression and Schizophrenia, October 2, Columbus, OH
- 2019 Stahl SM. Understanding Depression Treatment: From Mechanism to Clinical Practice, Asian College of Neuro-Psychopharmacology, October, 11, 2019, Fukuoka, Japan
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, October 17, 2019, Chicago, IL
- 2019 Stahl SM. Bipolar Spectrum, Diagnosis and Treatment, From Mania to Depression and Mixed Features in Between: Don't Use Antidepressants to Treat Depression? University of California, San Diego, October 24, 2019, San Diego, CA
- 2019 Stahl SM. Two Cases: Treatment Resistant OCD and Treatment Resistant Borderline Personality Disorder: What To Do When Nothing Works, University of California, San Diego, October 24, 2019, San Diego, CA

PRESENTATIONS AND ABSTRACTS (26)

- 2019 Stahl SM. Three Theories of Psychosis in the Modern Era: Not Just Dopamine, But Serotonin and Glutamate, University of California, San Diego, October 24, 2019, San Diego, CA
- 2019 Stahl SM. Psychiatric Pharmacogenomics: Cutting Edge, Ahead of its Time or 21st Century Psychiatric Snake Oil? University of California, San Diego, October 24, 2019, San Diego, CA
- 2019 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, November 5, 2019, Denver, CO
- 2019 Stahl SM. Make No Mix-Take: Depression and Mixed Features in Children and Adolescents, Neuroscience Education Institute Annual Meeting, November 6, 2019, Colorado Springs, CO
- 2019 Stahl SM. Goodnight Brain: The Science of Healthy Sleep, Neuroscience Education Institute Annual Meeting, November 7, 2019, Colorado Springs, CO
- 2019 Stahl SM. More Than Meets the Eye: Diagnosing and Treating Bipolar Depression, Neuroscience Education Institute Annual Meeting, November 7, 2019, Colorado Springs, CO
- 2019 Stahl SM. A Premier on Complementary and Alternative Medicine for Peripartum Depression, Neuroscience Education Institute Annual Meeting, November 8, 2019, Colorado Springs, CO
- 2019 Stahl SM. Neuropharmacology of Mental Energy, November 20, 2019, Phoenix, AZ
- 2019 Stahl SM. Brazil Webinar: Differentiating Second Generation Antipsychotics from First Generation Antipsychotics, November 25, 2019
- 2019 Stahl SM. Evil, Terrorism & Psychiatry: The T4 Project, The European University of Rome and the Vatican University, December 9, 2019
- 2020 Stahl SM. Dopamine and Its Receptors and Circuits, Grand Rounds, UC Riverside, January 3, 2020
- 2020 Stahl SM. Long Acting Injectable Anti-Psychotics for Diversion, Los Angeles County Jail, January 15, 2020
- 2020 Stahl SM. Acadia Dementia Related Psychosis Video, January 20, 2020
- 2020 Stahl SM. Neurobiology of Depression: What is New, Mexico City, January 30, 2020
- 2020 Stahl SM. The Bipolar Spectrum, Athens, Greece, February 15, 2020

PRESENTATIONS AND ABSTRACTS (27)

- 2020 Stahl SM. One Neurotransmitter to Rule them All. Lecture in Spain, February 21, 2020
- 2020 Stahl SM. NEI Train the Trainer, February 28-29, 2020
- 2020 Stahl SM. Tardive Dyskinesia and the Mechanism of Action of VMAT2 Inhibitors, Austedo Speaker Training, March 3, 2020
- 2020 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, Philadelphia, PA, March 10, 2020
- 2020 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, Washington DC, March 12, 2020
- 2020 Stahl SM. Newer Tricks of the Trade: What to do When Nothing Else Works, Department of Psychiatry Medical School, Harvard, April 3, 2020
- 2020 Stahl SM. Tardive Dyskinesia and the Mechanism of Action of VMAT2 Inhibitors, Virtual, April 6, 2020
- 2020 Stahl SM. Dopamine and Its Receptors, UCSD, Virtual, April 9, 2020
- 2020 Stahl SM. Cognition in Depression, UCSD, April 9, 2020
- 2020 Stahl SM. Expert Discussion on Schizophrenia in Adults and the New Antipsychotic, CAPLYTA, Virtual, April 14, 2020
- 2020 Stahl SM. Tardive Dyskinesia and the Mechanism of Action of VMAT2 Inhibitors, Virtual, May 4, 2020
- 2020 Stahl SM. The Curious Mystery of Dopamine and Its Receptors, Virtual, May 6, 2020
- 2020 Stahl SM. Tardive Dyskinesia and the Mechanism of Action of VMAT2 Inhibitors, Virtual, May 11, 2020
- 2020 Stahl SM. The New Antipsychotic CAPLYTA, Intra-Cellular National Broadcast, Virtual, June 2, 2020
- 2020 Stahl SM. Bipolar Depression, Sunovion Webinar, Virtual, June 5, 2020
- 2020 Stahl SM. The New Antipsychotic CAPLYTA, Intra-Cellular National Broadcast Q&A, Virtual, June 9, 2020
- 2020 Stahl SM. Bipolar Depression, Sunovion Webinar, Virtual, June 12, 2020

PRESENTATIONS AND ABSTRACTS (28)

- 2020 Stahl SM. Mechanism of Action of Dextromethorphan / Bupropion, Axsome Therapeutics Advisory Board, Virtual, June 12, 2020
- 2020 Stahl SM. Mechanism of Action of Brexpiprozole: Combining Norepinephrine, Dopamine and Serotonin Receptors, Otsuka Virtual Advisory Board, Virtual, June 25, 2020
- 2020 Stahl SM. Combining Mechanism of Action in Depression, Lundbeck Webinar, Virtual to the Middle East, June 26, 2020
- 2020 Stahl SM. Neuroscience of Dopamine, AbbVie Faculty Training, Virtual, July 20, 2020
- 2020 Stahl SM. The New Antipsychotic CAPLYTA, Intra-Cellular National Broadcast Q&A, Virtual, July 21, 2020
- 2020 Stahl SM. Using Plasma Drug Levels for Treatment Resistance Psychosis, UC Riverside Lecture, Virtual, July 22, 2020
- 2020 Stahl SM. Psychiatric Speaker Series: Tardive Dyskinesia (TD) Causes and Treatments, Virtual, July 23, 2020
- 2020 Stahl SM. Neuroscience of Dopamine, Allergan Speaker Training, Virtual, July 25, 2020
- 2020 Stahl SM. Schizophrenia Update, Live CME Webcast on Schizophrenia, July 29, 2020
- 2020 Stahl SM. Neuroscience of Dopamine, Allergan Speaker Training, Virtual, August 1, 2020
- 2020 Stahl SM. Bipolar Disorder Update, Daiichi Sankyo Brazil Webcast, August 12, 2020
- 2020 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, Virtual, August 26, 2020
- 2020 Stahl SM. Mechanism of Action of Rexulti, Brazil, Virtual, September 3, 2020
- 2020 Stahl SM. Psychopharmacology of Schizophrenia in Adolescents, ECNP, Virtual, September 14, 2020
- 2020 Stahl SM. How to Switch Antipsychotics, Brazil, Virtual, September 17, 2020
- 2020 Stahl SM. Three Theories of Psychosis: Dopamine, Serotonin & Glutamate, UC Riverside Lecture, September 23, 2020

PRESENTATIONS AND ABSTRACTS (29)

- 2020 Stahl SM. Recent updates in Schizophrenia, Mendoza Lecture, Virtual, September 24, 2020
- 2020 Stahl SM. Recent updates in Bipolar Disorder, Mendoza Lecture, Virtual, September 24, 2020
- 2020 Stahl SM. The Neurobiology, Diagnosis, and Management of Bipolar I Disorder, Virtual, September 24, 2020
- 2020 Stahl SM. Tris Scientific Advisory Board, Virtual, September 29, 2020
- 2020 Stahl SM. Psychiatric Speaker Series: Tardive Dyskinesia (TD) Causes and Treatments, Virtual, September 30, 2020
- 2020 Stahl SM. Role of Norepinephrine, Serotonin and Dopamine in Treatment of Depression, Otsuka Canada, Virtual, October 6, 2020
- 2020 Stahl SM. Mechanism of Action of Pimavanserin in Dementia Related Psychosis, Lexicon Working Group, Virtual, October 9, 2020
- 2020 Stahl SM. Mechanism of Action of Neuroactive Steroids in Depression, Sage Therapeutics MDD Strategic Working Group, Virtual, October 15, 2020
- 2020 Stahl SM. L-Methylfolate in Depression, Brazil Webcast, October 20, 2020
- 2020 Stahl SM. Psychiatric Speaker Series: Tardive Dyskinesia (TD) Causes and Treatments, Virtual, October 21, 2020
- 2020 Stahl SM. Virtual Poster Session, Lurasidone in Adolescents, Trace Armine Associated Receptor I Agonists in Schizophrenia, Virtual, October 21, 2020
- 2020 Stahl SM. Keeping Up with Advances in Schizophrenia, UCSD, October 22, 2020
- 2020 Stahl SM. Virtual Poster Session, Viloxazine in ADHD, Virtual, October 30, 2020
- 2020 Stahl SM. Neurobiology of Depression, UCSD, October 30, 2020
- 2020 Stahl SM. Advanced Psychopharmacology for Forensics, NEI Max Congress, November 4, 2020
- 2020 Stahl SM. Distinguishing SSRIs from SNRIs, Brazil Sanofi Virtual, November 4, 2020
- 2020 Stahl SM. Out of the Pipeline: Treatments for Schizophrenia, NEI Max Congress, November 5, 2020

PRESENTATIONS AND ABSTRACTS (30)

- 2020 Stahl SM. Novel Targets and Therapeutics for Schizophrenia, NEI Max Congress, November 5, 2020
- 2020 Stahl SM. Gun Violence and Mental Health, NEI Max Congress, November 7, 2020
- 2020 Stahl SM. Looking Over Dr. Stahl's Shoulder: Hot Topics from the Edition's Book, NEI Max Congress, November 8, 2020
- 2020 Stahl SM. Neurobiology and Case Presentation: Bipolar Depression, AbbVie Virtual, November 12, 2020
- 2020 Stahl SM. Anhedonia: Side Effects of Antidepressants or Antipsychotics or Unresolved Symptoms of Psychiatric Depression, Lundbeck, Middle East, Virtual, November 13, 2020
- 2020 Stahl SM. Future of Psychopharmacology, Artmed Publisher, Brazil, Virtual, December 1, 2020
- 2020 Stahl SM. Neuroscience Based Nomenclature for Drugs to Treat Psychosis, ACNP, Virtual, December 8, 2020
- 2020 Stahl SM. The Curious Mystery of Dopamine D3 vs. Dopamine D2 Partial Agonist, University Hospital Sharjah, Middle East, Virtual, December 4, 2020
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Now you See it, Now you Don't: The Power of Psychedelic Assisted Psychotherapy, NEI Podcast, January 30, 2021
- 2021 Stahl SM. Adherence in Psychopharmacology, NEI Synapse, January 30, 2021
- 2021 Stahl SM, The PsychopharmaStahlogy Show: Forgetting to be Addicted: Altering Compulsivity in the Addiction Process, NEI Podcast, February 12, 2021
- 2021 Stahl SM. Looking Over Dr. Stahl's Shoulder: Hot Topics from the Editor's Desk, Grand Rounds, University of California Riverside Department of Psychiatry, February 17, 2021
- 2021 Stahl SM. Hot Topics in Psychopharmacology, MedSummit Artmed, Brazil, February 25, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Forgetting your PTSD: Using Reconsolidation to Forget Traumatic Memories, NEI Podcast, March 2021
- 2021 Stahl SM. Hot Topics! The Latest in Psychopharmacology for Mood Disorders, NEI Synapse, March 10, 2021

PRESENTATIONS AND ABSTRACTS (31)

- 2021 Stahl SM. New Developments in Bipolar Spectrum Disorders: Challenging Diagnosis and Treatment, Virtual Lecture to Riyadh, Saudi Arabia and Middle East, March 26, 2021
- 2021 Stahl SM. Tardive Dyskinesia, April 8, 2021
- 2021 Stahl SM. The Latest “Tricks of the Trade: what to do when nothing works in the treatment of resistant psychiatric disorders, Harvard CME Symposium, April 9, 2021
- 2021 Stahl SM. Anxiety: Treat the Symptom or Treat the Disorder when First Line Therapies Fail? Harvard CME Symposium, April 10, 2021
- 2021 Stahl SM. The Role of Dopamine Partial Agonists at the Dawn of Psychosis, EPA (European Psychiatry Assn) Presentation, April 10, 2021
- 2021 Stahl SM. Selective Serotonin or Not So Selective Reuptake Inhibitors and the Potential Advantages of Selectivity and Escitalopram, Philippine Psychiatric Association, April 12, 2021
- 2021 Stahl SM. Novel Psychotropics, UCSD, April 15, 2021
- 2021 Stahl SM. Managing Mental Health Issues Throughout the Female Lifespan, UCSD, April 15, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Treatment of Resistant Depression and Suicide Prevention: Hot off the Press Ketamine Guidelines with Roger McIntyre, NEI Podcast, April 15, 2021
- 2021 Stahl SM. SIRS (Schizophrenia International Research Society) Symposium, TAAR1 Agonists in the Treatment of Schizophrenia, April 17, 2021
- 2021 Stahl SM. Bipolar Disorder, CPNP (College of Psychiatric and Neurologic Pharmacists), Satellite Symposium, April 20, 2021
- 2021 Stahl SM. Exploring the Role of Known and Emerging Neurotransmitters in Major Depressive Disorder and Anxiety, Otsuka Canada Lecture, April 22, 2021 and April 23, 2021
- 2021 Stahl SM. What’s new? An update on Novel Strategies to Treat Schizophrenia, Synapse, NEI Lecture, April 24, 2021
- 2021 Stahl SM. Postpartum Depression and Managing Mental Health Issues Throughout the Female Lifespan, Grand Rounds, University of California Riverside Psychiatry, April 28, 2021

PRESENTATIONS AND ABSTRACTS (32)

- 2021 Stahl SM. The PsychopharmaStahlogy Show: Shelter-in-Place during the Storm: Mental Health Consequences and Suicide Prevention during the COVID 19 Pandemic, NEI Podcast, May, 2021
- 2021 Stahl SM. Spotlight on Serotonin: Serotonin Dysfunction in Parkinson's Disease and Psychosis, APA (American Psychiatric Assn) Acadia Lecture, May 1, 2021
- 2021 Stahl SM. Cholinergic Regulation of Psychosis, KarXT Ad Board, May 13, 2021
- 2021 Stahl SM. Pharmacology of Treatment Options for Early-Onset Schizophrenia: Transition from Adolescence to Adulthood, H.O.P.E. Series, UK and Scandanavia Virtual, May 19, 2021
- 2021 Stahl SM. Combining Mechanisms of Action of Vortioxetine to Target Functional Impairment in Major Depressive Disorder, Lundbeck Dubai and Emirates Webinar, May 20, 2021
- 2021 Stahl SM. Tardive Dyskinesia, Austedo Webcast, May 20, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Beyond the Storm: An Update on Suicide Prevention and the Suicide Prevention Handbook with Christine Moutier, NEI Podcast, June 2021
- 2021 Stahl SM. Psychopharmacology of Antipsychotic Agents: A Revision of Their Receptor Profiles and Mechanism of Action, Otsuka Spain, June 7, 2021
- 2021 Stahl SM. Essential Psychopharmacology, Video Edition, recording of all chapters of the 5th edition of Stahl's Essential Psychopharmacology for the NEI website 2021, June 14-15, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Placebo and Nocebo Effects in Psychopharmacology with Joseph Goldberg, NEI Podcast, July 6, 2021
- 2021 Stahl SM. Using Plasma Antipsychotic Levels and the Point of Futility to Guide Dosing, University of California Riverside Psychiatry, Psychopharm Grand Rounds, July 28, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Mediators and Moderators in Psychopharmacology with Joseph Goldberg, NEI Podcast, August 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: Interpreting the Scientific Literature in Psychopharmacology with Joseph Goldberg, NEI Podcast, September 2021
- 2021 Stahl SM. Tardive Dyskinesia, Austedo Virtual Program, September 9, 2021
- 2021 Stahl SM. Agitation in Alzheimer's, Otsuka Advisory board, September 10, 2021

PRESENTATIONS AND ABSTRACTS (33)

- 2021 Stahl SM. Psychopharmacology Pre-Recording Session, September 28, 2021
- 2021 Stahl SM. Meeting the Minds, Brazil, The Brain and Uncertainty: Biological Bases and Pharmacological Management of Anxiety, Libbs, BRAZIL, September 28, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: What's New in the Fifth Edition of Stahl's Essential Psychopharmacology? NEI Podcast, October 2021
- 2021 Stahl SM. Trazodone, A Gold Player for Current Challenges in Antidepressant Therapy, Angelini Symposium, ECNP (European College of Neuropsychopharmacology), October 4, 2021
- 2021 Stahl SM. Beyond the D2 Blockade: Trace Amine Associated Receptor 1 as a Novel TAARget in Schizophrenia, Sunovion ECNP (European College of Neuropsychopharmacology), October 3, 2021
- 2021 Stahl SM. The Mysterious DAT and ADHD, South Africa Dinner Symposium, October 21, 2021
- 2021 Stahl SM. Novel psychotropics, 26th Annual Central New York Psychopharmacology Update, October 22, 2021
- 2021 Stahl SM. The Future of Psychopharmacology, for 2021 Psych Pharm Live Show, University of Cincinnati and Medscape CME conference, October 22, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: The Fifth Edition Video Series and How to Implement Best Learning Strategies for Understanding Psychopharmacology, NEI Podcast, November 2021
- 2021 Stahl SM. Forensic Academy, Short Circuits? Exploring the Neurobiology Behind the Violence and Aggression, NEI Congress, Colorado Springs, CO, November 3, 2021
- 2021 Stahl SM. Fighting for Mental Health: Improving Veteran Care, NEI Congress, Colorado Springs, CO, November 6, 2021
- 2021 Stahl SM. Total Eclipse of the TAAR, NEI Congress, Colorado Springs, CO, November 6, 2021
- 2021 Stahl SM. The Role of Partial Dopamine Agonists at the Dawn of Psychosis, Sandanavian Recordati Seminar, November 11, 2021
- 2021 Stahl SM. Tardive Dyskinesia, AUSTEDO Webcast, November 16, 2021
- 2021 Stahl SM. The PsychopharmaStahlogy Show: The Future of Psychopharmacology, NEI Podcast, December 2021

PRESENTATIONS AND ABSTRACTS (34)

- 2022 Stahl SM. The Art of Switching Antipsychotics, NEI Podcast, January 6, 2022
- 2022 Stahl SM. Neuropsychopharmacology: Where Are We Going Post-COVID? XXIII SINPF (Societa Italiana di Neuropsicofarmacologia) National Congress, Milan, Italy, Jan 26, 2022
- 2022 Stahl SM. The Latest “Tricks of the Trade” What to Do When Nothing Works in the Treatment of Resistant Psychiatric Disorders” University of California, Riverside, January 26, 2022
- 2022 Stahl SM. Long-Acting Injectable Antipsychotics, Alkermes Video, Las Vegas, NV, February 1, 2022
- 2022 Stahl SM. PsychopharmaStahlogy NEI Podcast, Dark Persuasion and Social Media, February 7, 2022
- 2022 Stahl S. Treatment Resistant Anxiety, University of California Riverside, March 23, 2022
- 2022 Stahl SM. PsychopharmaStahlogy NEI Podcast, Dark Persuasion: Can It Cause Dark Neuroplasticity?, March 29, 2022
- 2022 Stahl SM. Circuits of Psychosis and Cholinergic Regulation, Karuna Meetings, Boston, MA, March 31, 2022
- 2022 Stahl SM. Decision Making in the Treatment of Resistant Psychiatric Disorders: From Blood Levels to Dosing to Treatment Combinations, Harvard CME Conference, Boston, MA, April 2, 2022
- 2022 Stahl SM. Total Eclipse of the TAAR: Update on Trace Amines and Their Receptors, UCSD, April 14, 2022
- 2022 Stahl SM. Treatment Resistant Anxiety, UCSD, April 14, 2022
- 2022 Stahl SM. Expert Insights: Caplyta for Bipolar I and II Depression in Adults, National Broadcast and Launch, Dallas, TX, April 20, 2022
- 2022 Stahl SM. Move on Over: Diagnosing and Treating Tardive Dyskinesia, NEI Synapse meeting, Austin TX April 22, 2022
- 2022 Stahl SM. Jeopardy! Long Acting Injectables, NEI Synapse Meeting, Austin, TX April 22, 2022
- 2022 Stahl SM. Trazodone: A New Update for an Old Drug, Brazil psychiatrists, Virtual, May 10, 2022

PRESENTATIONS AND ABSTRACTS (35)

- 2022 Stahl SM. PsychopharmaStahlogy Show: Nicola Tesla with Co-Author Marko Perko Discussing Their Book Tesla: His Tremendous and Troubled Life, and The Role of Bipolar Disorder in his Life, Podcast, May 11, 2022
- 2022 Stahl SM. UCSD Neuropharm Lecture on Antidepressants to Graduate Psychopharmacology Course, May 12, 2022
- 2022 Stahl SM. PsychopharmaStahlogy Show, Creativity, Genius and Bipolar Disorder, Podcast, May 18, 2022
- 2022 Stahl SM. Brainwashing: A Haunting Past and Troubling Future for Psychiatry and Society, American Psychiatric Association, New Orleans, May 21, 2022
- 2022 Stahl SM. Neurocrine Presentation, Tardive Dyskinesia, American Psychiatric Association, New Orleans, May 21, 2022
- 2022 Stahl SM. Essential Psychopharmacology: What Is “Essential” About Psychopharmacology in the Post-COVID, Inclusive 21st Century? American Psychiatric Association, New Orleans, May 24, 2022
- 2022 Stahl SM. AbbVie National Broadcast, Bipolar Depression, Dallas, TX, June 1, 2022
- 2022 Stahl SM. Trazodone Once Daily: Vintage Wine in a New Bottle for Rapid Onset and Treatment of Major Depressive Disorder, Brazil, Virtual, June 3, 2022
- 2022 Stahl SM. Recent Innovations in Antidepressant Treatment, Janssen Symposium, Barcelona, Spain, June 10, 2022
- 2022 Stahl SM. Aripiprazole: From Clinical Profile to Clinical Use, Middle East Lecture, Virtual, June 24, 2023
- 2022 Stahl SM. Psychopharmacology for Serious Mental Illness in the Jail: Long-Acting Injectables, Catatonia and Other Relevant Topics, Los Angeles County Twin Towers Jail, June 29, 2022
- 2022 Stahl SM. PsychopharmaStahlogy Show, Podcast with Dr. Katherine Warburton, on Decriminalizing Serious Mental Illness, Diversion Programs and the New Cares Court Legislation, July 12, 2022
- 2022 Stahl SM. Case Conference, University of California, Riverside Lecture, Virtual, July 13, 2022
- 2022 Stahl SM. PsychopharmaStahlogy Show with Dr. Carolina Klein speaking on Forensic Psychiatry and Violence, Podcast, August 8, 2022
- 2022 Stahl SM. PsychopharmaStahlogy Show, Podcast with Dr. James Knoll, speaking on Forensic Psychiatry and Serial Murder, August 8, 2022

PRESENTATIONS AND ABSTRACTS (36)

- 2022 Stahl SM. University of California, Riverside, Psychopharmacology Lecture, Virtual, August 10, 2022
- 2022 Stahl SM. University of California, Riverside, Psychopharmacology Lecture, Virtual, September 14, 2022
- 2022 Stahl SM, Pain of the Body and Pain of the Soul: Psychopharmacology of the Association Between Depression and Pain, Meeting of the Minds 2022 | CNS, Cardiology and Gynecology, Virtual, September 15, 2022
- 2022 Stahl SM. Tardive Dyskinesia, Neurocrine National Broadcast, Dallas TX, September 21, 2022
- 2022 Stahl SM. PsychopharmaStahlogy Show, Podcast with Dr. Michael Cummings on Management of Treatment Resistant Psychosis, September 27, 2022
- 2022 Stahl SM. PsychopharmaStahlogy Show, Podcast with Dr. Jonathan Meyer on Utilizing Plasma Drug Levels to Choose Doses of Antipsychotic Drugs, October 6, 2022
- 2022 Stahl SM. ECNP Lecture on Neuroscience Based Nomenclature, October 18, 2022
- 2022 Stahl SM. Target Acquired? New Receptor Science in the Treatment of Schizophrenia, NEI Congress, Colorado Springs, CO, November 5, 2022
- 2022 Stahl SM. Reasons to Hope: Evidence-Based Actions for Suicide Prevention, NEI Congress, Colorado Springs, CO, November 5, 2022
- 2022 Stahl SM. Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation, NEI Congress, Colorado Springs, CO, November 6, 2022
- 2022 Stahl SM. Stahl SM. University of California, Riverside Psychopharmacology Lecture, Virtual, December 14, 2022
- 2023 Stahl SM. A New Strategy for Augmentation of Antidepressants in Treatment Resistant Depression, AbbVie Launch Video, Virtual, January 10, 2023
- 2023 Stahl SM. PsychopharmaStahlogy Show, Podcast on the Controversies of New Anti-amyloid Treatments for Alzheimers dementia, January 10, 2023
- 2023 Stahl SM. University of California, Riverside Psychopharmacology Lecture, Virtual, January 11, 2023
- 2023 Stahl SM. Recent update on the Neurobiology of Major Depressive Disorder: Neuroplasticity and Neuroinflammation, AbbVie Faculty Training, Virtual, January 18, 2023

PRESENTATIONS AND ABSTRACTS (37)

- 2023 Stahl SM. What's New in the Neurobiology of Major Depressive Disorder, AbbVie Speaker Training, Anaheim, CA, January 28, 2023
- 2023 Stahl SM, PsychopharmaStahlogy Show, Podcast on Newly Approved Treatments for Alzheimer's Dementia: Are They for Real? With Dr. Lon Schneider, February 7, 2023
- 2023 Stahl SM. University of California, Riverside Psychopharmacology Lecture, Virtual, February 8, 2023
- 2023 Stahl SM, Bipolar Depression, Intracellular Therapeutics, Harvard Club, NY, February 22, 2023
- 2023 Stahl SM, A New Option for Augmenting Treatment Resistant Major Depression, AbbVie, Omni New Haven Yale, February 23, 2023
- 2023 Stahl SM, A New Option for Augmenting Treatment Resistant Major Depression, AbbVie, Costa Mesa, CA, March 1, 2023
- 2023 Stahl SM. University of California, Riverside Psychopharmacology Lecture, Virtual, March 8, 2023
- 2023 Stahl SM, PsychopharmaStahlogy Show, Podcast on Treating ADHD: New Options and Controversies About Telepsychiatry Prescribing of Stimulants, March 9, 2023
- 2023 Stahl SM. University of California, Riverside Psychopharmacology Lecture, Virtual, March 15, 2023
- 2023 Stahl SM, A New Option for Augmenting Treatment Resistant Major Depression AbbVie, Detroit, March 21, 2023
- 2023 Stahl SM, Bipolar Depression, Intracellular Therapeutics, Nashville, March 28, 2023
- 2023 Stahl SM, A new option for augmenting treatment resistant major depression, AbbVie, Nashville, March 30, 2023
- 2023 Stahl SM, New Approaches: Novel Receptor Science in Schizophrenia, NEI Synapse, Nashville, March 30. 2023
- 2023 Stahl SM, Don't Forget about Neuropsychiatric Symptoms: Treating Agitation in Alzheimer's Disease, Nashville, March 30, 2023
- 2023 Stahl SM, Treatment Resistant Depression, For Living Legends CME Course, University of Miami, Boston, MA, April 1, 2023
- 2023 Stahl SM. University of California, Riverside Psychopharmacology Lecture, Virtual, April 12, 2023

PRESENTATIONS AND ABSTRACTS (38)

- 2023 Stahl SM, A New Option for Augmenting Treatment Resistant Major Depression, AbbVie, Tampa, April 20, 2023
- 2023 Stahl SM. University of California, San Diego Psychopharmacology Lecture, Virtual, April 27, 2023
- 2023 Stahl SM, Treatment Resistant Depression, For Psychopharmacology 2023: A MasterClass, Harvard University and Beth Israel Deconness Medical Center, Boston, April 29, 2023

TEXTBOOKS OF PSYCHOPHARMACOLOGY

- (TB-1) Stahl SM. Essential Psychopharmacology. Cambridge University Press, New York, 1996.
- (TB-2) Stahl SM. Psychopharmacology of Antidepressants. Martin Dunitz Press, London and Mosby, New York, 1997.
- (TB-3) Stahl SM. Psychopharmacology of Antipsychotics. Martin Dunitz Press, London, 1999.
- (TB-4) Stahl SM. Essential Psychopharmacology, 2nd Edition, Cambridge University Press, New York, 2000.
- (TB-5) Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder, Cambridge University Press, New York, New York, 2000.
- (TB-6) Stahl SM. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers, Cambridge University Press, New York, New York, 2002.
- (TB-7) Stahl SM. Essential Psychopharmacology: The Prescribers Guide. Cambridge University Press, New York, New York, 2005.
- TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)
- (TB-8) Stahl SM. Illustrated Insights – Sleep: Excessive Sleepiness. NEI Press, Carlsbad, CA 2005.
- (TB-9) Stahl SM. Essential Psychopharmacology: The Prescribers Guide Revised. 2nd edition, Cambridge University Press, New York, New York, 2006.
- (TB-10) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antipsychotics and Mood Stabilizers. Cambridge University Press, New York, New York, 2006.
- (TB-11) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antidepressants. Cambridge University Press, New York, New York, 2006.
- (TB-12) Stahl SM. Stahl's Essential Psychopharmacology, 3rd Edition. Cambridge University Press, New York, 2008.
- (TB-13) Stahl SM. Stahl's Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge University Press, New York, 2008.
- (TB-14) Stahl SM. Stahl's Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge University Press, New York, 2008.
- (TB-15) Stahl SM. Stahl's Illustrated: Antipsychotics, Cambridge University Press, New York, New York 2009.

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-16) Stahl SM. Essential Psychopharmacology: The Prescribers Guide 3rd Edition Cambridge University Press, New York, New York, 2009.
- (TB-17) Stahl SM. Stahl's Illustrated: Antidepressants. Cambridge University Press, New York, New York 2009.
- (TB-18) Stahl SM. Stahl's Illustrated: Mood Stabilizers. Cambridge University Press, New York, New York 2009.
- (TB-19) Stahl SM. Stahl's Illustrated: Chronic Pain and Fibromyalgia. Cambridge University Press, New York, New York 2009.
- (TB-20) Stahl SM. Stahl's Illustrated: Attention Deficit Hyperactivity Disorder. Cambridge University Press, New York, New York 2009.
- (TB-21) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antidepressants, 2nd Edition. Cambridge University Press, New York, New York, 2009.
- (TB-22) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antipsychotics and Mood Stabilizers, 2nd Edition. Cambridge University Press, New York, New York, 2009.
- (TB-23) Stahl SM and Davis RL. Best Practices for Medical Educators. NEI Press, 2009.
- (TB-24) Stahl SM. Stahl's Illustrated: Antipsychotics, 2nd Edition, Cambridge University Press, New York, New York, 2010.
- (TB-25) Stahl SM. Stahl's Illustrated: Anxiety and PTSD, Cambridge University Press, New York, 2010.
- (TB-26) Stahl SM. Essential Psychopharmacology Prescribers Guide 4th Edition, Cambridge University Press, London, 2011.
- (TB-27) Stahl SM. Essential Psychopharmacology Case Studies. Cambridge University Press, London, 2011.
- (TB-28) Stahl SM and Davis RL. Best Practices for Medical Educators, 2nd Edition. Cambridge University Press, 2011
- (TB-29) Stahl SM. Stahl's Self Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians. Cambridge University Press, 2012.
- (TB-30) Stahl SM and Grady M. Stahl's Illustrated: Drug Abuse and Disorders of Impulsivity. Cambridge University Press, New York, 2012.

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-31) Stahl SM. Stahls Essential Psychopharmacology, 4th Edition. Cambridge University Press, New York, 2013.
- (TB-32) Stahl SM. Stahls Essential Psychopharmacology: the Prescribers Guide, 5th Edition. Cambridge University, New York, 2014.
- (TB-33) Stahl SM and Morrissette DA,. Stahl's Illustrated: Violence: Neural Circuits, Genetics and Treatment, Cambridge University Press, New York, 2014.
- (TB-34) Stahl SM, The Stahl Neuropsychopharmacology Masterclass: Mood Disorders, Cambridge University Press, Cambridge, UK, 2015.
- (TB-35) Stahl SM, The Stahl Neuropsychopharmacology Masterclass: Antidepressants, Cambridge University Press, Cambridge, UK, 2015
- (TB-36) Stahl SM. And Schwartz T, Essential Psychopharmacology Case Studies. Cambridge University Press, Volume 2, Cambridge, 2016.
- (TB-37) Stahl SM. Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians. 2nd edition, Cambridge University Press, 2016.
- (TB-38) Stahl SM and Morrissette DA. Stahls Illustrated: Sleep and Wake Disorders, Cambridge University Press, New York, 2016
- (TB-39) Stahl SM. Stahl's Essential Psychopharmacology: The Prescribers Guide, 6th Edition. Cambridge University, New York, 2017.
- (TB-40) Stahl SM. Stahl's Essential Psychopharmacology: The Prescribers Guide – Children and Adolescents, Cambridge University Press, 2018
- (TB-41) Stahl SM, Morrissette DA, Stahl's Illustrated Dementia, Cambridge University Press, 2018
- (TB-42) Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide to Antipsychotics, Cambridge University Press, 2018
- (TB-43) Stahl SM. Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians, 3rd Edition, Cambridge University Press, 2019
- (TB-44) Meyer, JM, Stahl SM. Stahl's Handbooks – The Clozapine Handbook, Cambridge University Press, 2020
- (TB-45) Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 7th edition, Cambridge University Press, New York, 2021

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

- (TB-46) Goldberg JF and Stahl SM. Practical Psychopharmacology: Translating Findings from Evidence-Based Trials into Real-World Clinical Practice, Cambridge University Press, New York, 2021
- (TB-47) Moutier C, Pisani A and Stahl SM. Stahl's Handbooks: Suicide Prevention., Cambridge University Press, New York, 2021
- (TB-48) Stahl SM. Stahl's Essential Psychopharmacology 5th edition, Cambridge University Press, New York, 2021
- (TB-49) Cummings MA and Stahl SM. Management of Complex Treatment-resistant Psychotic Disorders, Cambridge University Press, New York, 2021
- (TB-50) Meyer JM and Stahl SM. Stahl's Handbooks: The Clinical Use of Antipsychotic Plasma Levels, Cambridge University Press, New York, 2021
- (TB-51) Cooper T, Maguire G and Stahl SM. Case Studies: Stahl's Essential Psychopharmacology, Volume 3, Cambridge University Press, New York, 2022
- (TB-52) Stahl SM. Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians, 4th Edition, Cambridge University Press, New York, 2022

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)

(in press)

- (TB-53) Hafizi S, Jones PB and Stahl SM. Cambridge Prescribing Guidelines for Psychiatrists, Cambridge University Press, New York, 2023
- (TB-54) Lynell ML, Jones PB and Stahl SM. Cambridge Textbook of Neuroscience for Psychiatrists, Cambridge University Press, New York, 2023

TEXTBOOKS OF PSYCHOPHARMACOLOGY

(in preparation)

- (TB-55) Stahl SM. Stahl's Essential Psychopharmacology: The Prescribers Guide – Children and Adolescents, Cambridge University Press, 2nd edition for 2023
- (TB-56) Stahl SM. Stahl's Select a Symptom and Guide to Treatment Resistance and Side Effects in Psychiatry: Deconstructing the DSM for Rational Prescribing: Symptoms and Circuits, Cambridge University Press for 2023
- (TB-57) Stahl SM and Segal, S. Stahl's Illustrated Drugs for Depression, 2nd Edition, Cambridge University Press, New York for 2023

TEXTBOOKS OF PSYCHOPHARMACOLOGY (Cont'd)
(in preparation)

- (TB-58) Schwartz T and Stahl SM. Case Studies: Stahl's Essential Psychopharmacology, Volume 4, Cambridge University Press, New York for 2023
- (TB-59) Stahl SM. Neuroscience, Drugs and Behavior: Essential Psychopharmacology STUDENT ADAPTATION, Cambridge University Press, New York for 2023
- (TB-60) Strawn JR and Stahl SM. Case Studies: Stahl's Essential Psychopharmacology, Volume 5, Cambridge University Press, New York for 2023
- (TB-61) Goldberg JF and Stahl SM. Clinical Reasoning and Decision-Making in Psychiatry, Cambridge University Press, New York for 2023
- (TB-62) Meyer JM and Stahl SM. Stahl's Handbooks: The Lithium Handbook, Cambridge University Press, New York for 2023
- (TB-63) Finley P and Stahl SM. Stahl's Handbooks: Drug Interactions with Psychiatric Medications, Cambridge University Press, New York for 2023
- (TB-64) Klein, C and Stahl SM. Forensic Case Studies: Stahl's Essential Psychopharmacology, Volume 6, Cambridge University Press, New York for 2023

EDITED BOOKS

- (EB-1) Stahl SM, Iversen SD and Goodman EC (Eds). Cognitive Neurochemistry: Assessment Techniques and Research Strategies for Understanding the Pharmacologic Basis of Human Neuropsychology. Oxford University Press, Oxford, 1987.
- (EB-2) Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J (Eds). Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York, 1992.
- (EB-3) Stein DJ, Lerer B and Stahl SM. (Eds). Evidence Based Psychopharmacology. Cambridge University Press, New York, 2005.
- (EB-4) Beyer CE and Stahl SM. (Eds.) Next Generation Antidepressants, Cambridge University Press, Cambridge, UK, 2010.
- (EB-5) Silberstein SD, Marmura MJ and Stahl SM (Ed). Essential Neuropharmacology, The Prescribers Guide, Cambridge University Press, Cambridge UK, 2010.
- (EB-6) Kalali A, Kwentus J, Preskorn S, Stahl SM (Eds), Essential CNS Drug Development, Cambridge University Press, New York, 2012
- (EB-7) Stein DJ, Lerer B, Stahl SM (Eds), Essential Evidence Based Psychopharmacology, 2nd Edition, Cambridge University Press, New York, 2012
- (EB-8) Pappagallo M, Smith H and Stahl SM. Essential Pain Pharmacology: Prescribers Guide. Cambridge University Press, New York, 2012.
- (EB-9) Stahl SM and Moore BA. (Eds) Anxiety Disorders: A Concise Guide and Casebook for Psychopharmacology and Psychotherapy Integration. Routledge Press, New York, 2013.
- (EB-10) Reis de Oliveira I, Schwartz T and Stahl SM. Integrating Psychotherapy and Psychopharmacology. Routledge Press, New York 2014.
- (EB-11) Zohar J, Stahl S, Moller H-J, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin G, Nutt D. Neuroscience Based Nomenclature, Cambridge University Press, Cambridge, UK, 2014
- (EB-12) Silberstein, SD, Marmura MJ, Hsiangkuo Y, Stahl SM. Essential Neuropharmacology, The Prescribers Guide, 2nd Edition, 2016, Cambridge University Press, New York.
- (EB-13) Warburton KD and Stahl SM. Violence in Psychiatry, Cambridge University Press, 2016
- (EB-14) Marazzitti D and Stahl SM. Evil, Terrorism and Psychiatry, Cambridge University Press, 2019

EDITED BOOKS (Cont.)

- (EB-15) Warburton KD and Stahl SM. Decriminalizing Mental Illness, Cambridge University Press, New York, 2021

OTHER BOOKS – NOVELS (fiction/thrillers)

- (Novel-1) Stahl SM. Shell Shock, the story of PTSD, Harley House Press, San Diego, 2015
- (Novel-2) Stahl SM. The T4 Project, the story of psychiatric euthanasia, Harley House Press, San Diego, in preparation

OTHER BOOKS – NONFICTION/TRADE

- (Trade-1) Perko M and Stahl SM. Tesla: His tremendous and troubled life, the story of Tesla's genius and bipolar disorder, Prometheus Books/Rowman and Littlefield, New York, 2022

PUBLICATIONS

1. 1971 Stahl SM, Zeller EA and Boshes B. On the effect of modulation of cerebral amine metabolism on the learning and memory of goldfish (*Carassius auratus*). Transactions of the American Neurological Association 96:310-312, 1971.
2. 1971 Stahl SM, Narotzky R, Boshes B and Zeller EA. Einfluß des zerebralen Amin-Stoffwechsels auf das Gedächtnis des Goldfisches. (Influences of Cerebral amine metabolism on the memory of goldfish). Die Naturwissenschaften 58:628-629, 1971.
3. 1973 Boshes B, Zeller EA, Arbit J, Blonsky ER, Dolkart M and Stahl SM. Influence of L-DOPA on selected aspects of learning and performance. In: Psycho-Physiological Approach of Behavior. Department of Neurology and Biochemistry, Northwestern University-McGraw Medical Center, Chicago, IL
4. 1973 Narotzky R, Griffit D, Stahl SM, Bondareff W and Zeller EA. Effect of Long-Term L-DOPA Administration of Brain Biogenic Amines and Behavior in the Rat. Experimental Neurology, Volume 38, No. 2, 218-230.
5. 1974 Meltzer HY and Stahl SM. Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Research Communications in Chemical Pathology and Pharmacology 7:419-431, 1974.
6. 1974 Spehlmann R and Stahl SM. Neuronal hyposensitivity to dopamine in the caudate nucleus depleted of biogenic amines by tegmental lesions. Experimental Neurology 42(3):703-706, 1974.
7. 1974 Stahl SM, Narotzky RA, Boshes B and Zeller EA. The effects of cerebral amine metabolism on operationally defined learning and memory processes of goldfish. Biological Psychiatry 9(3):295-323, 1974. (A.E. Bennett Basic Research Award paper).
8. 1975 Stahl SM, Daniels AC, Derda D and Spehlmann R. Injection of 6-hydroxydopamine and hydrogen peroxide into the substantia nigra and lateral ventricle of the cat: specific and non-specific effects on striatal biogenic amines. Journal of Neurochemistry 24:165-172, 1975.
9. 1975 Schmidt RT, Stahl SM and Spehlmann R. A pharmacologic study of the stiff-man syndrome: correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol excretion. Neurology 25(7):622-626, 1975.
10. 1975 Drachman DA and Stahl SM. Extrapyrimalid dementia and levodopa. Lancet I: 809, 1975.
11. 1976 Meltzer HY and Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bulletin 2(1):19-76, 1976.

PUBLICATIONS (2)

12. 1976 Spehlmann R and Stahl SM. Dopamine-acetylcholine imbalance in Parkinson's disease: possible regenerative overgrowth of cholinergic axon terminals. Lancet I:724-726, 1976.
13. 1976 Stahl SM. The human platelet as a model for the central nervous system amine-containing neuron. Ph.D. dissertation, Department of Pharmacological and Physiological Sciences Neuropharmacology, University of Chicago, 1976.
14. 1977 Stahl SM and Meltzer HY. Serotonin accumulation by skeletal muscle. Experimental Neurology 54:42-53, 1977.
15. 1977 Stahl SM. The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archives of General Psychiatry 34:509-516, 1977.
16. 1977 Hanley HG, Stahl SM and Freedman DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Archives of General Psychiatry 34:521-531, 1977.
17. 1978 Stahl SM and Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. Journal of Pharmacology and Experimental Therapeutics 205(1):118-132, 1978.
18. 1978 Stahl SM and Meltzer HY. The human platelet as a model for the dopaminergic neuron: kinetic and pharmacologic properties and the role of amine storage granules. Experimental Neurology 59:1-15, 1978.
19. 1979 Stahl SM, Ellinger G and Baringer JR. Progressive myelopathy due extramedullary hematopoiesis: case report and review of the literature. Annals of Neurology (5):485-489, 1979.
20. 1980 Stahl SM, Johnson KP and Malamud N. The clinical and pathological spectrum of brain-stem vascular malformations: long-term course simulates multiple sclerosis. Archives of Neurology 37:25-29, 1980.
21. 1980 Stahl SM, Layzer RB, Aminoff MJ, Townsend JJ and Feldon SF. Continuous cataplexy in a patient with a midbrain tumor: the limp-man syndrome. Neurology 30:1115-1118, 1980.
22. 1980 Stahl SM and Berger PA. Physostigmine in Gilles de la Tourette's syndrome. New England Journal of Medicine 302:298, 1980.
23. 1980 Stahl SM and Berger PA. Cholinergic treatment in the Tourette syndrome. New England Journal of Medicine 302(23):1310-1311, 1980.

PUBLICATIONS (3)

24. 1980 Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. American Journal of Psychiatry 137(10):1267-1269, 1980.
25. 1980 Davis KL, Hollister LE, Stahl SM and Berger PA. Choline chloride in Huntington's disease. Transactions of the American Neurological Association 105:464-467, 1980.
26. 1981 Stahl SM and Berger PA. Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. American Journal of Psychiatry 138 (2): 240-242, 1981.
27. 1981 Zelazowski R, Golden CJ, Graber B, Blose IL, Bloch S, Moses JA, Zatz LM, Stahl SM, Osmon DC and Pfefferbaum A. Relationship of cerebral ventricular size to alcoholics' performance on the Luria- Nebraska Neuropsychological Battery. Journal of Studies on Alcohol 42(9):749-756, 1981.
28. 1981 Stahl SM and Berger PA. Bromocriptine in dystonia. Lancet II:745, 1981.
29. 1982 Stahl SM, Levin B and Freedman DX. Serotonin depletion by Fenfluramine in the carcinoid syndrome. New England Journal of Medicine 306(7):429, 1982.
30. 1982 Stahl SM and Berger PA. Cholinergic and dopaminergic mechanisms in Tourette syndrome. In: Chase TN and Friedhoff AJ (Eds), Gilles de la Tourette Syndrome. Advances in Neurology, Volume 35, Chapter 18, Raven Press, New York, pp. 141-150, 1982.
31. 1982 Stahl SM and Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 32:889-892, 1982.
32. 1982 Stahl SM, Ciaranello RD and Berger PA. Platelet serotonin in schizophrenia and depression. In: Ho BT, Schoolar JC and Usdin E Eds), Serotonin in Biological Psychiatry, Advances in Biochemical Psychopharmacology, Volume 34, Raven Press, New York, 1982, pp.183-198.
33. 1982 Stahl SM and Berger PA. Neuroleptic effects in Tourette syndrome predict dopamine excess and acetylcholine deficiency. Biological Psychiatry 17(9):1047-1053, 1982.
34. 1982 Stahl SM, Davis KL and Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia and other dystonias. Journal of Clinical Psychopharmacology 2(5):321-328, 1982.

PUBLICATIONS (4)

35. 1982 Stahl SM, Yesavage JA and Berger PA. Pharmacologic characteristics of Meige dystonia: differentiation from tardive dyskinesia. Journal of Clinical Psychiatry 43(11):445-446, 1982.
36. 1983 Stahl SM, Woo DJ, Mefford IN, Berger PA and Ciaranello RD. Hperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. American Journal of Psychiatry 140:26-30, 1983.
37. 1983 Stahl SM and Kasser IS. Pentazocine overdose. Annals of Emergency Medicine 12(1):28-31, 1983.
38. 1983 Stahl SM, Lemoine PM, Ciaranello RD and Berger PA. Platelet alpha-2 adrenergic receptor sensitivity in major depressive disorder. Psychiatry Research 10:157-164, 1983.
39. 1984 Stahl SM and Kasser IS. High-dose naloxone for pentazocine overdose (correspondence). Annals of Emergency Medicine 13(1):66,1984.
40. 1984 Stahl SM, Berger PA, Newman RP and Lewitt P. Bromocriptine and lisuride in dystonias (correspondence). Neurology 34:135-136, 1984.
41. 1984 Thornton JE and Stahl SM. Case report of tardive dyskinesia and Parkinsonism associated with amoxapine therapy. American Journal of Psychiatry 141(5):704-705, 1984.
42. 1984 Stahl SM and Tinklenberg JR. Dietary enhancement of CNS neurotransmitters (commentary). Integrative Psychiatry 2:157-159,1984.
43. 1984 Uhr S, Stahl SM and Berger PA. Unmasking schizophrenia. VA Practitioner 1:42-47, 1984.
44. 1984 Uhr S, Berger PA, Pruitt B and Stahl SM. Treatment of Tourette's syndrome with RO22-1319, a D-2 receptor antagonist. New England Journal of Medicine 311(15):989, 1984.
45. 1984 Stahl SM. Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. Journal of Clinical Psychiatry 45(10)(sec.2):37-44, 1984.
46. 1985 Stahl SM. Serotonin agonists and beta-adrenergic agonists as a treatment for depressive disorder: a direct clinical application. Psychopharmacology Bulletin 21(1):43-47, 1985.

PUBLICATIONS (5)

47. 1985 Stahl SM. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker G (Ed), The Platelets: Physiology and Pharmacology, Academic Press, New York 1985, Chapter 13, pp 307-340.
48. 1985 Stahl SM. Akathisia and tardive dyskinesia: changing concepts. Archives of General Psychiatry 42:915-917, 1985. Stahl SM. Akathisia variants and tardive dyskinesia. Letter to the Editor in Archives of General Psychiatry 43:1015, 1986.
49. 1985 Stahl SM. Can CSF measures distinguish among schizophrenia, depression, movement disorders, and dementia? Psychopharmacology Bulletin 21(3):396-399, 1985.
50. 1985 Stahl SM. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacology Bulletin 21(3):663-671, 1985.
51. 1985 Stahl SM, Thornton JE, Simpson ML, Berger PA and Napolitano MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry 20:888-893, 1985.
52. 1985 Stahl SM. Approches nouvelles de la biologie de la depression (New approaches to the biology of depression). Psychiatrie Francophone 1:6-21, 1985.
53. 1985 Stahl SM, Uhr SB and Berger PA. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Biological Psychiatry 20:1098-1102, 1985.
54. 1985 Stahl SM, Thornton JE and Berger PA. Gamma-amino-butyric acid (GABA) and movement disorders: role of gamma-vinyl-GABA. In: Burrows G, Norman T and Dennerstein (Eds), Clinical and Pharmacological Studies in Psychiatric Disorders, John Libbey, London, 1985, pp. 216-221. (Vol.5 of Biological Psychiatry – New Prospects).
55. 1985 Jernigan TL, Sargent T, Pfefferbaum A, Kusubov N and Stahl SM. ¹⁸F-Fluorodeoxyglucose PET in Schizophrenia. Psychiatry Research 16:317-329, 1985.
56. 1985 King R, Faull K, Stahl S, Mefford I, Thiemann S, Barchas J and Berger P. Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior. Psychiatry Research 4(3):235-240, 1985.
57. 1986 Grandas-Perez F, Jenner PG, Nomoto M, Stahl S, Quinn NP, Parkes JD, Critchley P and Marsden CD. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease. Lancet April 19, 1986, 906.

PUBLICATIONS (6)

58. 1986 Uhr SB, Pruitt B, Berger PA and Stahl SM. Case report of four patients with Tourette syndrome treated with piquindone, a D₂ receptor antagonist. Journal of Clinical Psychopharmacology 6(2):128-130, 1986.
59. 1986 Stahl SM. Neuropharmacology of movement disorders: comparison of spontaneous and drug-induced movement disorders. In: Shah NS and Donald AG (Eds), Movement Disorders, Plenum Publishing Co., New York, 1986, pp. 1-36.
60. 1986 Stahl SM, Leenders KL and Bowery NG. Imaging neurotransmitters and their receptors in living human brain by positron emission tomography. Trends in Neurosciences 9(6):241-245, 1986.
61. 1986 Uhr SB, Pruitt B, Berger PA and Stahl SM. Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist. International Clinical Psychopharmacology 1:216-220, 1986.
62. 1986 Stahl SM and Palazidou L. The pharmacology of depression: studies of neurotransmitter receptors lead the search for biochemical lesions and new drug therapies. Trends in Pharmacological Sciences 7(9):349-354, 1986.
63. 1986 Stahl SM. Tardive dyskinesia: natural history studies assist the pursuit of preventive therapies. Psychological Medicine 16:491-494, 1986.
64. 1986 Stahl SM and Kravitz KD. A critical review of the use of laboratory tests in psychiatric disorders. In: Berger PA and Brodie HKH (Eds), American Handbook of Psychiatry, Volume VIII, Basic Books, Inc., New York, 1986, Chapter 35, pp. 1048-1084.
65. 1987 Williams JR, Spencer PS, Stahl SM, Borzelleca JF, Nichols W, Pfitzer E, Yunis EJ, Carchman R, Opishinski JW and Walford RA. Interactions of aging and environmental agents: the toxicological perspective. In: Baker SR and Rogul M (Eds), Environmental Toxicity and The Aging Processes, Progress in Clinical and Biological Research, Vol. 228, Alan R. Liss Inc., New York, 1987, pp. 81-135.
66. 1987 Nomoto M, Stahl SM, Jenner P and Marsden CD. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Movement Disorders 2(1):37-45, 1987.
67. 1987 Grandas F, Quinn N, Critchley P, Rohan A, Marsden CD and Stahl SM. Antiparkinsonian activity of a single oral dose of PHNO. Movement Disorders 2(1):47-51, 1987.

PUBLICATIONS (7)

68. 1987 Stahl SM. Needs and opportunities for innovation in psychopharmacology. Journal of the Royal Society of Medicine 80(7):413-417, 1987.
69. 1987 Stahl SM and Wets K. Indoleamines and schizophrenia. In: Henn FA and DeLisi LE (Eds), Handbook of Schizophrenia, Vol. 2: Neurochemistry and Neuropharmacology of Schizophrenia, Elsevier Science Publishers B.V., 1987, pp. 257-296.
70. 1987 Cohen JD, Van Putten T, Marder S, Berger PA and Stahl SM. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology 7(5):324-329, 1987.
71. 1987 Beer M, Hacker S, Poat J and Stahl SM. Independent regulation of β_1 - and β_2 -adrenoceptors. British Journal of Pharmacology 92:827- 834, 1987.
72. 1987 Martin-Iverson MT, Stahl SM and Iversen SD. Factors determining the behavioural consequences of continuous treatment with 4-propyl-9-hydroxynaphthoxazine, a selective dopamine D2 agonist. In: Rose FC (Ed), Parkinson's Disease: Clinical and Experimental Advances, John Libbey, London, 1987, pp. 169-177.
73. 1987 Coleman RJ, Grandas-Perez F, Quinn N, Jenner P, Nomoto M, Marsden CD and Stahl SM. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models. In: Rose FC (Ed), Parkinson's Disease: Clinical and Experimental Advances, John Libbey, London, 1987, pp. 179-187.
74. 1987 Stahl SM, Beer M, Hacker S, Poat J and Iversen LL. Beta₁- and Beta₂-adrenoceptor regulation in rat nervous system by chronic treatment with desipramine and beta-adrenoceptor agonists. Psychopharmacology Bulletin 23(3):473-475, 1987.
75. 1987 Cohen JD, Van Putten T, Marder SR and Stahl SM. Treatment of the symptoms of schizophrenia with piquindone: a new atypical neuroleptic. Psychopharmacology Bulletin 23(3):514-518, 1987.
76. 1987 Reiss AL and Stahl SM. Inpatient clinical research: its importance in psychiatry and psychopharmacology. In: Alarcon RD and Walter-Ryan WG (Eds), Psychiatric Medicine 4(4):407-416, 1987.
77. 1988 Stahl SM and Wets KM. Recent advances in drug delivery technology for neurology. Clinical Neuropharmacology 11(1):1-17, 1988.
78. 1988 Stahl SM, Jernigan T, Pfefferbaum A and Zatz L. Brain computerized tomography in subtypes of severe chronic schizophrenia. Psychological Medicine 18:73-77, 1988.

PUBLICATIONS (8)

79. 1988 Beer M, Richardson A, Poat J, Iversen LL and Stahl SM. In vitro selectivity of agonists and antagonists for Beta₁- and Beta₂-adrenoceptor subtypes in rat brain. Biochemical Pharmacology 37(6):1145-1151, 1988.
80. 1988 Reiss AL, Harris JC and Stahl SM. Inpatient psychiatric research. Psychiatric Annals 18(2):97-101, 1988.
81. 1988 Coleman RJ, Grandas-Perez F, Quinn N, Jenner P, Nomoto M, Marsden D and Stahl S. 4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models. In: Fahn S, Marsden CD, Calne DB and Goldstein M (Eds), Recent Developments in Parkinson's Disease, Vol. II, Macmillan Healthcare Information, New Jersey, 1988, pp. 269-278.
82. 1988 Gilbert F, Brazell C, Tricklebank M and Stahl SM. Activation of the 5HT_{1A} receptor subtype increases rat plasma ACTH concentration. European Journal of Pharmacology 147:431-439, 1988.
83. 1988 Stahl SM. Applications of new drug delivery technologies to Parkinson's disease and dopaminergic agents. Journal of Neural Transmission (Suppl) 27:123-132, 1988.
84. 1988 Martin-Iverson MT, Iversen SD and Stahl SM. Long-term motor stimulant effects of (+)-4-propyl-9-hydroxy-naphthoxazine (PHNO), a dopamine D-2 receptor agonist: interactions with a dopamine D-1 receptor antagonist and agonist. European Journal of Pharmacology 149:25-31, 1988.
85. 1988 Palazidou E, Beer M, Checkley S and Stahl SM. Pharmacologic exploitation of neurotransmitter receptors for the design of novel antidepressant drugs. Drug Design and Delivery 2:247-256, 1988.
86. 1988 Martin-Iverson MT, Stahl SM and Iversen SD. Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization. Psychopharmacology Berlin 95(4):534-539, 1988.
87. 1988 Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM and Jernigan TL. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry 45(7):633-640, 1988.
88. 1988 Stahl SM, Moratalla R and Bowery NG. Neurotransmitter receptor imaging in living human brain with positron emission tomography. Journal of Mind & Behavior 9:367-384, 1988.

PUBLICATIONS (9)

89. 1988 Stahl SM. The biochemistry of depression. Journal de psychiatrie biologique et therapeutique 30:44-53, 1988.
90. 1988 Stahl SM. Basal ganglia neuropharmacology and obsessive-compulsive disorder: the obsessive-compulsive disorder hypothesis of basal ganglia dysfunction. Psychopharmacology Bulletin 24:370-374, 1988.
91. 1988 Stahl SM. Treatment of the on-off dyskinesia syndrome of Parkinson's disease with new drug delivery technologies for selective dopamine-2 receptor agonists. In: Wolf ME and Mosnaim AD Eds), Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects, American Psychiatric Press, Washington, DC, 1988, pp. 233-242.
92. 1988 Broks P, Preston GC, Traub M, Poppleton P, Ward C and Stahl SM. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26(5):685-700, 1988.
93. 1988 Gilbert F, Dourish CT, Brazell C, McClue S and Stahl SM. Relationship of increased food intake and plasma ACTH levels to 5-HT_{1A} receptor activation in rats. Psychoneuroendocrinology 13(6):471-478, 1988.
94. 1988 Preston GC, Broks P, Traub M, Ward C, Poppleton P and Stahl SM. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology (Berlin) 95(2):208- 215, 1988.
95. 1988 Clarke CE, Boyce S, Sambrook MA, Stahl SM and Crossman AR. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn-Schmiedeberg's Archives of Pharmacology 338(1):35-38, 1988.
96. 1988 Schwartzman RJ, Alexander GM, Ferraro TN, Grothusen JR and Stahl SM. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Experimental Neurology 102(3):307-313, 1988.
97. 1988 Stahl SM and Wets KM. Clinical pharmacology of schizophrenia. In: Bebbington P and McGuffin P (Eds), Schizophrenia: the Major Issues (based on the Mental Health Foundation Conference, New Initiatives in Schizophrenia Research), Heinemann Professional Publishing, Oxford, 1988, pp. 135-157.
98. 1988 Carpenter WT, Schooler NR, Wise SS, Goldman H, Goldstein MJ, Hogarty GE, Jeste D, Kane JM, Klerman GL, Liberman RP, Paul SM, Robinson DS, Spring B, Stahl SM and Tamminga CA. Treatment, Services and Environmental Factors Panel. A National Plan for Schizophrenia Research: Report of the National Advisory Mental Health Council. NIMH, 1988, pp. 34-38.

PUBLICATIONS (10)

99. 1988 Coleman RJ, Jenner P, Marsden CD and Stahl SM. Effects of (+)-4-propyl-9-hydroxynaphthoxazine, a new dopamine agonist, in Parkinson's disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. For: 6th International Catecholamine Symposium, Jerusalem, Israel, June 14, 1987, Alan R.Liss, Inc. In: Liss AR (Ed). Progress in Catecholamine Research Part C: Clinical Aspects, 1988, pp. 19-23.
100. 1988 Preston GC, Brazell C, Ward C, Broks P, Traub M and Stahl SM. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. Journal of Psychopharmacology 2(2):67-79, 1988.
101. 1989 Carpenter WT, Schooler NR, Wise SS, Goldman H, Goldstein MJ, Hogarty GE, Jeste D, Kane JM, Klerman GL, Liberman RP, Paul SM, Robinson DS, Spring B, Stahl SM and Tamminga CA. Treatment Services, and Environmental Factors. A National Plan for Schizophrenia Research: Panel Recommendations. Schizophrenia Bulletin 14(3):425-437, 1988; and NIMH, 1989, pp. 82-92.
102. 1989 Stahl SM. Agonist-induced down-regulation of α_1 adrenergic receptors: possible biochemical rationale for novel antidepressants. In: Lerer B and Gershon S (Eds), New Directions in Affective Disorders, Springer-Verlag, New York, 1989, pp. 25-38.
103. 1989 Palazidou E, Papadopoulos A, Sitsen A, Stahl S and Checkley S. An α_2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology 97:115-117, 1989.
104. 1989 Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Iversen SD and Stahl SM. Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in Parkinsonian squirrel monkeys. Journal of Neurology, Neurosurgery and Psychiatry 52:289-290, 1989.
105. 1989 Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Hand E, Iversen SD and Stahl SM. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 39(3):329-335, 1989.
106. 1989 Preston GC, Ward CE, Broks P, Traub M and Stahl SM. Effects of lorazepam on memory, attention and sedation in man: antagonism by Ro 15-1788. Psychopharmacology (Berlin) 97(2):222-227, 1989.
107. 1989 McClue SJ, Brazell C and Stahl SM. Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT₂ receptor. Biological Psychiatry 26(3):297-302, 1989.

PUBLICATIONS (11)

108. 1989 Obeso JA and Stahl SM. New routes of administration for antiparkinsonian therapy. In: Calne DB (Ed), Drugs for the treatment of Parkinson's Disease, Handbook of Experimental Pharmacology, Springer-Verlag, Germany, 1989, pp. 531-541.
109. 1989 Coleman RJ, Temlett JA, Quinn NP, Stahl SM and Marsden CD. A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations. Clinical Neuropharmacology 12(1):37-45, 1989.
110. 1989 Palazidou E, Franey C, Arendt J, Stahl S and Checkley S. Evidence for a functional role of alpha₁ adrenoceptors in the regulation of melatonin secretion in man. Psychoneuroendocrinology 14(1-2):131-135, 1989.
111. 1989 Coleman RJ, Lange KW, Quinn NP, Loper AE, Bondi JV, Hichens M, Stahl SM and Marsden CD. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Movement Disorders 4(2):129-138, 1989.
112. 1989 Brazell C, Zentner GM, Gardner CR, Jenner P and Stahl SM. Delivery of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] by a novel orally administered osmotic tablet: behavioural effects in animal models of Parkinson's disease. In: Quinn NP and Jenner PG (Eds), Disorders of Movement, Academic Press, London, 1989, pp. 209-222.
113. 1989 Coleman RJ, Temlett JA, Nomoto M, Quinn NP, Jenner P and Stahl SM. The antiparkinsonian effects of transdermal +PHNO. In: Quinn NP and Jenner PG (Eds), Disorders of Movement, Academic Press, London, 1989, pp. 147-155.
114. 1990 Twist EC, Mitchell S, Brazell C, Stahl SM and Campbell IC. 5HT₂ receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration. Biochemical Pharmacology 39(1):161-166, 1990.
115. 1990 Traub M and Stahl SM. Therapeutic potential of a novel dopamine agonist, naxagolide. In: Koller WC and Paulson G (Eds), Therapy of Parkinson's Disease, Marcel Dekker Inc., New York, 1990, pp. 325-332.
116. 1990 Rausch JL, Stahl SM and Hauger RL. Cortisol and growth hormone responses to the 5-HT_{1A} agonist gepirone in depressed patients. Biological Psychiatry 28:73-78, 1990.
117. 1990 Stahl SM, Rausch JL and Hauger RL. 5HT_{1A} neuroendocrine diagnostic and efficacy markers in depression. In: Stefanis CN, Rabavilas AD and Soldatos CR (Eds), Psychiatry: A World Perspective: Proceedings of the VIII World Congress of Psychiatry, Athens, 12-18 October 1989, Vol. 2, Excerpta Medica, Elsevier Science Publishers B.V., Amsterdam, 1990, pp. 331-333.

PUBLICATIONS (12)

118. 1990 Coleman RJ and Stahl SM. Movement disorders. In: Dinan TG (Ed), Principles and Practice of Biological Psychiatry, Clinical Neuroscience Publishers, London, 1990, pp. 183-203.
119. 1991 Stahl SM. Pipothiazine. In: Dollery C (Ed), Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, pp. P120-P132.
120. 1991 Stahl SM. Trazodone (hydrochloride). In: Dollery C Ed), Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, pp. T115-T119.
121. 1991 Stahl SM. Serotonin receptors and the mechanism of action of antidepressants drugs. In: Racagni G, et al, (Eds), Biological Psychiatry, Vol. 2. Elsevier Science Publishers B.V., Amsterdam, 1991, pp. 898-900.
122. 1991 Brazell C, McClue SJ, Preston GC, King B and Stahl SM. 5-hydroxytryptamine (5HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [¹²⁵I]-iodoLSD binding at 5HT₂ receptors. Blood Coagulation and Fibrinolysis 2:17-24, 1991.
123. 1992 Stahl SM. Serotonin receptors and the mechanism of action of antidepressant drugs: postmortem, platelet and neuroendocrine studies in depressed patients. In: Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J, (Eds), Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York, 1992, pp. 119-134.
124. 1992 Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J. New vistas for serotonin 1A agonists in psychiatry. In: Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J, (Eds), Serotonin 1A Receptors in Depression and Anxiety, Raven Press, New York, 1992, pp. 201-205.
125. 1992 Freedman DX and Stahl SM. Pharmacology: policy implications of new psychiatric drugs. Health Affairs 11(3):157-163, 1992.
126. 1992 Stahl SM. Neuroendocrine markers of serotonin responsivity in depression. Progress in NeuroPsychopharmacology and Biological Psychiatry 16:655-659, 1992.
127. 1992 Stahl SM. Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychopharmacology Bulletin 28(1):3-9, 1992.
128. 1992 Freedman DX and Stahl SM. Contempo 1992: Psychiatry. Journal of American Medical Association 268(3):403-405, 1992.
129. 1993 Stahl SM. Mixed anxiety and depression: clinical implications. Journal of Clinical Psychiatry (suppl) 54(1):33-38, 1993.

PUBLICATIONS (13)

130. 1993 Stahl SM. Serotonergic mechanisms and the new antidepressants. Psychological Medicine 23:281-285, 1993.
131. 1993 Bronzo MR and Stahl SM. Galactorrhea induced by sertraline. Letter to the Editor, American Journal of Psychiatry 150(8):1269-1270, 1993.
132. 1993 Stahl SM, Hauger RL, Rausch JL, Fleishaker JC and Hubbell-Alberts EA. Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clinical Neuropharmacology 16(3):S19-S31, 1993.
133. 1993 Freedman DX and Stahl SM. Contempo 1993: Psychiatry. Journal of the American Medical Association 270(2):252-254, 1993.
134. 1993 Stahl SM. Alprazolam-XR: dosage considerations. Psychiatric Annals (suppl):27-31, 1993.
135. 1994 Stahl SM. New therapeutic advances in schizophrenia. In: Ancill R (Ed), Schizophrenia: Exploring the Spectrum of Psychosis, John Wiley & Sons Ltd., Sussex, 1994, pp. 137-152.
136. 1994 Stahl SM. Synaptic transmitters and neuromodulators. Ramachandran VS, (Ed). Encyclopedia of Human Behavior, Volume 4. Academic Press, San Diego, 1994, pp. 359-367.
137. 1994 Stahl SM and Hauger RL. Stress: An overview of the literature with emphasis on job-related strain and intervention. Advances in Therapy 11(3):110-119, 1994.
138. 1994 Stahl SM. Is serotonin receptor down regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacology Bulletin 30(1):39-43, 1994.
139. 1994 Gillin JC, Jernajczyk W, Valladares-Neto DC, Golshan S, Lardon M and Stahl SM. Inhibition of REM sleep by ipsapirone, A 5HT_{1A} agonist, in normal volunteers. Psychopharmacology 116:433-436, 1994.
140. 1995 Stahl SM. Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry (editorial). International Review of Psychiatry 7:3-4, 1995.
141. 1995 Stahl SM and Frakes DC. Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. International Review of Psychiatry 7:29-39, 1995.

PUBLICATIONS (14)

142. 1995 Kunovac JL and Stahl SM. Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. International Review of Psychiatry 7:55-67, 1995.
143. 1995 Rausch JL, LaFrance C and Stahl SM. Serotonin receptor-specific mediation of antidepressant treatment effects in depressed patients. International Review of Psychiatry 7:85-98, 1995.
144. 1995 Kunovac JL and Stahl SM. Future directions in anxiolytic pharmacotherapy. In: Pollack MH and Otto M, (Eds), The Psychiatric Clinics of North America 18(4):895-990, 1995.
145. 1995 Stahl SM and Soefje S. Panic attacks and panic disorder: the great neurologic imposters. In: Evans RW (Ed), Funny Spells, Seminars in Neurology 15(2):126-32, 1995.
146. 1995 Stahl SM and Kunovac JL. Neurotransmitter systems in obsessive compulsive disorder. In: Michaels R. (Eds). Psychobiological Foundations of Clinical Psychiatry, Psychiatry(3):64, Lippincott-Raven, Philadelphia, 1995, pp. 1-14.
147. 1996 Stahl SM. Phenomenology of anxiety disorders: clinical heterogeneity & comorbidity. In: Westenberg HGM, Murphy DL, and Den Boer JA (Eds), Advances in the Neurobiology of Anxiety Disorders, J. Wiley & Sons, Ltd., Chichester, U.K., Chapter 2, 1996, pp.21-38.
148. 1996 Seifritz E, Moore P, Trachsel, L, Bhatti T, Stahl SM and Gillin JC. The 5-HT_{1A} agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT₂ blockade. In: Neuroscience Letters 209:41-44, 1996.
149. 1996 Stahl SM. Diagnostic dilemmas in anxiety disorders. In: den Boer JA (Ed), Clinical Management of Anxiety; Theory and Practical Applications, Marcel Dekker Inc., New York, 1996, Chapter 2, pp 23-41.
150. 1996 Stahl, SM. Second messenger systems. Psychiatric Annals 26(4):183-184, 1996.
151. 1996 Stahl, SM. Two receptor superfamilies mediate fast and slow neurotransmission. Psychiatric Annals 26(5):244-253, 1996.
152. 1996 Stahl, SM. Beyond the second messenger: how molecular events mediate receptor downregulation. Psychiatric Annals 26(6):302-303, 1996.
153. 1996 Stahl, SM. The new antidepressants act by four distinct mechanisms. Psychiatric Annals 26(7):377-382, 1996.

PUBLICATIONS (15)

154. 1996 Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH and Cutler NR. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Journal of Clinical Psychiatry 57(7):287-291, 1996.
155. 1996 Gillin JC, Sohn WJ, Stahl SM, Lardon M, Kelsoe J, Rapaport M, Ruiz C and Golshan S. Ipsapirone, a 5HT_{1A} agonist, supresses REM sleep equally in depressed patients and normal controls. Neuropsychopharmacology 15(2):109-115, 1996.
156. 1996 Stahl, SM. Serotonin receptors. Psychiatric Annals 26(8):505-507, 1996.
157. 1996 Stahl, SM. Immediate actions of SSRIs (serotonin selective reuptake inhibitors). Psychiatric Annals 26(9):564-565, 1996.
158. 1996 Stahl, SM. Long-term actions of SSRIs (serotonin selective reuptake inhibitors). Psychiatric Annals 26(10):626-627, 1996.
159. 1996 Stahl, SM. Serotonin pathways: mediators of SSRI (serotonin selective reuptake inhibitors) therapeutic actions. Psychiatric Annals 26(11):695-696, 1996.
160. 1996 Stahl SM. Serotonin pathways: mediators of SSRI side effects. Psychiatric Annals 26(12):738-742, 1996.
161. 1996 Sussman N and Stahl MS. Update in the pharmacotherapy of depression. The American Journal of Medicine (suppl)6A(101):26S-36S, 1996.
162. 1997 Stimmel GL, Dopheide JA, and Stahl SM. Mirtazapine: an antidepressant with selective alpha-2 adrenoceptor antagonist effects. Pharmacotherapy 17(1):10-21, 1997.
163. 1997 Stahl SM. Remeron (mirtazepine): a novel antidepressant that disinhibits serotonin and norepenephrine by alpha-2 antagonism. Psychiatric Annals 27(1):14-16, 1997.
164. 1997 Stahl SM. Remeron (mirtazapine): designing specific serotonergic actions. Psychiatric Annals 27(2):138-144, 1997.
165. 1997 Stahl SM. Glutamate: the universal excitatory neurotransmitter. Psychiatric Annals 27(3):152-155, 1997.
166. 1997 Stahl SM. Excitotoxicity: too much glutamate may be hazardous to your health. Psychiatric Annals 27(4):240-242, 1997.
167. 1997 Stahl SM. Apoptosis: neuronal death by design. Journal of Clinical Psychiatry 58(5):183-185, 1997.

PUBLICATIONS (16)

168. 1997 Stahl SM. The cytochrome P450 system Part 1: 1A2 and 2D6. Psychiatric Annals 27(6):400-402, 1997.
169. 1997 Stahl SM. Excitotoxicity and neuroprotection. Journal of Clinical Psychiatry 58(6):247-248, 1997.
170. 1997 Stahl SM and Sussman N. Mirtazapine: A Clinical Profile. Primary Psychiatry 4(6):83, 1997.
171. 1997 Stahl SM. The cytochrome P450 system Part 2: 3A3, 4. Psychiatric Annals 27(7):469-470, 1997.
172. 1997 Stahl SM. Mental illness may be damaging to your brain. Journal of Clinical Psychiatry 58(7):289-290, 1997.
173. 1997 Stahl SM, Zivkov M, Reimitz PE, and Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatrica Scandinavica (suppl) 391(96):22-30, 1997.
174. 1997 Stahl SM. Are two antidepressant mechanisms better than one? Journal of Clinical Psychiatry 58(8):339-341, 1997
175. 1997 Sambunaris A, Keppel Hesselink J, Pinder R, Panagides J, and Stahl SM. Development of new antidepressants. Journal of Clinical Psychiatry 58 (Suppl 6):40-53, 1997.
176. 1997 Stahl SM. Mixed depression and anxiety: serotonin 1A receptors as a common pharmacological link. Journal of Clinical Psychiatry 58 (Suppl 8):20-26, 1997.
177. 1997 Stahl SM. Amyloid cascade hypothesis of Alzheimer's disease. Psychiatric Annals 27(8):528-537, 1997.
178. 1997 Stahl SM. Neuroprotection: rescuing the brain from endogenous assassins. Psychiatric Annals 27(9):606-609, 1997.
179. 1997 Stahl SM. Selecting an antidepressant by matching patient profiles with antidepressant profiles. Psychiatric Annals 27(9):610-612, 1997.
180. 1997 Stahl SM. "Awakening" from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. Journal of Clinical Psychiatry 58(9):381-382.

PUBLICATIONS (17)

181. 1997 Seifritz E, Stahl SM and Gillin JC. Human sleep EEG following the 5-HT_{1A} antagonist pindolol: possible disinhibition of raphe neuron activity. Brain Research 759(1997): 84-91, 1997.
182. 1997 Stahl SM. Estrogen makes the brain a sex organ. Journal of Clinical Psychiatry 58(10): 421-422.
183. 1997 Stahl SM. Sex therapy for Psychiatrists has a new partner: reproductive hormones. Journal of Clinical Psychiatry 58(11): 468-469.
184. 1997 Stahl SM. Serotonin: It's possible to have too much of a good thing. Journal of Clinical Psychiatry 58(12): 520-521.
185. 1997 Stahl SM. Antidepressant combinations and augmentation strategies for difficult cases, Part 1: The serotonin strategy versus the classical strategies. Psychiatric Annals 27_(10): 657-660.
186. 1997 Lydiard RB, Stahl S, Hertzman M, and Harrison WM. A double-blind placebo-controlled study comparing the effects of sertraline with amitriptyline on quality of life in the treatment of major depression. Journal of Clinical Psychiatry 58: (11) 484-491, 1997.
187. 1997 Stahl SM. Reproductive hormones as adjuncts to psychotropic medication. Directions in Psychiatry, Volume 17: 303-314. The Hatherleigh Company, New York, 1997.
188. 1997 Stahl SM. Antidepressant combinations and augmentation strategies for difficult cases, Part 2: The heroic strategy. Psychiatric Annals 27: (11) 722-724.
189. 1997 Stahl SM. Treatments of Alzheimer's Disease: past, present and future. Psychiatric Annals 27: (12) 771- 772.
190. 1998 Bhatti T, Seifritz E, Clark C, Golshan S, Moore P, Stahl S, Rapaport M, Kelsoe J, Gillin JC. Effects of a tryptophan-free amino acid drink challenge on normal human sleep and EEG and mood. Biological Psychiatry 43:52-29, 1998.
191. 1998 Stahl SM. Brain Fumes: Yes, We Have NO Brain Gas. Journal of Clinical Psychiatry 59: (1) 6-7, 1998.
192. 1998 Stahl SM. Drug Combinations and Augmentation Strategies for Difficult Cases of Obsessive Compulsive Disorder. Psychiatric Annals 28:(1): 8-12.
193. 1998 Stahl SM. Drug Combinations and Augmentation Strategies for Difficult Cases of Panic Disorder. Psychiatric Annals 28: (2): 69-70, 1998.

PUBLICATIONS (18)

194. 1998 Stahl SM. How Psychiatrists can build new therapies for impotence. Journal of Clinical Psychiatry 59: (2): 47-48, 1998.
195. 1998 Stahl SM. Basic Psychopharmacology of Antidepressants (Part 1): Antidepressants have seven distinct mechanisms of action. Journal of Clinical Psychiatry 59: (Suppl.4) 5-14, 1998.
196. 1998 Stahl SM. Basic Psychopharmacology of Antidepressants (Part 2): Estrogen as an adjunct to antidepressant treatment. Journal of Clinical Psychiatry 59: (Suppl.4) 15-24, 1998.
197. 1998 Stahl SM. Nitric Oxide Physiology and Pharmacology. Journal of Clinical Psychiatry 59:(3) 101-102, 1998.
198. 1998 Stahl SM. Brain Tonics for Brain Sprouts: How Neurotrophic Factors Fertilize Neurons. Journal of Clinical Psychiatry 59: (4) 149-150, 1998.
199. 1998 Stahl SM. Recognition Molecules Are Trailblazers for Axon Pathways. Journal of Clinical Psychiatry 59: (5) 215-216, 1998.
200. 1998 Stahl SM, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int. Journal of Neuropsychopharmacology. Vol.1, No.1, 11-18, 1998.
201. 1998 Stahl SM. When Neurotrophic Factors get on your nerves: therapy for neurodegenerative disorders. Journal of Clinical Psychiatry. 59: (6) 277-278, 1998.
202. 1998 Stahl SM. Not So Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry. 59: (7) 343-344, 1998.
203. 1998 Stahl SM. What Makes An Antipsychotic Atypical. Journal of Clinical Psychiatry. 59: (8) 403-404, 1998.
204. 1998 Seifritz E, Gillin JC, Kelsoe JR, Rapaport MH, Bhatti T and Stahl SM. Sleep EEG response to muscarinic and Serotonin _{1A} Receptor Probes in Patients with Major Depression and in Normal Controls. Biological Psychiatry 4 (7): 21-33, 1998.
205. 1998 Stahl SM. Neuropharmacology of Obesity: My Receptors Made Me Eat It. Journal of Clinical Psychiatry. 59: (9) 447-448, 1998.
206. 1998 Stahl SM. How To Appease the Appetite of Psychotropic Drugs. Journal of Clinical Psychiatry. 59: (10) 500-501.

PUBLICATIONS (19)

207. 1998 Stahl SM. Enhancing Cholinergic neurotransmission with the new cholinesterase inhibitors: implications for Alzheimer's Disease and Cognitive Disorders. Hospital Practice. Vol. 33 No. 11, 131-136.
208. 1998 Stahl SM. Selecting an antidepressant using mechanism of action to enhance efficacy and avoid side effects. Journal of Clinical Psychiatry. 59: (Suppl. 18) 23-29.
209. 1998 Stahl SM. Augmentation of antidepressants by Estrogen. Psychopharmacology Bulletin. 34 (3): 319-321.
210. 1998 Moore PJ, Gillin JC, Bhatti T, Seifritz E, Clark C, Stahl SM, Kelsoe J and Rapaport M. Rapid tryptophan depletion affects sleep EEG but not mood in fully remitted and depressed patients on serotonin reuptake inhibitors. Archives of General Psychiatry. 55: (6) 534-539.
211. 1998 Stahl SM. Getting Stoned Without Inhaling: Anandamide is the Brain's Natural Marijuana. Journal of Clinical Psychiatry. 59 (11): 566-567.
212. 1998 Stahl SM. Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor. Journal of Clinical Psychiatry. 59 (12): 642-643.
213. 1998 Stahl SM. Mechanism of Action of Serotonin Selective Reuptake Inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects (mechanism of action of SSRIs). Journal of Affective Disorders 12: 51 (3) 215-235.
214. 1999 Stahl SM. Peptides and Psychiatry, Part 1: How Synthesis of Neuropeptides Differs from Classical Neurotransmitter Synthesis. Journal of Clinical Psychiatry. 60 (1): 5-6.
215. 1999 Stahl SM. Substance P and the Neurokinins, Part 2: Novel Peptide Neurotransmitters in Psychopharmacology. Journal of Clinical Psychiatry. 60 (2): 77-78.
216. 1999 Stahl SM. Peptides and Psychiatry, Part 3: Substance P and Serendipity: Novel Psychotropics Are A Possibility. Journal of Clinical Psychiatry. 60 (3): 140-141.
217. 1999 Stahl SM. Why Settle For Silver, When You Can Go for Gold? Response vs. Recovery as the Goal of Antidepressant Therapy. Journal of Clinical Psychiatry 60: (4) 213-214.

PUBLICATIONS (20)

218. 1999 Stahl SM. Mergers and Acquisitions Among Psychotropics: Antidepressant Takeover of Anxiety May Now Be Complete. Journal of Clinical Psychiatry 60: (5) 282-283.
219. 1999 Stahl SM (Editor). What Makes An Antipsychotic Atypical? Journal of Clinical Psychiatry 60 (Supplement 10).
220. 1999 Stahl SM. Selecting An Atypical Antipsychotic by Combining Clinical Experience With Guidelines From Clinical Trials. Journal of Clinical Psychiatry. 60 (Supplement 10): 31-41.
221. 1999 Stahl SM. Antidepressants: The Blue-Chip Psychotropic for the Modern Treatment of Anxiety Disorders. Journal of Clinical Psychiatry. 60: (6) 356-357.
222. 1999 STAHL SM. Antipsychotic Polypharmacy, Part I: Therapeutic Option or Dirty Little Secret? Journal of Clinical Psychiatry. 60: (7) 425-426.
223. 1999 Stahl SM. Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. Journal of Clinical Psychiatry.60: (8) 506-507.
224. 1999 Shelton RC, Simon GE, Stahl SM, Treisman GJ and Williams JW. Fine Tuning the Treatment of Depression. Patient Care, Vol. 13, No. 13, 181-197.
225. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 1, Overview of Gene Activation by Neurotransmitters. Journal of Clinical Psychiatry. 60: (9) 572-573.
226. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 2: How Neurotransmitters Activate Second Messenger Systems. Journal of Clinical Psychiatry. 60: (10) 647-648.
227. 1999 Stahl SM. Reply to Masand P: "Relative Weight Gain Among Antipsychotics". Journal of Clinical Psychiatry. 60: (9) 707-708.
228. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 3: How Second Messengers "Turn On" Genes by Activating Protein Kinases and Transcription Factors. Journal of Clinical Psychiatry. 60: (11) 731-732.
229. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 4: Transferring the Message of Chemical Neurotransmission From Presynaptic Neurotransmission to Postsynaptic Gene Expression. Journal of Clinical Psychiatry. 60: (12) 813-814.

PUBLICATIONS (21)

230. 1999 Settle EC, Stahl SM, Batey SR, Johnston JA, and Ascher JA. Safety and tolerability of the sustained-release form of bupropion in depression: a review of results of three clinical trials. Clinical Therapeutics Volume 31; (3): 454-463, 1999.
231. 2000 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 5: How a Leucine Zipper Can Turn On Genes: Immediate-Early Genes Activate Late-Gene Expression in the Brain. Journal of Clinical Psychiatry. 61: (1) 7-8.
232. 2000 Stahl SM and Kunovac JL. Serotonin-Specific Anxiolytics: Now and in the Future. In: Montgomery S and Halbreich U, (Eds), Pharmacotherapy of Mood and Cognition, American Psychiatric Press, Inc., Washington,DC, 2000, pp. 355-366.
233. 2000 Stahl SM, Judd LL and Kunovac JL. Overview of New Anxiolytics: In: Montgomery S and Halbreich U, (Eds), Pharmacotherapy of Mood and Cognition, American Psychiatric Press, Inc. Washington, D.C.,2000, pp. 333-340.
234. 2000 Stahl SM. Blue Genes and the Monoamine Hypothesis of Depression. Journal of Clinical Psychiatry. 61: (2)77-78.
235. 2000 Stahl SM. Blue Genes and the Mechanism of Action of Antidepressants. Journal of Clinical Psychiatry. 61:(3) 164-165.
236. 2000 Stahl SM and Shayegan D. New Discoveries In The Development of Antipsychotics With Novel Mechanisms of Action: Beyond The Atypical Antipsychotics With Serotonin Dopamine Antagonism. In: Atypical Antipsychotics (MDT)/ed. by B.A. Ellenbroek and A.R. Cools, pp. 215-232, 2000.
237. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists. Journal of Clinical Psychiatry. 61: (4) 242-243.
238. 2000 Hoehn-Saric R, Ninan P, Black D, Stahl SM, Griest J, Lydiard B, McElroy S, Zajecka J, Harrison W, Clary C, Chapman D. Multicenter Double-Blind Comparison of Sertraline vs. Desipramine for Concurrent Obsessive-Compulsive Disorder and Major Depressive Disorder. Archives of General Psychiatry, Vol. 57, January, 76- 82, 2000.
239. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists,Part 2: Begin with the End in Mind. Journal of Clinical Psychiatry. 61: (5) 327-328.
240. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists. Part 3: Sharpen the Saw with Selective Choices of Continuing Medical Education Programs. Journal of Clinical Psychiatry 61 (6): 401-402.

PUBLICATIONS (22)

241. 2000 Stahl SM. Gold vs. Silver: the issue of functional vs. symptomatic recovery in depression (Pradham). Journal of Clinical of Psychiatry. 61: (6) 447-448.
242. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists, Part 4: Developing and Implementing the Vision. Journal of Clinical Psychiatry. 61: 7, 464-465.
243. 2000 Stahl SM. Polypharmacy of Two Atypical Antipsychotics. Letter to the Editor #2155. Journal of Clinical Psychiatry. 61: (9), 679-680.
244. 2000 Stahl SM. Paying Attention to Your Acetylcholine, Part I: Structural Organization of Nicotinic Receptors. Journal of Clinical Psychiatry. 61: (8), 547-548.
245. 2000 Stahl SM. Paying Attention to Your Acetylcholine, Part 2: The Function of Nicotinic Receptors. Journal of Clinical Psychiatry. 61: (9), 628-629.
246. 2000 Shayegan D and Stahl SM. Buspirone. In: Briley and Nutt (eds.) Milestones in Drug Therapy - Anxiolytics. Birkhauser Verlag, Basel, Boston, Berlin, 2000, pages 13-25.
247. 2000 Stahl SM. Placebo-Controlled Comparison of the Selective Serotonin Reuptake Inhibitors Citalopram and Sertraline. Biological Psychiatry Vol. 48, pages 894-901.
248. 2000 Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 1 "Their Similarities Are Different". J. Clin.Psychiatry 61: (10), 710-711.
249. 2000 Stahl SM. Commentary on the limitation of antidepressants in current use. In: Antidepressants, edited by B. E. Leonard, Birkhauser Verlag Basel 2001, pages 31-43.
250. 2000 Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: Illustrating Their Mechanisms of Action. J.Clin.Psychiatry 61: (11), 813-814.
251. 2000 Stahl SM. New Drug Discovery in the Postgenomic Era: From Genomics to Proteomics" J of Clinical Psychiatry 61: (12), 894-895.
252. 2000 Stein DJ and Stahl SM. Serotonin and Anxiety: Current Models. International Clinical Psychopharmacology, 2000; 2000: S1-6.
253. 2001 Shelton RC, Tollefson GD, Tohen M, Gannon KS, Jacobs T, Buras W, Bymaster FP, Zhang W, Spencer K, Feldman PD, Stahl SM and Meltzer HY. A Novel Augmentation Strategy for Treatment-Resistant Major Depression. Am J Psychiatry 2001; 158: 131-134.

PUBLICATIONS (23)

254. 2001 Stahl SM. Does Evidence From Clinical Trials in Psychopharmacology Apply in Clinical Practice? Journal Of Clinical Psychiatry 62: (1), p 6-7.
255. 2001 Ferguson, JM, Sahrivastava RK, Stahl SM, Hartford JT, Borian F, Leni John, McQuade RD, and Jody D. Re-emergence of Sexual Dysfunction in Patients with Major Depressive Disorder: Double-Blind Comparison of Nefazodone and Sertraline. Journal of Clinical Psychiatry 62: (1) 24-29.
256. 2001 Stahl SM, Nierenberg A and Gorman J. Evidence of Early Onset of Antidepressant Effect in Randomized Controlled Trials. J. Clinical Psychiatry, Vol 62, Supplement 4, p. 17-23.
257. 2001 Stahl SM. The Psychopharmacology of Sex: Part 1. Neurotransmitters and the 3 Phases of the Human Sexual Response. Journal of Clinical Psychiatry 62: (2) 80-81
258. 2001 Leon A, Blier P, Culpepper L, Gorman J, Hirschfeld R, Nirenberg A, Roose S, Rosenbaum J, Stahl SM and Trivedi M. An Ideal Trial to Test Differential Onset of Antidepressant Effect. Journal of Clinical Psychiatry, Vol. 62; Supplement 4, p. 34-36.
259. 2001 Stahl SM. The Psychopharmacology of Sex, Part 2. Effects of Drugs and Disease on the 3 Phases of Human Sexual Response. Journal of Clinical Psychiatry, 62: (3), P. 147-148.
260. 2001 Shelton RC, Keller MB, Gelenberg A, Dunner DL, Halbreich U, Hirschfeld R, Thase ME, Russel J, Lydiard RB, Crits-Cristophe P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G and Stahl SM. The Effectiveness of St. John's Wort in Major Depression: A Multi-Center Randomized Placebo Controlled Trial. The Journal of the American Medical Association 2001; 285: 1978-1986.
261. 2001 Hirschfeld RMA, Nierenberg A, Gorman JM, Roose SP, Leon AC, Blier P, Culpepper L, Rosenbaum JF, Stahl SM and Trivedi MH. Do Some Antidepressants Have a Faster Onset of Action Than Others? A Debate and Discussion. Journal Of Clinical Psychiatry, Vol. 62; Supplement 4, p. 37-40.
262. 2001 Stahl SM and Klitgaard H. New Developments in the Treatment of Epilepsy. A Teaching Monograph. CNS Spectrums, Volume 6 – Number 4 (suppl 2), April 2001.
263. 2001 Stahl SM. Why Drugs and Hormones May Interact in Psychiatric Disorders. J Clin Psychiatry 62: 4, 225-226.
264. 2001 Stahl SM. Effects of Estrogen on the Central Nervous System. J Clin Psychiatry 62: 5, p 317-18.

PUBLICATIONS (24)

265. 2001 Stahl SM. Sex and Psychopharmacology: Is Natural Estrogen a Psychotropic Drug in Women? Commentary on “Efficacy of Estradiol for the treatment of depressive disorders in perimenopausal women”. Archives of General Psychiatry, Vol 58, June; 537-538.
266. 2001 Stahl SM. Natural Estrogen as an Antidepressant for Women. Journal of Clinical Psychiatry, 62: 6, 404-405.
267. 2001 Stahl SM. Reply to Burt and Lane: Comparisons between two SSRIs their similarities are different. Biological Psychiatry, 50: 66-69.
268. 2001 Stahl SM. Fibromyalgia: The Enigma and the Stigma. Journal of Clinical Psychiatry, 62: (7), 501-502.
269. 2001 Stahl SM. Psychopharmacology of antidepressants – Ideal Therapy adds some mechanisms and subtracts some others. Japanese Journal of Clinical Psychopharmacology Vol. 4, no. 8, August 2001, p. 102-118.
270. 2001 Stahl SM. Gut Feelings About Irritable Bowel Syndrome. Journal of Clinical Psychiatry, 62: (8) 590-591.
271. 2001 Stahl SM. “Hit and Run” Actions at Dopamine Receptors, Part 1: Mechanism of Action of Atypical Antipsychotics. J Clin Psy 62 (9) 670-671.
272. 2001 Moore, P, Seifritz E, Schlosser A, Greenfield D, Stahl SM, Rapaport M and Kelsoe J. Rapid Tryptophan Depletion Plus a Serotonin 1A agonist: Competing Effects on Sleep in Healthy Men. Neuropsychopharmacology, Vol. 25, No. S5, p. S39-S44
273. 2001 Stahl SM. “Hit and Run” Actions at Dopamine Receptors, Part 2: Illustrating Fast Dissociation From Dopamine Receptors That Typifies Atypical Antipsychotics. J Clin Psychiatry 62 (10) 747-748
274. 2001 Stahl SM. Dopamine System Stabilizers, aripiprazole, and the Next Generation of antipsychotics Part 1 “Goldilocks” Actions at Dopamine Receptors. J Clin Psychiatry 62 (11) 841-842.
275. 2001 Stahl SM. Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 2. Illustrating Their Mechanism Of Action. J Clin Psychiatry 62 (12) 923-924.
276. 2002 Stahl SM. The Psychopharmacology of Energy and Fatigue. J Clin Psych 63: (1) 7-8.
277. 2002 Stahl SM. Antipsychotic Polypharmacy: Squandering Precious Resources? Journal of Clinical Psychiatry 63 (2); 93-94.

PUBLICATIONS (25)

278. 2002 Stahl SM. Selective Actions on Sleep or Anxiety by Exploiting GABA-A/Benzodiazepine Receptor Subtypes. Journal of Clinical Psychiatry 63: (3) 179-180.
279. 2002 Stahl SM Does Depression Hurt? Journal of Clinical Psychiatry 63: (4): 273-274.
280. 2002 Stahl SM and Niculescu AB. Molecular Biology Research in Psychiatry. In: Psychiatry as a Neuroscience, John Wiley and Sons Ltd.
281. 2002 Stahl SM. The Psychopharmacology of Painful Physical Symptoms in Depression. J. Clin. Psychiatry 63: (5) 382-383.
282. 2002 Stahl SM. Awakening to the Psychopharmacology of Sleep and Arousal: Novel Neurotransmitters and Wake-Promoting Drugs. J. Clin Psychiatry 63: (6) 467-468.
283. 2002 Stahl SM. Psychopharmacology of Wakefulness: Pathways and Neurotransmitters. J Clin Psychiatry 63: (7) 551-552.
284. 2002 Stahl SM, Mendels J and Schwartz G. Effects of Reboxetine on Agitation, Anxiety and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials. Journal Of Clinical Psychopharmacology Vol 22, No. 4, p. 388-392.
285. 2002 Stahl SM. Mirror, Mirror on the Wall, Which Enantiomer Is Fairest of Them All? J Clin Psychiatry 63: (8) 656-657.
286. 2002 Stahl SM. Antipsychotic Polypharmacy: Evidence Based or Eminence Based? Acta Psychiatrica Scandinavica Vol 106 No 5, 321-322.
287. 2002 Stahl SM. Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder. J Clin Psychiatry 63: (9) 756-757.
288. 2002 Stahl SM. Independent Actions on Fear Circuits May Lead to Therapeutic Synergy for Anxiety When Combining Serotonergic and GABAergic Agents. J Clin Psychiatry 63: 10, 854-855.
289. 2002 Lutz W, Stahl SM, Howard KI and Grissom GR. Some Relationships among assessments of depression, Journal of Clinical Psychology. Vol 58 (12), 1545-1553
290. 2002 Stahl SM. Can Psychopharmacologic Treatments That Relieve Symptoms Also Prevent Disease Progression? J Clinical Psychiatry 63: 11, 961- 962.

PUBLICATIONS (26)

291. 2002 Stahl SM, Entsuah AR and Rudolph RL. Comparative Efficacy Between Venlafaxine and SSRIs: A Pooled Analysis of Patients with Depression. Biological Psychiatry, 52 (12): 1166-1174, 2002.
292. 2002 Stahl M. The Metabolic Syndrome: Psychopharmacologists Should Weigh the evidence for Weighing the Patient. J. Clin Psychiatry 63: 12, 1094 – 1095.
293. 2003 Stahl SM. Reply to Welch R and Snaterse M. Combination Therapy: Is Clinical Practice Leading the Way or Are We Following the Pied Piper? J Clin Psychiatry. 64 (1): 94-96.
294. 2003 Stahl SM. Neurotransmission of Cognition, Part 1 Dopamine is a Hitchhiker in Frontal Cortex: Norepinephrine Transporters Regulate Dopamine. J Clinical Psychiatry 64: 1, 4-5.
295. 2003 Hollander E, Kaplan A and Stahl SM. A double-blind, placebo controlled trial of clonazepam in obsessive-compulsive disorder. World J Bio Psychiatry 4 (1): 30-34.
296. 2003 Stahl SM. Neurotransmission of Cognition, Part 2 Selective SRIs Are Smart Drugs: Regionally Selective Actions on Both Dopamine and Norepinephrine to Enhance Cognition. J. Clinical Psychiatry 64: 2, 110-111.
297. 2003 Stahl SM. Neurotransmission of Cognition, Part 3 Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. J Clin Psychiatry 64:3, 230-231.
297. 2003 Stahl SM. Neurotransmission of Cognition, Part 3 Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. J Clin Psychiatry 64:3, 230-231.
298. 2003 Stahl SM, Markowitz PH, Gutterman EM and Papadopoulos G. Co-Use of Donepezil and Hypnotics Among Alzheimer's Disease Patients Living in the Community. Journal of Clinical Psychiatry 64: 4, 466-472.
299. 2003 Stahl SM. At Long Last, Long-Lasting Psychiatric Medications: An Overview of Controlled Release Technologies. J. Clinical Psychiatry 64: 4, 355-356.
300. 2003 Stahl SM. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. The Primary Care Companion J Clin Psychiatry 5 (Suppl 3) 9-13.
301. 2003 Stahl SM. The Ups and Downs of Novel Antiemetic Drugs, Part 1 Substance P, 5-HT, and the Neuropharmacology of Vomiting. J Clin Psychiatry 64 5, 498-499.

PUBLICATIONS (27)

302. 2003 Stahl SM. The Ups and Downs of Novel Antiemetic Drugs, Part 2: An Illustration. J Clin Psychiatry 64: 6, 626-627.
303. 2003 Stahl SM. Antidepressants and Somatic Symptoms: Therapeutic Actions Are Expanding Beyond Affective Spectrum Disorders To Functional Somatic Syndromes. J Clin Psychiatry 64: 7, 745-746.
304. 2003 Stahl SM. Here Today and Not Gone Tomorrow: The Curse of Chronic Pain and Other Central Sensitization Syndromes. J. Clin Psychiatry 64: 8, 863-864.
305. 2003 Damatarca C, Stahl SM. Pain and Depression: Bridging the Body and Mind. Depression: Mind and Body. Volume 1, Number 1, p. 7-13.
306. 2003 Stahl SM. Deconstructing Psychiatric Disorders, Part 1: Genotypes, Symptom Phenotypes, and Endophenotypes. J. Clin Psychiatry 64: 9, 982-983.
307. 2003 Stahl SM. Reply to Freudenreich and Goff "Polypharmacy in Schizophrenia: A Fuzzy Concept". Journal of Clinical Psychiatry 64: 9, 1132-1133.
308. 2003 Stahl SM, Grady MM. Mechanism of Action Differences Between Current Antidepressants and those soon to be released. J. Clin Psych 64 (Suppl 13) 13-17.
309. 2003 Stahl SM. Key Issues and Unmet Needs in Schizophrenia. In: Dopamine in the Pathophysiology and Therapeutics of Schizophrenia: New Findings, New Directions. Eds: Shitij Kapur and Yves Lecrubier, pages 237-252.
310. 2003 Stahl SM. Deconstructing Psychiatric Disorders, Part 2: An Emerging, Neurobiologically Based Therapeutic Strategy for the Modern Psychopharmacologist. J. Clin Psych 64: 10, 1145-1146.
311. 2003 Stahl SM, Gergel I and Li D. Escitalopram in the Treatment of Panic Disorder: A Randomized, Double Blind, Placebo-Controlled Trial. Journal of Clinical Psychiatry 64: 11, 1322-1327.
312. 2003 Stahl SM, Zhang L, Damatarca C, Grady MM. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue and executive dysfunction in major depressive disorder. J Clin Psychiatry 64: (Suppl 4) 6-17.
313. 2003 Stahl SM. Symptoms and Circuits, Part 1, Major Depressive Disorder. J Clin Psychiatry 64: 11, 1282-1283.
314. 2003 Stahl SM. Symptoms and Circuits, Part 2: Anxiety Disorders. J.Clin Psychiatry 64: 12,1408-1409.

PUBLICATIONS (28)

315. 2003 Stahl SM and Shayegan D. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003 64 (supplement 19):6-12.
316. 2004 Stahl SM. Symptoms and Circuits, Part 3: Schizophrenia. J. Clin Psychiatry 65: 1, 8-9.
317. 2004 Stahl SM, Markowitz JS, Papadopoulos G. Examination of nighttime sleep related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion. Vol. 20, No. 4, p. 517-524.
318. 2004 Stahl SM. Psychopharmacology of Anticonvulsants: Do All Anticonvulsants Have the Same Mechanism of Action? J Clin Psych 65: 2, 149-150.
319. 2004 Damatarca C, Stahl J and Stahl SM. Psychopharmacologic Approaches to the Treatment of Anxiety. Drug Ben Trends, Volume 16, No. 2, 94-100.
320. 2004 Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Cur Med Chem, 11, 313-326.
321. 2004 Stahl SM. Anticonvulsants as Anxiolytics, Part 1: Tiagabine and other Anticonvulsants With Actions on GABA, J Clin Psych 65:3, 291-292.
322. 2004 Stahl SM, Nicolescu AB and Grady MM. Developments in Antidepressants. In: Advances on Management and treatment of Depression. Eds: Michael Thase and John Potokar.
323. 2004 Stahl SM. Anticonvulsants as Anxiolytics, Part 2: Pregabalin and Gabapentin as $\alpha\delta$ Ligands at Voltage-Gate Calcium Channels. J. Clinical Psychiatry 65: 4, 460-461.
324. 2004 Stahl SM. Focus: antipsychotic polypharmacy – evidence based prescribing or prescribing based evidence? Int J Neuropsychopharmacol 2004;7(2):113-6.
325. 2004 Stahl SM, Grady MM. Estrogen as an Antidepressant. Trends in Evidence-Based Neuropsychiatry (TEN) 6 (1): 23-27.
326. 2004 Stahl SM. Anticonvulsants and the Relief of Chronic Pain: Pregabalin and Gabapentin as Ligands at Voltage Gated Calcium Channels. J Clin Psychiatry 65:5, 396-397.
327. 2004 Stahl SM. Anticonvulsants as Mood Stabilizers and Adjuncts to Antipsychotics: Valproate, Lamotrigine, Carbamazepine, and Oxcarbazepine and Actions at Voltage-Gated Sodium Channels. J.Clin Psychiatry 65: 6, 738-739.

PUBLICATIONS (29)

328. 2004 Stahl SM. Mechanism of Action of Voltage Sensitive Sodium Channel Modulators. J Clin Psychiatry 65: 7, 894-895.
329. 2004 Gelenberg AF, Shelton RC, Crits-Cristoph P, Keller MB, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM and Halbreich U. The effectiveness of St. John's Wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Journal of Clinical Psychiatry 2004;65(8):1114-9.
330. 2004 Stahl SM, Pradko J. A Review of the Neuropharmacology of Bupropion SR: A Dual NE and DA Reuptake Inhibitor. Journal of Clinical Psychiatry Primary Care Companion. Volume 6, (4) 159-166.
331. 2004 Stahl SM. Mechanism of Action of Alpha 2 Delta Ligands: Voltage Sensitive Calcium Channel (VSCC) Modulators. Journal of Clinical Psychiatry 65: 8, 1033-1034.
332. 2004 Stahl SM, Freudenreich O, Goff DC. A Successful Antipsychotic Combination Trial. Quo Vadis? Acta Psychiatrica Scand 2004: 110: 241-242.
333. 2004 Stahl SM and Briley M. Understanding pain in depression. Human Psychopharmacology Clin Exp (suppl)19: S9-S13.
334. 2004 Stahl SM. Psychopharmacology of Anticonvulsants: Levetiracetam as A Synaptic Vesicle Protein Modulator. J. Clin. Psychiatry 65: 9, 1162-1163.
335. 2004 Stahl SM. Selectivity of SSRIs: individualizing patient care through rational treatment choices. Int J Psy Clin Prac, Volume 8, (Suppl 1), Pages 3-10.
336. 2004 Stahl SM. Drug Combinations for Bipolar Spectrum Disorders: Evidence-Based Prescribing or Prescribing Based Evidence? Journal Clinical Psychiatry 65: 10, 1298-1299
337. 2004 Stahl SM. Prophylactic Antipsychotics: Do They Keep You From Catching Schizophrenia? J Clin Psychiatry 65: 11, 1445-1446.
338. 2004 Stahl SM, Shayegan DK. Novel mechanisms of Action: Beyond atypical antipsychotics... in den Boer JA, ter Horst GJ and George M, Current and Future Developments in Psychopharmacology, Benecke, Amsterdam, p. 287-315.
339. 2004 Shayegan DK and Stahl SM. Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile. CNS Spectrums Oct; 9 (10 Suppl 11): p. 6-14
340. 2004 Stahl SM. Preemptive Analgesia: Is Pain Less Costly When You Pre-Pay For It? J Clin Psychiatry 65:12, 1591-1592.

PUBLICATIONS (30)

341. 2004 Shelton RC and Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression, Journal of Clinical Psychiatry 65(12):1715-19.
342. 2005 Stahl SM. Is Psychopharmacologic "Inoculation" Effective in Preventing Posttraumatic Stress Disorder? J Clin Psychiatry 66: (1): 5-6.
343. 2005 Grady MM, Stahl SM. Panic Attacks and Panic Disorders: the great imitators. In: Imitators of Epilepsy, second edition. Ed: Kaplan PW, Fisher RS. Demos Medical Publishing, p. 277-288.
344. 2005 Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacology, 8, 93-105.
345. 2005 Citrome L, Goldberg FJ and Stahl SM. Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harvard Rev Psychiatry, Volume 13, Number 1, January/February 2005, 28-42.
346. 2005 Stahl SM. Antidepressant treatment of psychotic depression: the role of the sigma receptor. CNS Spectrums, Volume 10, Number 4, 319-323.
347. 2005 Fava M, Rush JA, Thase ME, Clayton A, Stahl SM, Pradko JF and Johnston JA. 15 years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Primary Care Companion, 7: (3); 106-113.
348. 2005 Shayegan DS and Stahl SM. Emotion Processing, the Amygdala, and Outcome In Schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29: 840-845.
349. 2005 Stahl SM, Grady MM, Moret C, Briley M. Serotonin and norepinephrine reuptake inhibitors (SNRIs): A review of their pharmacology, clinical efficacy and tolerability in comparison to other classes of antidepressant. CNS Spectrums, Sept; 10 (9): 732-747.
350. 2005 Stahl SM. Possible Antipsychotic Effect of Fluvoxamine. Response to Letter to the Editor, CNS Spectrums, Volume 10 (10): 774-775.
351. 2006 Stahl SM. Finding What You Are Not Looking For: Strategies for Developing Novel Treatments in Psychiatry. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, Volume 3, No. 1, 3-9.
352. 2006 Stahl SM. Finding Better Answers for Sleep Disorders. Current Psychiatry Vol 5, No.1, January 2006 p. 68-70.

PUBLICATIONS (31)

353. 2006 Stahl SM, Grady M. High Cost Use of Second-Generation Antipsychotics under California's Medicaid Program. Psychiatric Services, Volume 57, Issue 1, p. 127-129.
354. 2006 Stahl SM. A rash proposal for treating bipolar disorder. Current Psychiatry Vol 5, No. 2, p. 92-100.
355. 2006 Stahl SM. What's Wrong with Multicenter Trials. Current Psychiatry Vol. 5, No. 3,, p. 37-41.
356. 2006 Rausch JL; Johnson ME; Kasik KE and Stahl SM. Temperature Regulation in Depression: Functional 5HT1A Receptor Adaptation Differentiates Antidepressant Response. Neuropsychopharmacology, 31, 2274-2280.
357. 2006 Stahl SM; Grady M; Santiago G; and Davis RL. Optimizing Outcomes in Psychopharmacology Continuing Medical Education (CME): Measuring Learning And Attitudes That May Predict Knowledge Translation into Clinical Practice. FOCUS Vol IV, No. 4, 487-495.
358. 2007 Stahl SM and Buckley PF. Negative Symptoms of Schizophrenia: a problem that will not go away. Acta Scandinavia Psychiatria 2007: 115: 4-11.
359. 2007 Buckley PF and Stahl SM. Pharmacological Treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-Sac? Acta Scandinavia Psychiatria 2007: 115: 93-200.
360. 2007 Stahl SM. Overview of Trends in Modern Psychopharmacology. CNS Spectrums 12: 2, 103-105.
361. 2007 Stahl SM Monoamine mechanisms in pain and depression. Neuropsychiatric Disease and Treatment 3 (Suppl 1) 9-12.
362. 2007 Stahl SM. Beyond the dopamine hypothesis to the NMDA Glutamate Receptor Hypofunction Hypothesis of Schizophrenia. CNS Spectrums 12: 4, 265-268.
363. 2007 Stahl SM. Novel Therapeutics for Schizophrenia: Targeting Glycine Modulation of NMDA Glutamate Receptors. CNS Spectrums 12:6 423-427.
364. 2007 Rollema H, Coe J, Chambers L, Hurst R, Stahl SM and Williams K. Alpha 4 Beta 2 nicotinic acetylcholine receptor partial agonists for the treatment of nicotine dependence: rationale, pharmacology and clinical efficacy. Trends in Pharmacological Science 28 (7): 316-325.

PUBLICATIONS (32)

365. 2007 Stahl SM. A Different Mechanism to Understand Activation/Sedation Side Effects of Ziprasidone. Response Letter to the Editor. Journal of Clinical Psychiatry 68: 6, 975-976.
366. 2007 Stahl SM. Genetics of Schizophrenia converge on the NMDA receptor. CNS Spectrums 12; 8, 583-588.
367. 2007 Stahl SM. Novel Therapeutics for Depression: L-methylfolate (6 (S)-5 methyltetrahydrofolate or MTHF) as a Trimonoamine Modulator and Antidepressant Augmenting Agent. CNS Spectrums 12, 10, 423-428.
368. 2007 Gharabawi GM; Rupnow MFT; Greenspan A; Kosik-Gonzalez C; Young Z and Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind study of risperidone and quetiapine in patients with schizophrenia and schizoaffective disorder. Current Medical Research and Opinion 23; 11, 2815-2822.
369. 2007 Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. International Journal of Neuropsychopharmacology 10, 575-578.
370. 2007 Nutt D; Demyttenaere K; Janka Z; Aare T; Bourin M; Canonico PL; Carrasco JL and Stahl SM. The Other Face of Depression, reduced positive affect: the role of catecholamines in causation and cure. Journal of Psychopharmacology 21; 5, 461-471.
371. 2007 Stahl SM; Ahmed S; Haudiquet V. Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Treatment With Venlafaxine ER. CNS Spectrums 2; 9, 703-711.
372. 2008 Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Sasntucci V, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, LeFur G and Griebel G. Stimulation of the Beta-3 adrenoceptor as a novel treatment for anxiety and depression disorders". Neuropsychopharmacology 33: 574-587.
373. 2008 Buckely P and Stahl SM. Letter to the Editor. Reply to: Repetitive transcranial magnetic stimulation as new technique for treatment of negative symptoms of schizophrenia. Acta Psychiatr Scand 117: 1, 79.
374. 2008 Zisook S, Glick I, Jefferson J, Wagner, K, Salzman C, Peselow E and Stahl S. Teaching Psychopharmacology: What Works and What Doesn't. Journal of Clinical Psychopharmacology 28 (1): 96-100 February 2008.
375. 2008 Stahl SM. Personalized Medicine, Pharmacogenomics, and the Practice of Psychiatry: On the Threshold of Predictive Therapeutics in Psychopharmacology? CNS Spectrums 13: 2, 115-118.

PUBLICATIONS (33)

376. 2008 Stahl SM. Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics? CNS Spectrums 13:4, 279-282.
377. 2008 Stahl SM and Wise DD. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 antagonist in Psychiatric Disorders. CNS Spectrums, 13:6, 467-483.
378. 2008 Wise D, Felker A and Stahl SM. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology. CNS Spectrums 13: 8, 647-655, 658-662.
379. 2008 Papakostas G, Stahl S, Krishen A, Seifert C, Tucker V, Goodale E and Fava M. Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the treatment of Major Depressive Disorder with High Levels of Anxiety (Anxious Depression). J Clin Psychiatry 69: 8, 1287-1292.
380. 2008 Stahl SM. L-methylfolate: a vitamin for your monoamines; Journal of Clinical Psychiatry 69: 9; 1352-1353.
381. 2008 Stahl SM and Felker A. Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants. CNS Spectrums 13: 10, 855-870.
382. 2008 Stahl SM. The Sigma Enigma: Can Sigma Receptors Provide a Novel Target for Disorders of Mood and Cognition? Journal of Clinical Psychiatry 69: 11; 1673-1674.
383. 2008 Stahl SM. Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines. CNS Spectrums 13 (12): 1027-1038.
384. 2009 Kim D, Maneen M and Stahl SM. Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia. Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics. Vol.6, 78-85.
385. 2009 Stahl SM, Mignon L and Meyer JM. What Comes First: Atypical Antipsychotics or The Metabolic Syndrome? Acta Psychiatrica Scand 119: 171-179.
386. 2009 Meyer JM and Stahl SM. The Metabolic Syndrome and Schizophrenia. Acta Psychiatrica Scand 119: 4-14.
387. 2009 Stahl SM. Vasomotor Symptoms and Depression in Women, Part 1. Journal of Clinical Psychiatry 70: 1, 11-13.

PUBLICATIONS (34)

388. 2009 Stahl SM. Multifunctional Drugs: A Novel Concept for Psychopharmacology. CNS Spectrums 14: 2, 71-73.
389. 2009 Stahl SM. Vasomotor Symptoms and Depression in Women, Part 2: Treatments that cause remission and prevent Relapses of Major Depressive Episodes Overlap with Treatments for Vasomotor Symptoms. Journal of Clinical Psychiatry 70: 3, 310-311.
390. 2009 Hayashi T and Stahl SM. Sigma 1 receptors and its role in the treatment of mood disorders. Drugs of the Future 34 (2): 137-146.
391. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Overview and Finding the Focus. CNS Spectrums 14: 4, 179-182.
392. 2009 Stahl SM. Norepinephrine and Dopamine Regulate Signals and Noise in the Prefrontal Cortex. J Clin Psychiatry 70:5, 617-618.
393. 2009 Mischoulon D, Fava M and Stahl SM. Letter to the Editor. Folate Supplementation: Is It Safe and Effective? J Clin Psychiatry 70: 5, 767-769.
394. 2009 Munk-Jorgensen P, Nielsen J, Nielsen RE and Stahl SM. Last Episode Psychosis. Acta Psychiatrica Scandinavica. 119:417-418.
395. 2009 Stahl SM and Briley M. Why Psychiatrists should not ignore pain in their patients -focus on fibromyalgia? Human Psychopharmacology 24: S1-S2.
396. 2009 Stahl SM. Fibromyalgia – pathways and neurotransmitters. Human Psychopharmacology 24: S11-S17.
397. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Storyboarding a Presentation and the Rule of Small Multiples. CNS Spectrums 14: 6, 288-294.
398. 2009 Stahl SM. The Prefrontal Cortex Is Out of Tune in Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry 70: 7, 950-951.
399. 2009 Stahl SM, Lombardo I, Loebel A and Mandel F. Efficacy of Ziprasidone in Dysphoric Mania: Pooled Analysis of 2 Double Blind Studies. Journal of Affective Disorders 122' 30-45.
400. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Audience Response Systems. CNS Spectrums 14: 8, 412-414.
401. 2009 Stahl SM. Epigenetics and Methylomics in Psychiatry. J Clin Psychiatry 70: 9, 1204-1205.

PUBLICATIONS (35)

402. 2009 Stahl SM. Mechanism of Action of Trazodone: a Multifunctional Drug. CNS Spectrums 14: 10, 536-546.
403. 2009 Stahl SM. Combining Antidepressant Therapies From the Initiation of Treatment: A Paradigm Shift for Major Depression. J Clin Psychiatry Nov; 70(11):1493-4.
404. 2009 Stahl SM. Crisis in Army Psychopharmacology and Mental Health Care at Fort Hood. CNS Spectrums 14:12, 677-684.
405. 2010 Stahl SM. Mechanism of Action of Stimulants in Attention Deficit/Hyperactivity Disorder. J Clin Psychiatry Jan; 71 (1): 12-13.
406. 2010 Sussman N and Stahl SM. The Future of Novel Drug Discovery in CNS. IN SESSION with Stephen M. Stahl, M.D.,Ph.D. Primary Psychiatry 17 (1): 32-34.
407. 2010 Stahl SM. Enhancing Outcomes from Major depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacological Mechanisms from the Initiation of Treatment, CNS Spectrums 15: 2; p 677-691.
408. 2010 Stahl SM. Mechanism of Action of α 2A-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder With or Without Oppositional Symptoms, Journal of Clinical Psychiatry 71:3, p 223-224.
409. 2010 Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A and Post A. Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Journal of Clinical Psychopharmacology Volume 30, Number 2, 135-144.
410. 2010 Stahl SM. Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders. CNS Spectrums 15: 4, 220-230.
411. 2010 Stahl SM. Circuits of Sexual Desire in Hypoactive Sexual Desire Disorder. Journal of Clinical Psychiatry 71:5, 518-519.
412. 2010 Stahl SM, Fava M, Trivedi M, Caputo A, Shah A and Post A. Agomelatine in the Treatment of Major Depressive Disorder: An 8 week, Multicenter, Randomized, Placebo-controlled Trial. Journal of Clinical Psychiatry 71: 5; 616-626.
413. 2010 Stahl SM. Fooling Mother Nature: Epigenetics and Novel Treatments for Psychiatric Disorders. CNS Spectrums 15: 6, 358-365.
414. 2010 Stahl SM. Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology. Neuropsychopharmacology 35: 6, 1413-1414.

PUBLICATIONS (36)

415. 2010 Stahl SM. Targeting Circuits of sexual Desire as a Treatment Strategy for Hypoactive sexual Desire Disorder. Journal of Clinical Psychiatry 71: 7, 821-822.
416. 2010 Stahl SM, Davis RL, Kim DH, Lowe Gellings N, Carlson RE Jr, Fountain K and Grady MM. Play it Again: The Master Psychopharmacology Program as an Example of Interval Learning in Bite-Sized Portions. CNS Spectrums 15: 8, 491-504.
417. 2010 Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PF, Harvey PD, Loebel A, Watsky E, Siu CO and Romano S. A Post Hoc Analysis of Negative Symptoms And Psychosocial Function in Patients with Schizophrenia: A 40-Week, Randomized, Double-Blind Study of Ziprasidone versus Haloperidol Followed by a 3 Year Double-Blind Extension Trial. Journal of Clinical Psychopharmacology Volume 30, Number 4, 425-430.
418. 2010 Mignon L and Stahl SM. Current Depression Landscape: A State of the Field Today. In: Next General Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Eds: Beyer CE and Stahl SM. Cambridge University Press, New York, NY, 1 - 11.
419. 2010 Grady M and Stahl SM. Antidepressants: Recent Developments. In Encyclopedia of Psychopharmacology. Spring Publishing, New York, 101-108.
420. 2010 Stahl SM. Illustrating the Circuits of Sexual Desire. Journal of Clinical Psychiatry 71: 9, 1113-1114.
421. 2010 Nutt D and Stahl SM. Searching for perfect sleep: the continuing evolution of GABA_A receptor modulators as hypnotics. J Psychopharmacology 24 (11); 1601-1602.
422. 2010 Stahl SM. The Serotonin-7 Receptor as a Novel Therapeutic Target. Journal of Clinical Psychiatry 71: 11, 1414-1415.
423. 2010 Loonen AJM and Stahl SM. The Mechanism of Drug-induced Akathisia. CNS Spectrums 15; 11, 491-494.
424. 2010 Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatrica Scand 122: 440-441.
425. 2010 Loonen AJM and Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatrica Scand 122: 435-437.

PUBLICATIONS (37)

426. 2010 Kim D and Stahl SM. Antipsychotic Drug Development. In: Current Topics in Behavioral Neurosciences 4: Behavioral Neurobiology of Schizophrenia and Its Treatment. Eds: Geyer MA, Ellenbroek BA and Marsden CA. Springer Publishing, p. 123-139.
427. 2011 Munk-Jorgensen P, Christiansen B, Stahl SM and Licht, RW. Happy new year 2011. Acta Psychiatr Scand 123: 1; 1-3.
428. 2011 Stahl SM, Sommers B and Allers K. Multifunctional pharmacology of flibanserin: Possible mechanism of action in hypoactive sexual desire disorder. J Sex Med 8: 15-27.
429. 2011 Mattei C, Rapagnani MP and Stahl SM. Ziprasidone Hydrochloride: what role in the management of schizophrenia? Journal of Central Nervous System Disease 3: 1-16.
430. 2011 Schwartz TL and Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neuroscience and Therapeutics 17; 110-117.
431. 2011 Schwartz TL, Stahl SM, Pappadopulos E and Karayal ON. Ziprasidone in the treatment of bipolar disorder. In: Bipolar Psychopharmacotherapy: Caring for the Patient, 2nd edition. Eds: Akiskal H and Tohen M, Wiley Press, p 223-244.
432. 2011 Schwartz TL and Stahl SM. Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives. In: Depression: From Psychopathology to Pharmacotherapy. The Future of Antidepressants. Eds: Cryan FJ and Leonard BD. S. Karger AG, Basel, Switzerland 2010, p 254-267.
433. 2011 Loonen AJM, Stahl SM and van Praag HM. Letter to the Editor. Reply to: Case Studies are not sufficient. Acta Psychiatr Scand 123: 493-494.
434. 2011 Sauve W and Stahl SM. Psychopharmacological Treatment of PTSD. In: Handbook for the Treatment of PTSD in Military Personnel. Eds: Moore BA and Penk WE, Guilford Press, p 155-172.
435. 2011 Schwartz TL, Siddiqui UA and Stahl SM. Vilazodone: A Brief Pharmacologic And Clinical Review of the Novel SPARI (Serotonin Partial Agonist and Reuptake Inhibitor). Therapeutic Advances in Psychopharmacology Volume 1 Issue 3, 81-87.
436. 2011 Morrisette DA and Stahl SM. Affective Symptoms in Schizophrenia. In: Drug Discovery Today: Therapeutic Strategies, Volume 8, Issues 1-2, p 3-9.

PUBLICATIONS (38)

437. 2012 Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short- term treatment of schizophrenia: a post hoc analysis of pooled patient data from 4 Phase II, Placebo- and active-controlled trials, Human Psychopharmacology. 27: 24-32.
438. 2012 Stahl SM, Psychotherapy as an epigenetic “drug”: psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. Journal of Clinical Pharmacy and Therapeutics. 37: 249-253.
439. 2012 Brandt MR, Beyer CE and Stahl SM. TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals, special issue "Emerging Pain Targets and Therapy", 5, 114-132.
440. 2012 Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ. A Plan for mental illness. Nature, Vol 483, 269.
441. 2012 Schwartz TL, Sachdeva S and Stahl SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia, Current Pharmaceutical Design 18, 1580-1592
442. 2012 Grady M and Stahl SM. Practical Guide for Prescribing MAOI: Debunking Myths and Removing Barriers. CNS Spectrums 17, 2-10.
443. 2012 Stahl SM. CNS Spectrums: a new publisher, a new editor-in-chief, and new vistas. CNS Spectrums 17, 1.
444. 2012 Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatrica Scandinavica 125: 349-351.
445. 2012 Grady M and Stahl SM. A horse of a different color: how formulation Influences medication effects. CNS Spectrums 17. 63-69.
446. 2012 Gellings-Lowe N and Stahl SM. Antidepressants in pain, anxiety and depression. In: Pain Comorbidities. Giamberardino MA and Jensen TS (Eds), IASP Press, 409-423.
447. 2012 Tarazi F and Stahl SM. Iloperidone, asenapine and lurasidone: a primer on Their current status. Expert Opinion on Pharmacotherapy 13 (13); 1911-1922.
448. 2012 Gellings Lowe N, Rapagnani MP, Mattei C and Stahl SM. The Psychopharmacology of Hallucinations: Ironic Insights Into Mechanisms of Action. In: The Neuroscience of Hallucinations. Eds: Jardri R, Thomas P, Cachia A and Pins D. Springer Press, 471-492.

PUBLICATIONS (39)

449. 2012 Griebel G, Beeske S and Stahl SM. The V1b receptor antagonist SSRI49415 in the treatment of major depressive and generalized anxiety disorders: results from four double-blind, placebo-controlled studies. J Clin Psychiatry 73: 11, 1403-1411.
450. 2012 Schwartz TL, Sachdeva S and Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Frontiers in Pharmacology Volume 3, 1-11.
451. 2012 Stahl SM. Structural Imaging of schizophrenia: is the modern psychiatrist becoming a "disease scene investigator?". Acta Psychiatrica Scandinavica 126: 231-232.
452. 2012 Morrisette DA and Stahl SM. Optimizing Outcomes in Schizophrenia: Long Acting Depots and Long Term Treatment. CNS Spectrums 17: 10-21.
453. 2012 Lum CT and Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectrums 17: 107-120.
454. 2012 Sfera A and Stahl S. A Century of Schizophrenia Where We Came From, Where We Are now and Where We are Going. Romanian Journal of Psychopharmacology 12: 201-217.
455. 2012 Chang TE and Stahl SM. Developments in Psychopharmacology for Major Depressive Disorder. FOCUS 10: 452-460.
456. 2013 Stahl SM. The Tyranny of the majority and the interchangeability of drugs. Acta Psychiatrica Scandinavica 127: 4-5.
457. 2013 Stahl SM. Kick-off Editorial for 2013: Thanks to our Reviewers. CNS Spectrums, 18: 1; 5.
458. 2013 Stahl SM. Off label prescribing: Best Practice or Malpractice. CNS Spectrums, 18: 1, 1-4.
459. 2013 Stahl SM. The Last Diagnostic and Statistical Manual (DSM): replacing Our symptom-based diagnoses with a brain circuit-based classification of mental Illnesses. CNS Spectrums 18, 65-68.
460. 2013 Stahl SM, Cucchiario J, Sinonelli, D, Severs J, Pikalov A and Loebel A. Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-month, Open-Label Study. J Clin Psychiatry 74: 5, 507-515.

PUBLICATIONS (40)

461. 2013 Stahl SM, Lee-Zimmerman C, Cartwright S and Morrissette DA. Serotonergic Drugs for Depression and Beyond. Current Drug Targets 14: (5); 578-585.
462. 2013 Stahl SM. Classifying psychotropic drugs by mode of action and not by Target disorder. CNS Spectrums 18, 113-117.
463. 2013 Stahl SM, Eisenach JC, Taylor CP, Cheung RY, Thorpe A and Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacologic activities. Trends in Pharmacological Science. 34: 6; 332-339.
464. 2013 Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ and Warburton KD. "Meta-guidelines" for the Management of patients with schizophrenia. CNS Spectrums 18, 150-162.
465. 2013 Morrissette DA and Stahl SM, Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In Ritsner MS, Polypharmacy in Psychiatric Practice, Volume.I, 107-125.
466. 2013 Schwartz TL, Siddiqui U and Stahl SM. Translating Basic Science into Clinical Practice while Dosing the Second Generation antipsychotics. In: Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, p 55-78.
467. 2013 Stahl SM. Translating from neuroscience to psychiatry (and back translating from psychiatry to neuroscience) Acta Psychiatrica Scandinavica 128: 103-104.
468. 2013 Stahl SM. Controversies in treating bipolar Depression. CNS Spectrums 18, 175-176
469. 2013 Stahl SM. Mechanism of action of ketamine. CNS Spectrums 18, 171-174.
470. 2013 Stahl SM. Mechanism of Action of dextromethorphan/quinidine: comparison with ketamine. CNS Spectrums 18, 225-227.
471. 2013 Grady MM and Stahl SM. Novel Agents in Development for the treatment of depression. CNS Spectrums 18, Supplement 1, 37-41.
472. 2013 Stahl SM. Role of $\alpha 1$ adrenergic antagonism in the mechanism of action Of iloperidone: reducing extrapyramidal symptoms. CNS Spectrums 18, 285-288.
473. 2013 Stahl SM. Emerging Guidelines for the Use of Antipsychotic Polypharmacy. Revista de Psiquiatria Y Salud Mental 6 (3): 97-100.

PUBLICATIONS (41)

474. 2013 Inset TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kipfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH and Sahakian BJ. Innovative Solutions to Novel Drug Development in Mental Health. Neuroscience and Biobehavioral Reviews 37: 2438-2444.
475. 2014 Opler LA, Medalia A, Opler MG and Stahl SM. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectrums 19: 142-156
476. 2014 Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M and Stahl SM. A Proposal For An Updated Neuropsychopharmacological Nomenclature. European Neuropsychopharmacology, 24: 1005-1014
[x.doi.org/10.11016/j.euroneuro.2013.08.004](https://doi.org/10.11016/j.euroneuro.2013.08.004)
477. 2014 Stahl SM. Long-Acting injectable antipsychotics: shall the last be first? CNS Spectrums 19, 3-5.
478. 2014 Stahl SM. Kick-off editorial for 2014: Thanks to our reviewers. CNS Spectrums 19, 1-2.
479. 2014 O'Day J. A., Dardashti L. J., Delgado D. M., Schwartz E. H., Broderick C. L. and Stahl S. M. Genetics and Epigenetics of Mental Illness: Implications for Diagnosis and Treatment. Wiley Encyclopedia of Forensic Science. 1–9. Eds A. Jamieson and A.A. Moenssens, John Wiley, Chichester
480. 2014 Stahl SM. Mechanism of action of the SPARI vilazodone: (serotonin partial agonist Reuptake inhibitor) CNS Spectrums 19, 105-109.
481. 2014 Stahl SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectrums 19, 207-212.
482. 2014 Stahl SM. Clozapine: Is Now the Time for More Clinicians to Adopt this Orphan? CNS Spectrums 19, 279-281.
483. 2014 Grady MM and Stahl SM. Antidepressants: Recent Developments (Category: Drugs and Drug Classes). Encyclopedia of Psychopharmacology DOI 10.1007/978-3-642-27772-6_362-2, p 1-9.
484. 2014 Stahl SM. Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectrums 19, 357-365.
485. 2014 Morrissette DA and Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums 19, 439-448.

PUBLICATIONS (42)

486. 2014 Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S and Warburton K. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectrums 19, 449-465.
487. 2014 Stahl SM. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectrums 19, 475-487.
488. 2014 Shapiro DN and Stahl SM. Novel and Investigational Drugs in Depression. International Neuropsychiatric Disease Journal 2 (6): 328-347.
489. 2014 Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM and Fava M. Effect of Adjunctive L-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial. J Clin Psychiatry 75: 8, 855-863.
490. 2014 Morrissette DA and Stahl SM. Modulating the Serotonin System in the treatment of major depressive disorder. CNS Spectrums 19, Supplement 1, 57-69.
491. 2015 Burton B, Feigenbaum A, Grant M, Hendren R, Singh R, Siriwardena K, Phillips III J, Sanchez-Valle A, Waisbren S, Gillis J, Prasad S, Merilainen M, Lang W and Stahl SM. A Randomized, Double-Blind study Exploring ADHD Symptoms and Executive Function in People with Phenylketonuria Randomized to Sapropterin Dihydrochloride or Placebo. Molecular Genetics and Metabolism 114: 415-424; doi: 10.1016/j.ymgme.2014.11.011.
492. 2015 Stahl SM, Kick Off Editorial for 2015: thanks to our reviewers; CNS Spectrums 20: 7-8
493. 2015 Stahl SM. Mechanism of action of Flibanserin, a Multifunctional Serotonin Agonist and Antagonist (MSAA), in Hypoactive Sexual Desire Disorder. CNS Spectrums 20: 1-6
494. 2015 Stahl SM, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors); CNS Spectrums 20: 93 – 97
495. 2015 Stahl SM, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine; CNS Spectrums 20: 455-459

PUBLICATIONS (43)

496. 2015 Stahl SM, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release, CNS Spectrums 20: 331 - 336
497. 2015 Stahl SM Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters, CNS Spectrums 20: 515 – 519
498. 2015 Stahl SM Is impulsive violence an addiction? The Habit Hypothesis, CNS Spectrums 20: 165 – 169
499. 2015 Culpepper, L, Muskin PR, Stahl SM, Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability, American Journal of Medicine 128, S1-S15
500. 2015 Warburton KD, Stahl SM, Treat the treatable: a comprehensive and optimistic approach to treating psychiatric violence, CNS Spectrums 20: 170 – 171 (editorial)
501. 2015 Schaufenbil RJ, Kornbluh R, Stahl SM, Warburton KD, Forensic focused treatment planning: a new standard for forensic mental health systems CNS Spectrums 20: 250 – 253
502. 2015 Zohar J, Stahl SM, Moller H-J, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin GM, Nutt D, A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature, European Neuropsychopharmacology, 25: 2318-25
503. 2015 Stahl SM, Using neuroscience for naming psychotropic drugs, CNS Spectrums 21: 219-220 (editorial)
504. 2015 Maxwell NM, Nevin RL, Stahl SM, Block J, Shugarts S, Wu AH, Dominy S, Solano-Blanco MA, Kappelman-Culver S, Lee-Messer C, Maldonado J, Maxwell AJ, Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy doi: 10.1002/ccr3.238; Clinical Case Reports 3:379-87.
505. 2015 Shapiro DN and Stahl SM, Psychopharmacology Child and Adolescent, Wiley Encyclopedia of Forensic Science. 1–9. eds A. Jamieson and A.A.Moenssens, John Wiley: Chichester. doi: 10.1002/9780470061589.fsa1105. Published 16th June 2014.
506. 2016 Stahl SM, Kick-off editorial for 2016: thanks to our reviewers, CNS Spectrums 21:7-8

PUBLICATIONS (44)

507. 2016 Stahl SM, Mechanism of action of brexpiprazole: comparison with aripiprazole, CNS Spectrums 21:1 - 6
508. 2016 Stahl SM Mechanism of action of cariprazine, CNS Spectrums 21: 23-127
509. 2016 Stahl SM Mechanism of action of suvorexant, CNS Spectrums 21:215 – 218
510. 2016 Stahl SM Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT_{2A} and 5HT_{2C} receptors, CNS Spectrums 21: 271 – 275
511. 2016 Stahl SM, Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome, CNS Spectrums 21: 355-359.
512. 2016 Stahl SM, Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? CNS Spectrums 21: 419-423.
513. 2016 Meyer JM, Cummings MA, Proctor G, Stahl SM, Psychopharmacology of Persistent Violence and Aggression, Psychiatr Clin N Am 39 (2016) 541–556.
514. 2016 Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl, SM, Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction, Case Reports in Psychiatry Volume 2016, Article ID 5606098, 7 pages (<http://dx.doi.org/10.1155/2016/5606098>).
515. 2016 Moore BA, Morrisette DA, Meyer JM, Stahl SM, "Unconventional" Treatment Strategies for Schizophrenia: Polypharmacy and Heroic Dosing BJPsychBull 1-5, 41:164-168, doi: 10.1192/pb.bp.115.053223.
516. 2017 Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Phaus J, Simon JA, Kingsberg SA, Meston C. Stahl SM, Wallen K, Worsley R, HSDD Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review, Mayo Clinic. (<http://creativecommons.org/licenses/by-nc-nd/4/>; Mayo Clin.Proc. 92:114-128.
517. 2017 Nutt D, Stahl S, Drago F, Zohar J, Wilson S, Inverse agonists – What do they mean for psychiatry? European Neuropsychopharmacology, 27: 87-90, (<http://dx.doi.org/10.1016/j.euroneuro.2016.11.013>).
518. 2017 Sabbag SA, Alhajji L, Saveanu RV, Stahl SM, Nemeroff CB, Teaching Neurobiology in Psychiatry, chapter in Hermans, MHM, Hoon, TC, Pi,(Eds), EH Mental Health and Illness Worldwide: Education about Mental Health and Illness. Springer, New York, Chapter 11, 2018

PUBLICATIONS (45)

519. 2017 Stahl SM Neuroscience-based Nomenclature: Classifying Psychotropics by Mechanism of Action Rather Than Indication, Current Psychiatry 2017; 16: 15-16
520. 2017 Keppel Hesselink, JM, Kopsky DJ, Stahl SM, Bottlenecks in the Development of Topical Analgesics: Molecule, Formulation, Dose-Finding and Phase III Design, J Pain Res 2017; 10:635-41
521. 2017 Stahl SM Kick off editorial for 2017: CNS Spectrums is on the move, CNS Spectrums 2017, 22:5-6
522. 2017 Stahl SM Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice, CNS Spectrums 2017; 22:1-4
523. 2017 Stahl SM, Mixed-up About How to Diagnose and Treat Mixed Features in Major Depressive Episodes, CNS Spectrums (2017), 22, 111–115
524. 2017 Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostracher M, Rosenblat JD, Sole E, Suppes T, Takeshima M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS, Guidelines for the Recognition and Management of Mixed Depression, CNS Spectrums, 22: 203–219
525. 2017 Stahl SM, Does Treating Hearing loss prevent or slow the progress of dementia: Hearing is not all in the ears, but who’s listening, CNS Spectrums, 22: 247-250, DOI: <https://doi.org/10.1017/S1092852917000268>.
526. 2017 Shapiro D, Stevens D, Stahl SM, Flibanserin – the female Viagra? International Journal of Psychiatry in Clinical Practice, 21:4, 259-265 DOI:10.1080/13651501.2017.1315138,
527. 2017 Stevens DM, Weems JM, Brown L, Barbour KA, Stahl SM, The Pharmacodynamic Effects of Combined Administration of Flibanserin and Alcohol, AJ Clin Pharmacy and Therapeutics, 42: 598-606, DOI: 10.1111/jcpt.12563
528. 2017 Stahl SM, Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors, CNS Spectrums, 22: 305-311
529. 2017 Stahl SM, Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes, CNS Spectrums, 22: 375-384
530. 2017 Stahl SM, Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum, CNS Spectrums, 22, 427-434
531. 2017 Stahl SM, Morrissette DA, Does a “whiff” of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Wiley Bipolar Disorders, 19: 595-596, DOI: 10.1111/bdi.12542

PUBLICATIONS (46)

532. 2018 Cummings MA, Proctor GJ, Stahl SM, Deuterium Tetrabenazine for Tardive Dyskinesia, Clinical Schizophrenia & Related Psychoses, Winter 2018, 214-220.
533. 2018 Lemoine P, Stahl SM, Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties, CNS Spectrums, 22:15-25
534. 2018 Hesselink Keppel JM, Stahl SM, Phenytoin in Bipolar Depression: An Old Chapter, but Not Yet Properly Evaluated, Journal of Mood Disorders and Therapy, 1: 24-28
535. 2018 Stahl SM, Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects, CNS Spectrums, 23: 1-6
536. 2018 Stahl SM, Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough, CNS Spectrums, 23: 113-116
537. 2018 Stahl SM, Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate, CNS Spectrums, 23: 187-191
538. 2018 Stahl SM, Comparing pharmacological mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectrums 23:
539. 2018 Stahl SM, New Hope for Alzheimer’s Dementia as Prospect for Disease Modification Fade: Symptomatic Treatments for Agitation and Psychosis, CNS Spectrums 23: 291-297
540. 2018 Muse MD and Stahl SM, Anxiety Disorders: Evidence-Based Integrated Biopsychological Treatment in Cognitive Behavior, Psychopharmacology: The Clinical Evidence Based Biopsychological Integration, Wiley Blackwell, Chichester, UK, 2018
541. 2018 Marazziti D, Stahl SM, Evil, terrorism, and psychiatry, CNS Spectrums, 23: 117-118
542. 2018 Marazziti D, Stahl SM, Serotonin and Love Supporting Evidence From a Patient Suffering From Obsessive-Compulsive Disorder, Journal of Clinical Psychopharmacology, 38: 1-2

PUBLICATIONS (47)

543. 2019 Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM, Guidance for Switching from Off-Label Antipsychotics to Pimavanserin for Parkinson's Disease Psychosis: An Expert Consensus, CNS Spectrums, 23: 402-413
544. 2019 McIntyre RS, Anderson N, Baune BT, Brietzke E, Burdick K, DiSimplicio M, Fossati P, Harmer C, Gorwood P, Harrison J, Harvey P, Holmes E, Ji J, Mansur RB, Medalia A, Miskowiak K, Ramey T, Rong C, Rosenblat JD, Young A, Stahl SM, Expert consensus on screening assessment of cognition in psychiatry, CNS Spectrums, 24: 154-162
- 545: 2019 Sauve W, Stahl SM, Psychopharmacological and Neuromodulation Treatment of PTSD, 2nd Edition, Handbook for the Treatment of PTSD in Military Personnel, Moore BA and Penk WE, Guilford Press: 155-172.
546. 2019 Fountoulakis KN, Stahl SM, Biological Psychiatry and Psychopharmacology, in Fountoulakis KN, Nimatoudis I (Eds), Psychobiology of Behavior, Springer Nature Switzerland AG 2019, 13:397-458; doi.org/10.1007/978-3-030-18323-3
547. 2019 Marazziti D, Stahl SM, Simoncini, M, Baroni S, Mucci F, Palego L, Betti L, Massimetti G, Giannaccini G, Dell'Osso L, Psychopharmacology and Ethnicity: A Comparative Study on Senegalese and Italian Men, World Journal of Biologic Psychiatry 2020;21(4):300-7; doi.org/10.1080/15622975.2019.1583373.
548. 2019 Stahl SM, Placebo Response Rate is Ruining Drug Development in Psychiatry: Why Is This Happening and What Can We Do About It? Acta Psychiatrica Scandinavia, 2019; 139: 105-107
549. 2019 Stahl SM, Morrissette DA, Mixed Mood States: Baffled, Bewildered, Befuddled and Bemused, Bipolar Disorders 2019;21(6):560-1. doi.org/10.1111/bdi.12787
550. 2019 Stahl SM, Mechanism of Action Dextromethorphan / Bupropion: A Novel on NMDA Antagonist with Multimodal Activity, CNS Spectrums, 2019; 24: 461-466
551. 2019 McIntyre RS, Suppes T, Early W, Patel M, Stahl SM. Cariprazine Efficacy in Bipolar I Depression With and Without Concurrent Manic Symptoms: Post Hoc Analysis of Three Randomized, Placebo-Controlled Studies, CNS Spectrums, 2019; 25(4), 502–510. <https://doi.org/10.1017/S1092852919001287>
552. 2019 O'Connor PJ, Kennedy DO, Stahl SM. Mental Energy: Plausible Neurobiology Mechanisms and Emerging Research on the Effects of Natural Dietary Components, Nutritional Neuroscience, doi.org/10.1080/1028415X.2019.1684688

PUBLICATIONS (48)

553. 2020 Stahl SM, Laredo SA, Morrissette DA, Cariprazine as a Treatment Across the Bipolar I Spectrum from Depression to Mania: Mechanism of Action and Review of Clinical Data, Therapeutic Advances in Psychopharmacology, 2020;10:2045125320905752
554. 2020 Pompili M, Vazquez GH, Forte A, Morrissette DA, Stahl SM. Pharmacological Treatment of Mixed States, Psychiatric Clinics of North America, 2020;43(1):167-86.
555. 2020 Marazziti D, Stahl SM. Novel challenges to psychiatry from a changing world, CNS Spectrums <https://doi.org/10.1017/S1092852919001858>
556. 2020 Delgado D, Breth A, Hills, Warburton K, Stahl SM. Economics of Decriminalizing Mental Health Illness: When Doing the Right Thing Ironically Costs Less, CNS Spectrums, 2020; 25:566-570
<https://doi.org/10.1017/S1092852919001792>
557. 2020 Warburton K, McDermott BE, Gale A, Stahl SM. Survey of National Trend in Psychiatric Patients Found Incompetent to Stand Trial: Reason for Re-Institutionalization of People With Serious Mental Illness in the United States, CNS Spectrums, 2020; 25:245-51. <https://doi.org/10.1017/S1092852919001585558>.
558. 2020 Rose B, Broderick C, Delgado D, Kornbluh R, Stahl SM. Breaking down long term chronic aggression, CNS Spectrums, 2020; 25:216-222.
<https://doi.org/10.1017/S1092852919001317>
559. 2020 Daugherty B, Warburton K, Stahl, SM. A Social History of Mental Illness, CNS Spectrums, 2020: 25:584-92. <https://doi.org/10.1017/S1092852920001364>
560. 2020 Warburton K, Stahl SM. Editorial Balancing the Role of Institutionalization in the Treatment of Serious Mental Illness, CNS Spectrums, 2020; 25:115-118.
<https://doi.org/10.1017/S1092852920000176>
561. 2020 Poole J, Reddy H, Maguire G, Stahl SM. New Pharmacological Approaches, Psychiatric Clinics of North America, 2020; 43:399-413.
<https://doi.org/10.1016/j.psc.2020.02.008>
562. 2020 Marazziti D, Stahl SM. The relevance of COVID-19 pandemic to psychiatry, World Psychiatry 2020; 19:261
563. 2020 Cummings MA, Scott C, Arguello JC, Arias A-LW, Breth AM, Delgado D, Harvey PD, Meyer JM, O'Day J, Pollock M, Proctor G, Rector T, Rose B, Schwartz E, Thordason H, Warburton KD, and Stahl SM. The Cal-DSH Diversion Guidelines, CNS Spectrums 2020; 25: 701-13. <https://doi.org/10.1017/S1092852920001819>

PUBLICATIONS (49)

564. 2020 Cummings JL, Devanan DP, Stahl SM. Dementia-Related Psychosis and the Potential Role for Pimavanserin, CNS Spectrums, DOI: 10.1017/S1092852920001765
565. 2021 Stahl SM, Sy S, Maguire GA. How and When to Treat the Most Common Adverse- Effects of Antipsychotics: Expert Review from Research to Clinical Practice, Acta Psychiatrica Scandinavica DOI: 10.1111/acps.13266
566. 2021 McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Jaramillo CL, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl SM. Synthesizing the Evidence for Ketamine and Esketamine in Treatment Resistant Depression: Guidance and International Perspective, Am J Psychiatry (doi:10.1176/appi.ajp2020.20081251
567. 2021 De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, Stahl S, Inturrisi CE, Pappagallo M, Traversa S, Manfredi PL. REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study, Frontiers in Pharmacology, doi 10.3389/fphar.2021.6718
568. 2021 Fava M, Stahl S, Pani L, DeMartin S, Alimonti A, Bettini E, Wessel T, de Somer M, Caron J, Pappagallo M, Vitolo OV, DiGuglielmo G, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Traversa S, Inturrisi CE, Manfredi PL. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2a Double-Blind Randomized Trial, American Journal of Psychiatry doi.org/10.1176.appi.ajp.2021.21020197
569. 2021 Albert U, Lamba P and Stahl SM. Early Response to Trazodone in Major Depressive Disorder: Review of the Clinical Data and Putative Mechanism for Faster Onset of Action, CNS Spectrums doi.org/10.1017/S10928529210000304
570. 2021 Fountoulakis KN and Stahl SM. Precision and Personalized Assessment, Diagnosis and Treatment in Psychiatry, CNS Spectrums, doi.org/10.1017/S1092852920000139.
571. 2021 Ingram M, Maguire G, Stahl SM. Multifunctional Antidepressant Medications, Advances in Psychiatry and Behavioral Health, 1:185-203
572. 2021 Stahl SM, Segal S. The Third Generation of Therapeutic Innovation and the Future of Psychopharmacology, Current Psychiatry, 20: 6-25
573. 2021 Marazziti D, Stahl SM. Response to the Letter to the Editor “Psychiatry’s Undeclared Identity Crisis in a Changing World” by Richard Skaff, CNS Spectrums <https://doi.org/10.1017/S1092852921000559>

PUBLICATIONS (50)

574. 2022 Pandi-Perumal SR, Zaki NFW, Qasim M, Morsy NE, Manzar D, BaHammam AS, Jahrami H, Ramasubramanian C, Karthikeyan R, Supasitthumrong T, Moscovitch A, Trakht I, Gupta R, Narasimhan M, Partonen T, Reiter RJ, Morris G, Berk M, Kennedy SH, Stein DJ, Stahl SM, Charney DS, Seeman MV. Neuropsychiatric Consequences of COVID-19 Pandemic: A Synthetic Review From a Global Perspective, Alpha Psychiatry, DOI: 10.5152/alphapsychiatry.2022.21783
575. 2022 Fountoulakis KN, and Stahl SM. The Effect of Antipsychotic Treatment on Brain Morphology in Schizophrenia: A Systematic Review of Longitudinal Magnetic Resonance Studies with a Randomized Allocation to Treatment Arms, J Psychopharmacology DOI: 10.1177/02698811221087645 journals.sagepub.com/home/jop
576. 2022 Grover D, Tom M, Maguire G, Stahl SM, Polypharmacy – Purpose, Benefits and Limitations, Current Medicinal Chemistry , 1-9; <http://dx.doi.org/10.2174/0929867329666220107153813>
577. 2022 Thase ME, Stahl SM, McIntyre RS, Matthews-Hayes T, Rolin D, Patel M, Harrington A., Maletic V, Jackson WC, Vieta E. Screening for bipolar I disorder and the rapid mood screener: results of a nationwide healthcare provider survey CNS Spectrums 26(2), 181–183. <https://doi.org/10.1017/S1092852921000201>
578. 2022 Hong J, Vernon D, Kunovac J, Stahl SM. Emerging Drugs for the Treatment of Major Depressive Disorder, Expert Opinion on Emerging Drugs, DOI: 10.1080/14728214.2022.2117297
579. 2022 Bettini E, Stahl SM, DeMartin S, Mattarei A, Sgrignani J, Carignani C, Locatelli P, Pappagallo M, Inturrisi CE, Bifari F, Cavalli A, Alimont A, Pani L, Fava M, Traversa S, Folli F, Manfredi PL. Pharmacological Comparative Characterization of REL-1017 (esmethadone HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-methyl-D-aspartate Receptors, Pharmaceuticals **2022**, 15, 997. <https://doi.org/10.3390/ph15080997>
580. 2022 Bettini E, De Martin S, Mattarei A, Pappagallo M, Stahl SM, Bifari F, Inturrisi CE, Folli F, Traversa S, Manfredi PL, The N-Methyl-d-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid and Gentamicin, Pharmaceuticals 2022, 15, 882, <https://doi.org/10.3390/ph15070882>
581. 2022 Stahl SM, DeMartin S, Mattarei A, Bettini E, Pani L, Guidetti C, Folli F, deSomer M, Traversa S, Inturrisi CE, Pappagallo M, Gentilucci M, Alimont A, Fava M, Manfredi PL, Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling, Int. J. Mol. Sci. **2022**, 23, 12196. <https://doi.org/10.3390/ijms232012196>

PUBLICATIONS (51)

582. 2022 Dodd S, Norman TR, Carvalho AF, Eyre H, Stahl SM, Berk M. Psilocybin in Neuropsychiatry: A Review of its Pharmacology, Safety and Efficacy, 2022, CNS Spectrums <https://doi.org/10.1017/S1092852922000888>
583. 2022 Yohn, S, Weiden P Felder CC and Stahl SM, Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic, Trends in Pharmacological Sciences, 2022, Vol. 43, No. 12 <https://doi.org/10.1016/j.tips.2022.09.006>
584. 2022 Van den Eynde V, Wegdan R. Abdelmoemin WR, Abraham M, msterdam JD, Anderson IM, Andrade C, Baker GB, Beekman ATF, Berk M, Birkenhäger TK, Blackwell BB, Blier P, Blom MBJ, Bodkin AJ, Cattaneo CI, Dantz B, Davidson J, Dunlop BW, Estévez RF, Feinberg SS, Finberg JPM, Fochtmann LJ, Gotlib D, Holt A, Insel TR, Larsen JK, Mago R, Menkes DB, Meyer JM, Nutt DJ, Parker G, Rego MD, Richelson E, Ruhé HG, Sáiz-Ruiz J, Stahl SM, Steele T, Thase ME, Ulrich S, van Balkom AJLM, Vieta E, Whyte I, Young AH and Gillman PK The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression, CNS Spectrums 2022 <https://doi.org/10.1017/S1092852922000906>
585. 2022 Mattingly G, Matthews-Hayes T, Patel MD, Kramer K, Stahl SM. A survey of health care professionals and patients: do we need a new nomenclature for atypical antipsychotics? Prim Care Companion CNS Disord. 2023;25(0):22m03331.
586. 2022 Cooper T, Seigler M, Stahl SM, Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions, J Psychopharmacol DOI: 10.1177/02698811231158891 journals.sagepub.com/home/jop
587. 2022 Fava M, Stahl SM, DeMartin S, Mattarei A, Bettini E, Coai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL, Esmethadone-HCl (REL-1017): a promising rapid antidepressant, Eur Archives of Psychiatry and Clinical Neuroscience <https://doi.org/10.1007/s00406-023-1051-71-4>
588. 2023 Demyttenaere K and Stahl SM, Co-administration in the treatment of depression: deconstructing the Tower of Babel? European Neuropsychopharmacology, <https://doi.org/10.1016/j.euroneuro.2023>.

IN PRESS PUBLICATIONS

1. Striebel JM, Oday J, Haghghat N, Stahl SM. Pimavanserin in Biological Therapies, Kaplan and Sadock, 11th edition, in press.
2. Cummings MA, Arias AL, Proctor GJ, Stahl SM. Psychopharmacology of Chronic Aggression and Violence in Forensic Settings, in Kennedy HG and Davoren M, Seminars in Forensic Psychiatry, Gaskell, Royal College of Psychiatrists, Cambridge University Press.
3. Osimo E, and Stahl SM, Neurotransmitters and receptors, in Lynell ML, Jones PB and Stahl SM, Cambridge Textbook of Neuroscience for Psychiatrists, Cambridge University Press, New York, 2023
4. Stead U, and Stahl, SM, Sleep, Regulation of Sleep and Arousal, Effects of Sleep Deprivation, in Lynell ML, Jones PB and Stahl SM, Cambridge Textbook of Neuroscience for Psychiatrists, Cambridge University Press, New York, 2023
5. McIntyre RS, Maj M, Alsuwaidan M, Baune BT, Berk M, Cuijipers P, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly-Uson J, Mansur B, McCallister H, Murrough J, Nemeroff C, Nierenberg A, Rosenblat JD, Rush J, Sanacora G, Schatzberg A, Shelton R, Stahl SM, Thase M, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Treatment resistant depression: scope, definitions, synthesis of the evidence and treatment guidelines, World Psychiatry, 2023

SUBMITTED PUBLICATIONS

1. McIntyre RS, Durgam S, Huo J, Koauer SG, Stahl SM, The efficacy of lumateperone in patients with bipolar depression with and without mixed features, J Clin Psychiatry
2. Goldberg JF, Steinman MQ, Stahl SM, Safety and tolerability of trazodone once a day in the treatment of major depressive disorder: a review of the clinical data and the potential underlying mechanisms
3. Fond G, Mallet J, Urbach M, Benros Me, Berk M, Correll CU, Kulkarni J, Liora PM, Misdrahi D, Rey R, Schurhoff F, Somi M, Sommer, IEC, Stahl SM, Pignon B, Berna F, Adjunctive agents to antipsychotics in schizophrenia: umbrella review and GRADE recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
4. Grant ML, Jurecki ER, McCandless SE, Stahl SM, Bilder DA, Sanchez-Valle A, Dimmick D, Neuropsychiatric function improvement in pediatric patients with PKU
5. Rossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, Fornaro M, Gillman K, Cannaneo CI, Van den Eynde V, Stahl S, Iasevoli F, de Bartolmeis A, Selegiline efficacy and safety in Psychiatry: a systemic review and meta analysis

IN PREPARATION PUBLICATIONS

1. Stahl SM, Cummings JL, Gonzalez, ST, Brubaker M, Patel M, Seizler K, Brunner E, Pathophysiology of agitation in Alzheimer's dementia: potential role of neurotransmitter systems
2. Stahl et al., Efficacy and safety of iloperidone in acute and mixed mania associated with bipolar I disorder: a double blind, placebo controlled study
3. Stahl et al., comparing VMAT2 inhibitors
4. Mattingly G et al, Tele mental health and ADHD: an international expert consensus guideline

BRAINSTORMS IN PREPARATION

1. Approved - lemborexant
2. Approved – lumateperone
3. Approved - bremelanotide
4. Approved - brexanolone
5. Approved - pisolitant
6. Approved - solrimefetol
7. Filed - pimavanserin for DRP
8. Approved- olanzapine samidorphan
9. Approved- viloxazine
10. NMDA mu
11. Esmethadone
12. Psilocybin
13. MDMA
14. Mysterious DAT
15. Brexpiprazole for agitation
16. dxm/bup for agitation and or TRD
17. Roluperidone
18. Trace amines
19. KarXT M1/M4
20. Neurosteroids
21. Fab 4 cognition